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A BSTRACT
In this thesis a diverse range o f  topics related to paediatric HIV and HCV infection are 
investigated inform ation is provided on the more specific areas o f  coinfection, disease 
m onitoring m ethodologies and the impact o f  mode o f acquisition o f  infection. Four unique 
epidem iological cohorts o f  vertically and parenterally HIV, HCV and H IV/IICV  coinfected 
children are analysed. A LT reference ranges adjusted for age and sex in children under five 
years o f age show  that ALT levels greater than 60U/1 in boys and 55U/1 in girls should be 
regarded as elevated in the first 18 months o f life while thereafter the upper lim its o f 
normal ALT levels are lower; 40U/1 in boys and 35U/1 in girls. There are no differences 
found between vertically and parenterally HCV-only infected groups in their genotype 
profile, proportion with consistent viraemia, consistently elevated ALT levels or evidence 
o f  two or m ore m arkers o f  disease progression. Parenterally HIV infected children are 
described for the first tim e and only 12% found to progress to m oderate/severe clinical 
sym ptom s or im m unosuppression during follow-up. The lack o f  treatm ent in this group 
(11%  treated) suggests a m ore favourable disease progression in parenterally than vertically 
HIV infected children. The possible detrimental effects o f  A RT on ALT levels in 
HIV/HCV coinfected children are dem onstrated along with the possible need for 
differential m anagem ent o f  children infected via different routes given the faster 
progression to im m unosuppression in parenterally coinfected children. The survey o f 
current practices and policies for care o f  HIV/HCV coinfected children reveals that in 
general the m anagem ent practices vary widely in term s o f  testing high risk groups for 
coinfection, which laboratory tests to carry out in com parison to those perform ed on HIV- 
only and H CV-only infected children and the opinions on optim al treatm ent for this group 
em phasise the im portance o f  research in this area to inform clinical guidelines.
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1. PAED IA TR IC  HCV AND HIV INFECTION: M ODE OF AC Q UISITIO N , 
PRO G RESSIO N  AND C O INFECTIO N
1.1 G lobal epidem iology and biology o f Hepatitis C virus (HCV)
HCV is a noncytopathic virus o f the Flaviviridae family w hich infects the liver, replicates 
at a high rate and in 10-30% o f  patients causes acute, limited infection with norm ally 
asym ptom atic inflam m atory liver disease reconciled by the cellular im m une response 
(Chisari 2005, H oofnagle 2002). However, HCV can cause chronic hepatitis in 70-90%  o f 
infected people, with elevated alanine am inotransferase (A LT) levels and progressive 
hepatic fibrosis, cirrhosis, liver failure and hepatocellular carcinom a (Chisari 2005, 
Hoofnagle 2002). Six genotypes and over 90 subtypes o f  HCV have been isolated since its 
discovery in 1988 (Choo et al 1989). Repeated percutaneous exposure to contam inated 
blood is the m ost efficient m ode o f  HCV transm ission. HCV transm ission via accidental 
needlestick injuries, sex w ith an infected partner or m other-to-child transm ission is less 
efficient (A lter 2007). O ver the last 20 years, HCV has em erged as a global public health 
concern with an estim ated 180 m illion people currently infected w orldw ide (W HO 2007). 
This equates to a global prevalence o f approxim ately 3%, but prevalence rates vary greatly 
by geographical region and also between specific sub-groups within countries or regions. 
Specifically, injecting drug users are the highest risk group with recent global prevalence 
estim ates o f  at least 50% (Aceijas and Rhodes 2007). In N orthern and Central Europe HCV 
prevalence ranges from 0.1%  to 1.2% on a population level, com pared to higher prevalence 
in Southern Europe o f  2.5%  to 3.5%, although there are isolated areas o f  Italy and Greece 
where HCV prevalence is as high as 20% due to historical w idespread unsafe medical 
procedures (Esteban et al 2007). In Eastern Europe the extensive injecting drug use
epidem ic and the substantial use o f  unsafe medical procedures has resulted in higher 
prevalence rates up to 10% in blood donors and health workers and as high as 92% in high 
risk groups such as haem ophiliacs (Esteban el al 2007, Aceijas el al 2004).
1.2 A cquisition o f paediatric HCV infection
1.2.1 Vertical transm ission
HCV infection in children is predom inantly acquired via m other-to-child transm ission 
(M TCT) and occurs in approxim ately 5% o f  children born to HCV infected mothers, 
although transm ission rates can be as high as 15% depending on maternal HIV coinfection 
status and maternal HCV RNA viral load (Newell and Pem brey 2002, Tovo et al 1997, 
Zanetti et al 1998, EPHN 2001, Gibb et al 2000, Granovsky et al 1998, Resti et al 1998, 
Thom as 1998, Paccagnini et al 1995, Ruiz-Extrem era et al 2000). Prevention o f  M TCT 
relies on the diagnosis and treatm ent o f women infected with HCV before they becom e 
pregnant as there is currently no treatm ent suitable for use in pregnancy and no post­
exposure prophylaxis available to the newborn, as there is for HIV infection. Studies have 
investigated the risk o f  M TCT during delivery with the hypothesis that, like HIV, vertical 
transm ission o f  HCV m ay be reduced by elective caesarean section but to date there is 
strong evidence that elective caesarean section does not reduces the risk o f HCV 
transm ission despite some findings o f  a protective effect in sm aller studies (EPHN 2001, 
Gibb et al 2000a, Tovo et al 1997). Similarly, HCV has been found in breast milk but there 
is strong evidence to suggest that M TCT does not occur through breastfeeding and 
breastfeeding is not contraindicated am ong HCV infected m others (K um ar and Shahul 
1998, Lin et al 1995, M ast et al 2005, EPHN 2001).
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1.2.2 Parenteral transm ission
HCV infection via contact with contam inated blood or blood products is now rare after the 
im plem entation o f donor screening in many countries in the early 1990s, however, blood 
safety is not a priority in some countries and others lack the resources to im plem ent donor 
screening (A lter 2007, H ladik et al 2006). The most im portant factor in the spread o f HCV 
infection is unsafe m edical injections with approxim ately 2.3 to 4.7 m illion people 
w orldw ide infected in this way, mostly in resource limited settings (Kane et al 1999) 
accounting for approxim ately 40%  o f HCV infections w orldw ide (Hauri et al 2004). In 
resource-lim ited countries, sterile syringes are often unavailable, injections are often 
adm inistered by non-health professionals and the use o f  oral m edication is not prioritised 
(Alter 2007). An exam ple o f the potential impact o f these unsafe procedures was 
dem onstrated by the reuse o f  glass syringes during the treatm ent o f schistosom iases in 
Egypt until the early 1980s which resulted in the largest outbreak o f  iatrogenic transm ission 
o f  a bloodbourne pathogen ever recorded and the effects o f  which are still seen today in the 
form o f high population prevalence rates stem ming from this initial reservoir o f  infection 
(A lter 2007, Frank et a l 2000). In addition, HCV has also been shown present in the 
environm ent on needles, syringes and infusion bags and the infectivity o f the virus after 
drying and storage has been confirm ed (Kamili et al 2007). The transm ission o f HCV via 
contact with infected individuals or family m em bers has been investigated and some 
limited evidence suggests that HCV prevalence is higher in children with infected parents, 
independent o f  possible M TCT or other routes o f transm ission (El-Raziky et al 2004). 
Despite the predom inance o f  vertically transm itted HCV infection in children there remain 
children infected parenterally as a result o f  isolated, usually hospital-based outbreaks and 
there is com pelling evidence to suggest that procedures causing these outbreaks continue
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globally (Hl-Raziky et al 2004, G ibb et al 2000, O ’Riordan et al 1998, Prati 2006, Patel et 
al 2006, Davaalkham et al 2006).
1.3 M onitoring H C V -related infection/disease progression
1.3.1 Liver biopsy
In the absence o f  H CV-related clinical symptom s, liver biopsy is som etim es used to assess 
the extent o f  liver fibrosis and the likely risk o f progression to liver disease, but this is an 
invasive technique for w hat is largely an asym ptom atic disease and the benefits o f biopsy 
can not always be justified  in many cases, especially in children. New, non-invasive 
techniques such as the Fibro Scan are being developed (K ettaneh et al 2007, Stauber and 
Lackner 2007) but clinicians rely largely on biochemical m arkers o f  infection such as ALT 
levels to indicate liver-related abnorm alities which m ay require further investigation. The 
com bination of, for exam ple, elevated ALT levels with persistence o f HCV RNA viraem ia 
can also indicate individuals at higher risk o f HCV-related disease progression (EPHN 
2005a). There is, how ever, a general dissatisfaction with the sensitivity o f  serum ALT as a 
marker o f  liver disease, especially in the case o f chronic HCV infection where despite 
normal ALT levels, som e patients have been found to have some evidence o f  liver 
abnorm alities (Prati et al 2002).
1.3.2 ALT levels
ALT levels provide a m easure o f  liver function with high levels often indicating some 
degree o f im pairm ent. However, the definitions o f  abnormal ALT levels vary and levels are 
also affected by age, sex and race, m aking their interpretation in term s o f  liver function
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difficult (Jamal et al 2003). D efinitions o f normal or abnorm al ALT and the resulting 
clinical decisions have been largely based on reference ranges o f  normal ALT' levels 
provided by laboratories carrying out the test. The populations from which these reference 
ranges have been extrapolated are undefined and are likely to vary widely. Consequently, a 
num ber o f recent studies have called into question the use o f  these reference ranges (Prati 
2002, M oham adnejad et a l 2003, Brinkm ann et al 2003, Piton el al 1998, Kariv et al 2006) 
and identified new adult reference ranges calculated from defined “healthy" populations 
which in general have shown the revised upper limit o f normal to be lower than those 
currently used. For exam ple, a significantly lower upper limit o f normal for ALT levels in 
17,496 healthy subjects aged 15-90 years, 37.5U/1 com pared to 52U/1 recom m ended by 
laboratory reference ranges, was found (Kariv et al 2006). These studies also indicate the 
im portance o f  accounting for sex and body mass index (BM I) when calculating the 
appropriate ALT ranges for individuals. Piton et al identified four appropriate upper limits 
o f ALT levels: 31U/1 for fem ales with BMI<23, 42 U/l for males w ith BM I<23, 44 U/l for 
females with BM I>23 and 66 U/l for males with BM I>23 after com paring different 
m ethods for identifying the “true” upper limit o f normal, w hich in some cases varied by 
2 0 % - 45%  (Piton et al 1998).
Such evidence from adult studies suggest that the true upper limit o f normal ALT levels is 
lower than previously identified and therefore it is possible that those patients with 
“norm al” ALT levels who go on to develop liver disease in fact had abnorm al ALT levels if 
one applies upper lim its suggested by these studies. This may help explain why the 
sensitivity and specificity o f  A LT levels in identifying patients with liver abnorm alities is
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not always high and may be im portant in term s o f increasing the accuracy o f this 
com m only used biological marker.
ALT levels are also used to indicate liver function in paediatric populations, often to assess 
the extent o f liver dam age due to hepatitis B, chronic hepatitis C, autoim m une hepatitis or 
non-alcoholic fatty liver disease (Zacharakis et al 2007, Kerkar 2005, EPHN 2005a, 
Davison et al 2006, Q uiros-Tejeira et al 2007). As with adults, many paediatric studies 
refer to normal or elevated A LT levels but few provide details o f  the specific values or the 
populations and m ethods by w hich these were defined. Com m only studies define elevated 
ALT levels as tw ice the upper lim it o f  normal but w ithout indicating w hat the upper limit 
o f normal is in term s o f  A LT levels. Previous studies attem pting to quantify reference 
ranges for ALT levels have been based on cross-sectional data collated from several 
different populations. In a clinical setting, ALT levels are assum ed to be normal or 
abnormal based on reference ranges from laboratories, as with adults, and a com m only used 
upper lim it o f  this norm al range is approxim ately 80U/1 in children younger than 12 months 
and 40U/1 in children older than 12 m onths (Nelson Paediatrics 17th Edition, EPHN 2005a). 
However, to date few studies have investigated the accuracy o f  these ranges and therefore 
guidelines on the appropriate reference ranges for ALT levels in children and their variation 
with sex or BMI, shown to be im portant in adults studies, rem ain unqualified.
1.3.3 Genotype
Five major HCV genotypes have been identified with varying geographical distributions. 
Genotype la  is prevalent in northern Europe and the USA, genotypes lb  and 2 in southern 
Europe, 3 in the Indian subcontinent and am ong drug users in Europe and 4 in Africa and
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the M iddle East (D usheiko et al 1994). Adult studies have linked IICV genotype with 
differential disease progression and response to interferon (IFN) therapy (Le Guillou- 
Guillem ette et al 2007, Torres-Puente et al 2008, Powis et al 2008) but similar studies in 
children are limited. Recently, Bortolotti et al dem onstrated increasing prevalence o f 
genotypes 3 and 4 in vertically infected children in Italy between 1990 and 2002 and higher 
rates o f  spontaneous viral clearance early in life in children with genotype 3. They also 
found a high proportion o f  children with genotype 3 responding to IFN therapy and 
speculated that the increase in prevalence o f  genotypes 3 and 4 in recent years could 
significantly im pact on the epidem iology o f  paediatric HCV infection in years to come 
(Bortolotti et al 2005).
1.3.4 HCV RNA viral load
The extent to w hich HCV RNA viral load predicts disease progression in HCV infected 
children rem ains unclear, predom inantly due to a lack o f  prospective data for large num bers 
o f infected children over a long enough period o f  time. As a result, its usefulness as a tool 
for m onitoring HCV progression may be limited but associations have been made between 
active HCV infection and a high proportion o f  positive HCV RNA test results in the 
context o f  a large European prospective study. In addition, low HCV viral activity was 
associated with viral clearance in the same study (EPHN 2005a). In adult studies the 
majority o f  evidence points tow ards a lack o f association between RNA viral load and 
severity o f liver disease (H eller and Seef 2005, M cCorm ick et al 1996, Puoti et al 1999, 
Gervais et al 2001, Poynard et al 2001, D eM oliner et al 1998, Freeman et al 2003). 
However, a few studies have found increased liver severity am ong HCV infected adults 
with high viral loads (H isada et al 2005, Kato et al 1993, M ita et al 1994. Gretch et al
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1994), although this may be due to the specialised groups studied in these cases, e.g. 
injecting drug users (H eller and Seef 2005). Both in adult and paediatric studies, no cut-offs 
for HCV RNA viral load which either predict worse or better HCV-related disease 
progression have been identified and therefore the predom inant use o f  viral load 
inform ation is to m onitor the presence o f  infection, often in response to treatment. There 
has been some research on the prognostic value o f HCV RNA viral load in predicting HIV 
disease progression w ithin a UK cohort o f HIV/HCV coinfected m ales with inherited 
bleeding disorders. In this group, an HCV RNA viral load m easurem ent o f greater than 5.9 
lo g l0cp/ml predicted progression to AIDS and all-cause m ortality (H errero-M artinez et al
2002).
1.3.5 Treatm ent
Currently available treatm ent is not suitable for children less than 3 years o f  age (Jacobson 
et al 2002), and although prom ising results have been obtained in older children treated 
with a com bination o f  peg-IFN  and ribavirin this com bination therapy has not been 
rigorously evaluated in younger children (W irth et al 2005). A dditionally, in children there 
are issues relating to the side effects o f IFN treatm ent and specifically its negative effect on 
growth. However, despite this, there is a low rate o f treatm ent discontinuation in paediatric 
treatm ent trials (Fischler 2007).
1.4 Natural history o f paediatric HCV infection
M ost available inform ation about paediatric HCV infection is derived from a limited 
num ber o f  cohorts o f  vertically infected children, who were followed up after their m others
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were identified as infected during screening in pregnancy (Newell and Pembrey 2002, Seef 
1997, EPHN 2000, Ferrero et al 2003, Resti et al 2003, EPHN 2005a). The natural history 
o f HCV acquired parenterally during childhood rem ains unqualified due to the small 
numbers o f  children infected in this way and the limited longitudinal studies available. 
A dditionally, the asym ptom atic nature o f  HCV infection in childhood means that a great 
many parenteral HCV infections likely remain undiagnosed until much later in adolescence 
or adulthood.
At present, the duration o f  follow-up o f vertically HCV -only infected children is too short 
to determ ine long-term  disease progression, but three m odalities in the natural history o f 
vertically acquired HCV infection have been identified; an estim ated 20% o f children may 
clear infection, 50% will develop chronic asym ptom atic infection (interm ittent viraemia, 
usually norm al A LT levels and hepatom egaly rarely) and 30% will develop chronic active 
infection (persistent viraem ia, frequently abnormal ALT levels and in some cases 
hepatom egaly) (EPHN  2005a). Evidence suggests that chronic HCV acquired parenterally 
in childhood is m ild w ith a low rate o f progression even after 20 years o f  infection and that 
eradication o f  HCV w ithout treatm ent is more com mon than in patients acquiring infection 
in adulthood (Vogt et a l 1999). Overall, HCV is considered to be a slow -m oving fibrotic 
disease (Guido et al 2003).
The literature relating to the natural history o f  paediatric HCV infection focuses on patterns 
and clearance o f  viraem ia, ALT levels and progression to liver fibrosis. Patterns o f 
viraem ia vary over tim e and so assessing difference in positivity can be problem atic; 
however, in a recent study 44%  o f  105 vertically HCV infected children were found to have
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persistently positive HCV RNA PCR test results (EPHN 2005a). A com parative figure for 
parenterally infected children is not available.
Clearance o f  viraem ia has been reported in paediatric studies, however, the range o f 
estim ates for viral clearance in both vertically and parenterally infected children is wide, 
ranging from 0-93%  and 13-55% respectively, though two thirds o f these studies include 
fewer than 20 children (EPH N 2000, Vogt et al 1999, Ni et al 1994, Bortolotti et al 1997, 
Palom ba et al 1996, O ’Riordan et al 1998, Ceci et al 2001, M atsuoka et al 1994, 
Rerksuppaphol et al 2004, Sasaki et al 1997, Giacchino et al 1998) (Table 1.1). In a recent 
European study, 21%  o f  155 vertically infected children were found to have cleared 
viraemia, at a m edian age o f  14.9 m onths (EPHN 2005a). In another study, 67 HCV- 
infected children who had acquired infection during preoperative blood transfusions were 
followed up and viral clearance occurred in 45% (Vogt et al 1999). In a direct com parison 
o f clinical outcom es in vertically and transfusion infected children, viral clearance was 13% 
and 27% respectively but this difference was not statistically significant (Rerksuppaphol et 
al 2004). A dditionally, children vertically coinfected with both HIV and HCV appear to be 
considerably less likely to clear their HCV infection than those infected with HCV only 
(EPHN 2005a).
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Table 1.1 C learance o f HCV viraem ia in published paediatric studies
Study details No. HCV infected 
children
Mode of acquisition 
of HCV infection
Proportion clearing 
HCV viraemia 
(95% Cl)
European Paediatric 
HCV Network 2005
155 vertical 21% 15.1 -2 8 .6 % )
Rerksuppaphol et al 
2004
16 vertical 13% 1 .6 -3 8 .3 % )
Resti et al 2003 62 vertical 19% 10.4-31.4%)
Ceci et al 2001 30 vertical 93% 7 7 .9 -9 9 .2 % )
Tovo et al 2000 104 vertical 17% 10 .6 -26 .0% )
Giacchino et al 1998 9 vertical 33% 7.5 -  70.1%)
Bortolotti et al 1997 14 vertical 14% 1 .8 -4 2 .8 % )
Sasaki et al 1997 11 vertical 45% 16 .7 -76 .6% )
Palomba et al 1996 7 vertical 0
Vogt et al 1999 67 parenteral 45% 3 2 .6 -5 7 .4 % )
Rerksuppaphol et al 
2004
15 parenteral 18% 4 .3 -4 8 .1 % )
O ’Riordan et al 1998 12 parenteral 42% 15 .2 -72 .3% )
Sasaki et al 1997 17 parenteral 18% 3 .8 -4 3 .4 % )
N i et al 1994 8 parenteral 13% 0.3 -  52.7%)
Matsuoka et al 1994 22 parenteral 55% 3 2 .2 -7 5 .6 % )
ALT levels have been shown to peak (up to 5 tim es the level o f norm al) early in life in 
vertically infected children; in 70 vertically HCV infected children, ALT levels peaked 
during the first 6 m onths in 37% and between 6 and 12 m onths o f  age in 63% (Resti et al
2003). This was also seen in another recent European study w here ALT levels in 187 HCV- 
only infected children were shown to peak in the first 2 years o f  life (EPHN 2005a).
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Additionally, this study found at least one abnormal ALT level (> 40U I/L) in 44% o f 
children and an abnorm al A LT level more than 75% o f  the time in 33% o f  children (EPHN 
2005a). Rerksuppaphol et al found persistently abnormal ALT levels (>55IU/1) in 7% o f  15 
parenterally infected children and in 25% o f 16 vertically infected children (Rerksuppaphol 
et al 2004). This suggests that elevated ALT levels may be m ore frequent in vertically 
infected children but it is im portant to highlight the different definitions o f ‘abnorm al' used 
to assess ALT levels and the difficulties in subsequent com parisons between studies.
In a study o f 112 children living in Italy and Spain with chronic HCV infection acquired 
before 10 years o f  age from any source, 78% had fibrosis during a m edian o f  seven years o f 
infection (Guido et al 2003) and similarly, 83% o f 224 HCV infected children from Spain, 
Italy and Belgium with vertical or parenteral HCV exposure, showed progression to chronic 
infection during a m ean o f  six years o f follow-up (Jara et al 2003). In the former study, 
fibrosis stage was positively associated with age at biopsy and duration o f  infection with 
83% o f  patients w ith fibrosis infected for longer than ten years (Guido et al 2003). The 
relationships betw een A LT level, gender, HCV genotype, route o f  infection and 
developm ent o f  fibrosis are unclear but in a study o f 112 parenterally and vertically 
infected European children, these factors did not determ ine fibrosis stage (Guido et al 
2003).
Once chronic infection has developed, the source and time o f  infection is reported as not 
associated with serological or histological features (Jara et al 2003). Two percent o f 
children with chronic HCV infection acquired vertically and parenterally were found to 
develop severe hepatitis and cirrhosis over a mean period o f  6.2 years o f  follow-up in a
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study o f 224 children (Jara et al 2003); persistent liver dam age was found in most o f these 
children which suggests that progression to liver disease should be expected in chronically 
infected children who thus require close monitoring. This is highlighted by the higher rate 
o f fibrosis seen in adolescents in com parison to younger children (Jara et al 2003). In 
contrast to previously m entioned studies on clearance o f  viraem ia, a study o f  HCV natural 
history in perinatally infected children suggested that clearance o f  the virus was unlikely 
and that most children w ould develop chronic HCV, despite intervals o f  rem ission o f 
inflam m atory activity seen in some children (Palom ba et al 1996). This was also shown in 
a study o f  vertically infected children where 81% o f  62 children were found to develop 
chronic HCV (Resti et a l 2003).
1.5 G lobal epidem iology and biology o f Human Im m unodeficiency Virus (HIV) 
infection
The hum an im m unodeficiency virus (HIV) is the causative agent o f  acquired immune 
deficiency syndrom e (A ID S) w hich is characterised by opportunistic infection and cancers 
associated with the im m une system  (Barre-Sinoussi et al 1983, G ottlieb et al 1981). HIV is 
a ribonucleic acid (RN A) virus which prim arily targets the CD4 cells o f  the im mune system 
and prim ary infection is associated with a reduction in CD4 cells and an increase in plasm a 
HIV RNA viral load w ithout clinical m anifestations (Ho et al 1995). In general there are 
three stages o f  HIV infection; rapid viral replication lasting several weeks after which an 
im mune response, which may be accom panied by sym ptom s, occurs and HIV antibodies 
are produced (seroconversion), followed by a clinically asym ptom atic period during which 
viral replication continues and finally clinical sym ptom s develop. This period from primary 
infection lasts approxim ately ten years in untreated persons, following which the untreated
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HIV infected person develops AIDS and usually dies w ithin two years (M unoz et al 1989, 
G oedert et al 1989, M ocroft et al 1997, Rothenberg et al 1987, Zaba et al 2004).
In 2007 the estim ated num ber o f people living with HIV w orldw ide was 33.2 m illion with
2.5 m illion new infections and 2.1 m illion AIDS-related deaths in 2007 alone. The majority 
o f people living with HIV (67%  o f 33.2 million) and the largest group o f those newly 
infected with HIV (38%  o f 2.5 m illion) live in sub-Saharan A frica and 61%  o f  those living 
with HIV in this region are w om en (UNAIDS 2007. In Europe the highest rates o f newly 
diagnosed HIV infection are in the East (211 per m illion people) in com parison with the 
lower rates in W estern Europe (83 per m illion people) and the lowest rates o f all in Central 
Europe (9 per m illion people). In Eastern Europe the predom inant mode o f  transm ission 
continues to be injecting drug use, although heterosexual transm ission is on the increase, 
while in Central and W estern Europe heterosexual transm ission rem ains the principal route 
o f infection (EuroH IV  2007).
1.6 A cquisition o f paediatric HIV infection
Paediatric HIV infection occurs predom inantly via m other-to-child transm ission which 
may occur before (across the placenta), during (via m icrotransfusions during labour), and 
after delivery (through breastfeeding) (Nduati et al 2000, Newell 1998). The most 
im portant factors associated with an increased risk o f M TCT o f  HIV are maternal plasm a 
HIV RNA viral load, vaginal delivery, and mode and duration o f  breastfeeding (Thorne and 
Newell 2000, W ilfert and Stringer 2004, Scarlatti 2004, M ofenson 2003). Elective 
caesarean section delivery before onset o f labour and rupture o f  m em branes, prophylactic 
antiretroviral therapy during pregnancy, intrapartum and/or neonatally, and breastfeeding
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avoidance, independently, substantially reduce m other-to-child transm ission rates, (Thorne 
and Newell 2000) which range from 15% to 40% w ithout intervention. In settings where all 
interventions can be safely im plem ented, the advent o f  highly active antiretroviral therapy 
(HAART) has reduced the HIV vertical transm ission rates to below  2% (ECS 2006, 
W arszawski et al 2008).
Less is known about paediatric HIV infection acquired parenterally via receipt o f  infected 
blood or blood products or contact with non-sterile hospital instrum ents despite an 
estim ated 80,000 to 160,000 individuals (children and adults) infected in this way annually 
(Kane et al 1999). In the early years o f  the HIV epidemic parenteral acquisition o f  infection 
was most com m on am ong specific subgroups like haem ophiliacs who received large 
amounts o f transfused blood or associated products (Jones in M ok and Newell 1995). 
However, this group o f  parenterally infected children is now relatively small due to the 
im plem entation o f  donor screening in most developed countries in the early 1990s but there 
remain groups o f children infected through unsafe medical injections and new infections 
are occurring globally w ith often large numbers o f children infected from  a single source 
(Bagchi 2007, M orris 2006, V isco-Com andini et al 2002, Yerly et al 2001, Popova et al 
1999, Hersh et al 1993, Pokrovski 1992, Hersh et al 1991). Parenterally HIV infected 
children are unique both in term s o f  the way in which they were infected and the fact that 
they often have significant com orbidities given the circum stances under which infection 
occurred (Popova et a l 1999) (Table 1.2). The published literature on parenterally HIV 
infected children w orldw ide is sparse as the m ajority o f  outbreaks are in less developed 
countries where surveillance and reporting o f  infected cases is poor. However, increases in 
surveillance techniques dem onstrate the extent o f the parenteral epidemic. For exam ple, in
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Romania national AIDS case surveillance definitions were revised in 1989 and reported 
AIDS cases rose from 13 in 1989 to 1168 by the end o f  1990. 93.7%  o f  these 1168 AIDS 
cases were children o f  whom 1086 (99.3% ) were under 4 years o f  age and 683 (62.4% ) 
were abandoned children living in public institutions (Hersch et al 1991). Four hundred and 
twenty three o f  the paediatric cases were the result o f blood transfusions and infection via 
im proper use o f  needles and syringes is strongly suspected to be the cause o f most o f  the 
other cases (Hersh et a l 1991). O ther large outbreaks are being discovered and recent 
screening in Kazakhstan has identified 72 HIV infected children and although inform ation 
is scarce, it is reported that six o f these children have died to date. Recent estim ates from 
Kazakhstan suggest that a m inim um  total o f 2700 children may have been infected with 
HIV by contam inated blood transfusions or nosocomial transm ission (M orris 2006).
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Table 1.2 Details of published studies on parenterally HIV infected children
Study author and 
publication year
Setting Details
M orris 2006 Kazakhstan children Retrospective screening has identified 72 children 
with HIV, 6 o f whom have died. Screening continues 
and an estimated minimum total o f  2700 children 
could be HIV infected.
Yerly et al 2001
Popova et al 1999
Libyan children -  a sub-sample o f  a larger 
group o f  approximately 400 children infected 
with HIV from a hospital source.
Russian children
148 children screened for HIV, HCV and HBV 
infection. 147 HIV infected, 47% and 33% o f whom 
were also HCV and HBV infected respectively.
124 nosocomial infections identified during hospital 
treatment. Approx 9 years after infection, 26% o f 124 
children had died.
Hersch et al 1993
Hersch et al 1991
Abandoned Romanian children living in public 
institutions.
Romanian surveillance
101 children screened for HIV infection, 20% 
infected, all less than 4 years o f  age.
Revised surveillance techniques resulted in 1168 
cases o f AIDS reported by 1990. 1094 in children 
under 13 years o f age. 1086 younger than 4 years of 
age and 683 abandoned and living in public 
institutions.
1.7 Natural and treated history o f paediatric HIV infection
The characteristics o f  paediatric HIV in vertically infected children has been well 
docum ented both in treated and untreated individuals (Blanche et a l 1997, ECS 2004, FX3S 
Pediatrics 2001, Thorne et al 2002, Pliner et al 1998, Palum bo et al 1998, Dunn et al 2003, 
Prendergast et al 2007, Little et al 2007). In the absence o f  effective antiretroviral therapy 
(ART) or other supportive prophylactic m anagem ent, a quarter o f vertically HIV-only 
infected children will have progressed to serious disease or death by the age o f  1 year, with 
a 40%  cum ulative incidence o f HIV-related disease or death by 6 years o f  age (The French 
Pediatric HIV Infection Study Group and European Collaborative Study 1997, ECS 2001) 
(Figure 1.1). H IV -related disease progression is measured by levels o f im m unological and 
virological m anifestations, specifically CD4 cell count and HIV RNA viral load, and the 
presence o f non-specific clinical symptoms such as hepatom egaly, splenom egaly, 
lym phadenopathy and H IV-related manifestations or opportunistic infection. HIV infection 
in children is categorised according to clinical and im munological categories defined by the 
Centres for Disease Control (CDC), last updated in 1994. These guidelines categorise HIV 
infected children in term s o f  w hether they are asym ptom atic, m ildly symptom atic, 
m oderately sym ptom atic or severely sym ptom atic (Table 1.3) and whether they have no 
im m unosuppression, m oderate im m unosuppression or severe im m unosuppression (Table 
1.4). The W orld Health Organisation also provides guidelines on clinical and 
im munological categories for the staging o f  HIV infection in children w hich are sim ilar to 
those produced by the CDC (WFIO 2005).
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Figure 1.1 Progression to CDC clinical categories in untreated vertically HIV infected
children (ECS 2001)
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Since recom m endations for the use o f more active com bination antiretroviral ARTs were 
introduced in 1997-98 and paediatric antiretroviral therapy became more widely available 
for children at an earlier stage in their disease progression before serious clinical or 
immunological deterioration, children have been shown to be substantially less likely to 
progress to serious H IV-related diseases or death and most HIV-infected children now 
treated with com bination ART remain symptom free for at least ten years (ECS 2001) 
(Figure 1.2).
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Figure 1.2 Progression to CDC clinical categories in treated vertically HIV infected 
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Table 1.3 Centres for Disease Control Clinical categories for HIV infected children (CDC 1994)
CDC Clinical Category_________________ Definition
Category N (asymptomatic) No signs or symptoms considered to the result o f HIV infection or only one o f the conditions listed
in Category A
Category A (mildly symptomatic) Two or more o f the following conditions but none o f the conditions listed in Categories B and C
- Lymphadenopathy larger than 0.5cm at more than 2 sites
- Hepatomegaly
- Splenomegaly
- Dermatitis
- Parotitis
- Recurrent or persistent upper respiratory infection, sinusitis or otitis media
Category B (moderately symptomatic) Symptomatic conditions other than those listed for Category A or C that are attributed to HIV 
infection. Some examples include but are not limited to
- Anaemia, neutropenia or thrombocytopenia persisting for longer than 30 days
- Bacterial meningitis, pneumonia or sepsis
- Persistent oropharyngeal candidiasis in children less than 6 month o f age
- Cardiomyopathy
- Cytomegalovirus infection, w ith onset before one month o f age
- Diarrhoea, recurrent or chornic
- Hepatitis
- Recurrent herpes simplex virus stomatitis
- Herpes simples virus bronchitis, pneumonitis or oesophagitis with onset before one month of age
- Herpes zoster involving at least two distinct episodes or more than one skin area
- Leiomyosarcoma
- Lymphoid interstitial pneumonia or pulmonary lymphoid hyperplasia complex
- Nephropathy
- Nocardiosis
- Persistent fever lasting longer than one month
- Toxoplasmosis, onset before one month o f age
- Disseminated varicella
Category C ( severely symptomatic) Any condition listed in the 1987 surveillance case definition of AIDS, with the exception of
lymphoid interstitial pneumonia
Table 1.4 Centres for Disease Control Immunological categories for HIV infected children (CDC 1994)
Children aged 1 to 5 years Children aged 6 to 12 yearsCDC immunological category
Category 1
(no immunosuppression) 
Category 2
(moderate immunosuppression) 
Category 3
(severe immunosuppression)
Definition
Children younger than 12 
months of age
CD4 cell count greater than 
1499 cells/mm3
CD4 cell count between 740 and 
1499 cells/mm3 
CD4 cell count below 
750 cells/mm3
CD4 cell count greater than 
999 cells/mm’
CD4 cell count between 500 
and 999 cells/mm1 
CD4 cell count below 
55 cells/mm1
CD4 cell count greater than 
500 cells/mm3
CD4 cell count between 200 and 
499 cells/mm3 
CD4 cell count below 
200 cells/mm3
Few studies have reported inform ation on parenterally HIV infected children and therefore 
the natural history o f  children infected in this way and the impact o f  underlying morbidity 
and age at infection rem ains unqualified. Popova et al presented inform ation on 124 
nosocom ially infected children from Russia o f  whom 33 (26% ) had died 9 years after 
infection. They suggested that in the first year o f  life, HIV infection in these children could 
rapidly progress to AIDS due to their background o f  often severe disease prior to 
contracting HIV (Popova et al 1999).
A ssociations between m ode o f  acquisition and/or age at acquisition o f infection and HIV 
disease progression are difficult to interpret because o f  confounding factors including 
com orbidities, and delayed diagnosis after parenteral infection. A study o f  UK 
haem ophiliacs infected with HIV showed a higher survival rate ten years after 
seroconversion, a longer tim e from infection to AIDS diagnosis and longer survival after 
AIDS diagnosis in patients seroconverting before 15 years o f  age com pared to those 
seroconverting at older age groups up to 55 years o f age (Darby et al 1996). M ore recently, 
data from over 13000 parenterally HIV infected individuals were analysed and the 
estim ated survival o f  children infected before 14 years o f  age was higher than in other age 
categories and sim ilar in those infected before five years o f age and those infected between 
five and 14 years o f  age (Collaborative Group on AIDS incubation and HIV survival 2000).
It may therefore be hypothesised that, as is found in adults, the earlier a child is infected 
with HIV the slower the progression to severe disease. However, it is biologically plausible 
that those vertically infected or infected early in infancy may elicit a faster and more severe
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disease progression as a result o f  an under-developed im mune system at the time o f 
infection. Several studies have investigated this to a certain extent by looking at differences 
in the disease progression o f vertically infected children acquiring infection in utero and 
those acquiring infection post-partum  or via breastfeeding. One study dem onstrated that 
children who were infected in utero had a significantly lower mean initial HIV RNA viral 
load after infection and a more gentle decrease in viral load than those who were infected 
through breastfeeding. H owever in m ultivariable Cox Proportional Hazards analysis, the 
tim ing o f  infection was not associated with the risk o f progression to AIDS or death in 
infected children (Rouet et al 2003). Similarly, Shearer et al dem onstrated differences in 
initial peak HIV RNA viral load between those vertically infected early or and those 
infected late but this difference disappeared shortly after birth and both groups 
subsequently responded to the virus in a similar way (Shearer et a l 1997). However, 
m ortality was significantly lower for those with late versus early vertical infection in a 
m eta-analysis study o f  m ortality in infants bom  to HIV infected m others in Africa (Newell 
et al 2004).
1.8 Treatm ent o f paediatric HIV infection
There are three classes o f  antiretroviral drugs currently available for the treatm ent o f HIV 
in children; Nucleoside Reverse Transcriptase Inhibitors (NRTIs), N on-N ucleoside Reverse 
Transcriptase Inhibitors (NNRTIs) and Protease Inhibitors (Pis) (Table 1.5).
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Table 1.5 Principle antiretroviral drugs available for use in children
NRTIs NNRTIs Pis
Abacavir Efavirenz Lopinavir-R itonavir
Lamivudine N evirapine N elfinavir
Didanosine A m prenavir
Stavudine Ritonavir
Tenofovir Fosam prenavir
Zalcitabine
Zidovudine
Em tricatabine
Saquinavir
There are several guidelines for the treatment o f HIV infected children from organisations 
including CDC, Paediatric European Network for the treatm ent o f AIDS (PENTA) and 
W HO in addition to individual country national guidelines, for exam ple CHIVA in the UK, 
but all are sim ilar in that they recom mend different tim es for initiation o f  treatm ent 
depending on the age o f  the child and their clinical and im munological status (Table 1.6) 
and different therapy regim es depending on the age o f  the child (Table 1.7). The debate as 
to when to initiate treatm ent stems from the need to balance the prevention o f disease 
progression against the issues o f  adherence, life-long treatm ent dependence, resistance, the 
limited available paediatric drugs and treatm ent side effects. Recent findings from the large 
South African Children w ith HIV Early A ntiretroviral Therapy Study showed that early 
initiation o f therapy resulted in 96% survival in com parison to 84% survival in those 
randomised to deferred initiation o f therapy (Violari et al 2007). Additionally, a recent 
European m ulti-centre study o f vertically HIV infected children dem onstrated a beneficial 
effect o f  HAART initiation before five m onths o f age on CD4 cell count recovery (ECS 
2006).
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category A or above (Sharland et al 2004)
Age
Infants younger than 1 year
Children 1 to 3 years of age 
Children 4-8 years of age 
Children 9-12 years of age
Children 13-17 years of age
Clinical indication for treatment 
CDC stage B or C
CDC stage C 
CDC stage C 
CDC stage C
CDC stage C
Immunological/virological indication for treatment
• All children with CD4%<25-35%
• Strongly consider children with viral load>l million cp/ml
• Many experts treat all asymptomatic infants
• All children with CD4%<20%
• Strongly consider children with viral load>250 00 cp/ml
• All children with CD4%<15%
• Strongly consider children with viral load>250 000 cp/ml
• All children with CD4%<15% but with less urgency than 
younger children
• Strongly consider in children with viral load>250 OOOcp/ml
• All adolescents with CD4 cell count between 200 and 3 
cell/mm3
Table 1.7 Sum m ary o f PENTA recom m endations on which ART to start in children  
with CDC clinical stage B or greater (Sharland et al 2004)
Age Recommended treatment regime
Infants 2 NN RT1 + PI (Lopinavir/r or Nelfinavir) 
or
2NRTI1 + NNRTI (Nevirapine)
Children 2NRTI1 + PI (Lopinavir/r or Nelfinavir) 
or
2NRTI1 + NNRTI (Efavirenz or Nevirapine2)
Dual NRTI combination recommended: zidovudine plus lamivudine or didanosine; didanosine plus 
lamivudine; abacavir and lamivudine. D4T is not recommended as first-line therapy.
“Nevirapine would be the preferred for children under 3 years o f age
1.9 HIV coinfections
In addition to HCV, there are a number o f other viral infections which, given shared 
transm ission routes, are com m on among adults and children infected with HIV. The 
interactions betw een HIV and other infections are com plex but it is possible that 
inform ation may be gained about HIV/HCV coinfection by looking at the way these other 
coinfections present. Recent estim ates suggest that approxim ately 10% o f  HIV infected 
adults are coinfected w ith Hepatitis B virus (HBV) (Soriano et al 2006). In many resource 
rich countries, including the majority o f Europe and the United States, infants are 
immunised against HBV infection resulting in a limited population o f H IV/HBV coinfected 
children from which inform ation can be gathered. Inform ation available on HIV/HBV 
coinfection is thus predom inantly based on adult populations, w hich could be extrapolated 
to inform paediatric research. However, differing disease outcom es have been reported 
from vertically infected children in com parison to older children, possibly indicating 
differences between HIV/HBV coinfected adults and children (HPPM CS 2006). Evidence 
from adult studies suggests that the effect o f HBV coinfection on HIV disease progression 
is minimal with no im pact on progression to AIDS or virological and im munological
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responses to HAART. (Lessell and Leen 2004, Puoti et al 2002, Cooley and Sasadeusz 
2003, Konopnicki et al 2005, N unez and Soriano 2005). Despite this, studies have shown 
an increase in liver-related m ortality among HIV/HBV coinfected patients in com parison to 
those HIV-only infected and higher rates o f chronic HBV infection and HBV replication in 
coinfected patients (Konopnicki et al 2005, Puoti et al 2002). Despite this seemingly 
detrimental effect o f  HIV infection on HBV progression, ALT levels have been found to 
remain lower than in HBV only infected individuals (Puoti et al 2002). It is biologically 
plausible that the w eakened immune system in HIV infected individuals may limit their 
ability to mount an im m une response to HBV infection and therefore the aspects o f  HBV 
infection which norm ally result in destruction or inflam m ation o f liver cells by the body’s 
own im mune system may occur to a lesser extent. Given the sim ilarities between HBV and 
HCV infection, it may be possible that similar responses occur in HIV/HCV coinfected 
individuals.
In contrast to HIV/HBV  coinfection, research focussing on H IV/Cytom egalovirus (CM V) 
coinfection is com m on am ong paediatric populations given the possible vertical 
transm ission o f  both viruses and the increased likelihood o f  CM V infection in HIV infected 
versus uninfected infants (Kovacs et al 1999, Doyle et al 1996). In the m ajority o f cases, 
CM V is transm itted through breastfeeding post-partum , although a small num ber o f 
transm issions occur inutero and the clinical consequences o f  CM V acquired in this way are 
worse. As HIV is predom inantly transm itted from mother to child intrapartum the majority 
o f children with CM V/HIV coinfection will not have acquired both infections at the same 
time and this may im pact on the disease progression o f both or either infections. However, 
the im pact o f CM V on HIV disease remains controversial. Evidence suggests that children
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with vertically acquired HIV who become coinfected with CM V in utero or infancy, in 
addition to having higher rates o f  central nervous system disease, also have significantly 
higher rates o f  HIV disease progression and immune deficiency than those with HIV only 
(Kovacs et al 1999, Doyle et al 1996). Furthermore, children with sym ptom atic HIV 
disease were found to have a higher prevalence o f active CM V infection com pared to those 
with asym ptom atic disease and in those asym ptom atic children, CM V infection 
significantly increased m ortality (Frenkel et al 1990). CM V is an A ID S-defining illness 
and, in adults, usually occurs due to a resurgence o f previously acquired latent infection. 
However, acquisition o f  CM V early in infancy in children means that the role o f HIV in the 
clinical presentation o f  CM V likely differs to that in adults and it rem ains unclear from 
these studies w hether im m une deficiencies in HIV infected children allow  the em ergence o f 
CMV disease or w hether CM V infection directly causes more rapid HIV disease 
progression (Chandw ani et al 1996). In contrast, a recent Spanish study reported no 
association betw een H IV/CM V coinfection acquired in the first year o f life and HIV 
disease progression, im m unosuppression or survival, further em phasising the com plexity o f 
HIV/CM V coinfection and HIV coinfections in general (M arin Gabriel et al 2007).
1.10 H IV/H CV coinfection
HIV and HCV share transm ission routes, specifically injecting drug use and blood 
transfusion, m aking coinfection relatively com mon, although sexual transm ission o f HCV 
is much less frequent than for HIV (Bica et al 2001, Bonacini and Puoti 2000, Quirishi et al 
2003, Rosenthal et al 2003). With ART for HIV infection im proving and prolonging life in 
infected individuals (Bica et al 2001, Rosenthal et al 2003, Rockstroh and Spengler 2004),
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the prevalence and effect o f  secondary infections and com orbidities such as HCV has 
increased in adult HIV infected populations (Bonacini and Puoti 2000). Symptoms related 
to HCV infection were not previously observed in coinfected patients because progression 
to liver disease or associated cancers can take as long as 20 years after HCV infection and 
life expectancy in HIV infected individuals was short. HCV-related m ortality has become a 
leading cause o f death in HIV-infected adults (Braitstein et al 2004, Sulkowski et al 2005). 
The extent to which this situation is true in coinfected children is unclear.
1.11 Acquisition of H IV /H C V coinfection in children
Both HIV and HCV can be vertically transmitted from an infected mother to her child, but 
in Europe the num ber o f  coinfected children is small. Vertical transm ission o f  HIV occurs 
more often from w om en coinfected with HIV and HCV than from those infected with HIV 
only (Giovannini et a l 1990, Hershow et al 1997, Paccagnini et a l 1995, Papaevangelou et 
al 1998, Thom as DL et al 1998, Tovo et al 1997). For exam ple, in a study o f nearly 500 
m other-child pairs, HIV transm ission occurred from 16% (53/326) o f mothers infected with 
HIV only, com pared with 26%  (42/161) o f HIV/HCV -coinfected women, suggesting that 
HIV/HCV coinfection nearly doubles the HIV M TCT rate (odds ratio (OR) 1.82, p=0.001) 
(Hershow et al 1997). However, the sample sizes and transm ission rates used in these 
studies often vary considerably; furthermore, some studies have not com pared transm ission 
from coinfected m others with HIV-only infected mothers. Reported HIV transm ission rates 
from H IV /HCV-coinfected mothers range from 13.3% to 30% in settings where 
interventions to prevent m other -to -ch ild  transm ission o f  HIV are available and where few 
HIV-infected women breastfeed (Paccagnini et al 1994, Papaevangelou et al 1998, Thom as
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DE et al 1998, Tovo el al 1997). The lowest HIV transm ission rates reported, from the 
most recent studies, likely reflect the use o f zidovudine in pregnancy to reduce M TCT 
(Connor el al 1994). There have been few studies to assess the effect o f HIV/HCV 
coinfection on HIV transm ission rates in the past five years. Despite one recent study 
finding the HIV M TCT rate to be 6.2% (10/161), lower than the 11.2% (55/491) o f 
coinfected women from the same study investigated between 1992 and 2000 (EPHN 2001, 
TPHN 2005c), the im pact o f HAART on the prevention on HIV M TCT, which became 
widely used after 2000, in a m aternally H IV/HCV-coinfected population remains unclear. 
The effect o f HIV/HCV coinfection on vertical transm ission o f  HCV has received more 
recent attention than that o f  HIV transmission. There is substantial evidence to support an 
increase in HCV vertical transm ission from mothers coinfected with HIV com pared with 
mothers infected with HCV only. One study including more than 100 children born to 
HIV/HCV coinfected m others found HCV transm ission rates to be significantly higher with 
a 2.3 times increase (95%  Cl 1.6-3.4) (EPHN 2001). Furtherm ore, acquisition o f HCV 
infection is more likely in infants who also become infected with HIV (Papaevangelou et al 
1998, Thom as et al 1998), which implies that transm ission o f HIV in utero may facilitate 
transm ission o f  HCV. However, it is also plausible that coinfected w om en who transm it 
HIV have both high HIV RNA and HCV RNA viral loads and are thus prone to transm it 
both viruses. Treatm ent during pregnancy to prevent HIV transm ission by lowering HIV 
RNA viral load may also be vital to the prevention o f M TCT o f both these viruses (England 
et al 2006).
Few studies have focussed on M TCT o f  HIV/HCV coinfection. Reported transm ission rates 
range from 3.6% to 9.5%  (Papaevangelou et al 1998, Thom as DL el al 1998, Nigro et al
1997), with the lower transm ission rates from the two studies including more than 150 
coinfected mothers (Thom as et al 1998, Tovo et al 1997). This evidence suggests that, 
while transm ission o f HCV or HIV from coinfected mothers is more likely than from singly 
infected mothers, the M TCT o f both viruses sim ultaneously occurs less frequently than 
single-virus transm ission from a coinfected mother.
Parenteral acquisition o f HIV/HCV coinfection is rarely reported yet given the ways in 
which children acquire HIV or HCV parenterally it is likely that parenteral acquisition o f 
coinfection is under-reported. For example, 47% o f 147 parenterally HIV infected children 
were found to be coinfected with HCV in a study carried out on a sub-group o f Libyan 
children known to be nosocom ially infected with HIV (Yerly et a l 2001).
1.12 Disease progression in H IV/H CV coinfected children
In adult studies, evidence o f  the im pact o f HIV/HCV coinfection on HIV disease is limited 
in com parison to that on HIV only infected adults. W hereas in four studies including 1 lb- 
1685 coinfected people there was no evidence o f  an effect o f HCV coinfection on 
progression to HIV disease (Staples et al 1999, Dorrucci et al 1995, Sulkowski et al 2002, 
Rockstroh et al 2004), in two further studies with 650-1157 coinfected patients, HIV 
progression was substantially accelerated (Carlos et al 2004, Grueb et al 2000). 
Specifically, in the study by Carlos and co-workers in Spain on 902 HIV infected patients, 
72% (650/902) o f  whom were also infected with HCV, CD4 cell count two years after the 
initiation o f  therapy was significantly lower in coinfected individuals com pared with HIV- 
only infected individuals (p<0.001) (Carlos et al 2004). In response to treatment, the mean
increase in CD4 cell count over a two year period was significantly lower than in HCV- 
coinfected individuals (11%  v.v 19%, p<0.05) and the mean decrease in plasm a HIV RNA 
over the same period was significantly lower in coinfected patients than in HIV-only 
infected individuals (5%  v.v 54%, p<0.05), although this HIV RNA viral load association 
was not significant in m ultivariable analysis adjusting for sex, age, CD4 cell count, use o f 
HAART, and adherence to therapy (Carlos et al 2004). D ifferences in the effect o f 
HIV/HCV coinfection on HIV disease progression between studies may be partly explained 
by suggestions that coinfected individuals with HCV genotype 1 are at an increased risk o f 
progression to A IDS-related m ortality compared with those with HCV non-genotype 1, 
although this relationship is not yet supported by strong evidence (Yoo et al 2005).
The effect o f  paediatric HIV/HCV  coinfection on progression o f  HIV disease remains 
unclear. Only two studies (both around ten years old) have investigated this area in children 
to date and no differences betw een coinfected and HIV-only infected children were 
reported (Papaevangelou et a l 1998, Nigro et al 1997), although plasm a HIV-RNA viral 
load at six m onths o f age in coinfected children was higher than in infants with HIV 
infection only (a non-statistically significant difference) (Papaevangelou et al 1998).
In HCV infected adults it is w idely acknowledged that coinfection with HIV accelerates the 
course o f H CV -associated liver disease progression, particularly in patients who are more 
im munodeficient. HIV/HCV coinfection is thus associated with increased liver fibrosis 
progression, increased rate o f liver decom pensation, cirrhosis, hepatocellular carcinoma, 
and liver-related mortality, particularly due to the hepatotoxicity o f  many drugs used to 
treat HIV infection (Bonacini and Puoti 2000, Rosenthal et al 2003. Rockstroh and
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Spenglcr 2004, M ohsen et al 2002, Nelson and Thom as 2001, Tedaldi et al 2003, Fuster et 
al 2004, M athews and Bhagani 2003). However, in HCV only infected children it is 
generally assumed that progression o f HCV-related disease is slower than in HCV only 
infected adults (although there are few studies where timing o f infection in adults is known 
with any precision); the same may be true o f  HIV/HCV coinfected children (Guido et al 
1998, G arcia-M onzon et al 1998).
Only four studies have reported results on progression o f  HCV in coinfected infants, with 
between two and 26 coinfected children included. Three studies report chronically evolving 
hepatitis in at least 50% o f  coinfected children (Papaevangelou et al 1998, Thom as et al 
1998, N igro et al 1997), which is similar to that found in HCV-only infected children 
(EPHN 2005a). One study reported the proportion o f coinfected children with persistently 
abnormal ALT levels (>40 UI/1) to be similar to that in HCV-only infected children, but the 
proportion o f coinfected children with a high proportion o f positive HCV RNA PCR results 
was greater than in H CV-only infected children, albeit not significantly so (EPHN 2005a). 
Overall, insufficient details and a lack o f formal com parisons limit conclusions about HCV 
disease progression in the context o f  paediatric HIV/HCV coinfection (England et al 2006).
1.13 Treatm ent o f H IV/H C V  coinfected children
The current guidelines for HIV/HCV coinfection treatm ent in adults vary depending on the 
stage at which HIV and/or HCV is diagnosed. If patients are identified before HIV therapy 
is indicated then HCV treatm ent should be considered in order that a better response to HIV 
therapy might be elicited once necessary (as HCV treatm ent is a one-off course it is
51
anticipated that the infection could be eliminated before HIV progression indicated 
treatment). If coinfection is diagnosed at a point where the patient requires, or is currently 
receiving, HIV therapy then this treatm ent should be optim ised before FICV treatm ent is 
considered (England et al 2006).
To date, there are no studies focussing specifically on the treatm ent o f  either HCV or HIV 
in children coinfected with both viruses. Decisions regarding the treatm ent o f coinfection in 
these children are based on adult data or extrapolate recom m endations for the treatm ent o f 
paediatric HIV or HCV alone. The concom itant use o f ART and anti-HCV therapy is 
com plicated by the interactions o f many drugs as most HAART agents have the potential to 
cause hepatotoxicity (N elson et al 2005). Treatment with IFN alfa-2b plus ribavirin is most 
com m only recom m ended for effective HCV treatment in children. Although recent trials 
show prom ising results for the use o f  pegylated IFN (W irth et al 2005), ribavirin can 
enhance the phosphorylation o f  didanosine, thus increasing the risk o f  associated toxicity 
and therefore the use o f  both these agents simultaneously should be avoided (England et al 
2006). Similarly, ribavirin and zidovudine are both associated with anaem ia and, where 
possible, should not be adm inistered together (England et al 2006). Didanosine and 
zidovudine are both m ajor com ponents o f many antiretroviral regim ens, especially those 
available to children, where the hepatotoxic nature o f  many HIV drugs is more problem atic 
given the limited num ber o f  paediatric treatm ents available. It is therefore harder to find 
paediatric anti-HIV therapy that does not exhibit hepatotoxic properties. All NNRTIs are 
hepatotoxic, especially nevirapine, which can cause or intensify liver disease in HCV- 
infected children (Alberti et al 2005). Pi-based com bination antiretroviral therapy regim ens 
including Lopinavir, Ritonavir, Nelfinavir, and Indinavir have inconsistently been reported
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as associated with exacerbation o f chronic liver disease, albeit in rare cases (Alberti et al 
2005). Treatm ent com binations including NRTIs are more appropriate, although some have 
been shown to cause severe hepatotoxicity in rare cases (W orking group o f ART and 
medical m anagem ent o f  HIV infected children 2006). At present there are no guidelines on 
how to resolve these issues in children and so the m anagem ent o f  paediatric coinfection 
remains difficult and continues to be based on guidelines for the treatm ent o f HIV and 
HCV separately (England et al 2006).
IFN-based HCV treatm ent is not recommended in children before 3 years o f  age but HIV 
treatm ent may be started im mediately in infants with clinical sym ptom s and severe 
im munological and virological im pairm ent and increasingly in those w ithout symptom s 
(W orking group o f  A RT and medical m anagement o f HIV infected children 2006, Violari 
et al 2007). This m eans that in many cases HIV treatm ent will com m ence long before HCV 
therapy can be considered (Alberti et al 2005). As HCV infected children exhibit few 
clinical sym ptom s in the first ten to 15 years and are therefore unlikely to require HCV 
treatment, HIV treatm ent may continue for many years w ithout the need for concom itant 
HCV therapy. However, as it remains unclear whether HIV coinfection increases HCV 
disease progression in children, the possibility that HCV treatm ent in this group may be 
necessary earlier than in HCV-only infected children must be considered. As with adult 
populations, HIV treatm ent in HIV/HCV coinfected children should be initiated as per 
guidelines for HIV-only infected children. However, close m onitoring is essential to ensure 
that HIV treatm ent is not exacerbating HCV progression and the use o f  nevirapine should 
be avoided where possible. If and when HCV therapy becom es necessary, care should be 
taken to ensure than CD4 cell counts are above the recom m ended levels for the initiation o f
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HIV therapy before initiation o f interferon, which is known to lower the CD4 cell count 
(Chung et al 2004). Additionally, it may be necessary to modify the HIV treatm ent to 
ensure drug interactions, specifically between ribavirin and zidovudine or didanosine, do 
not result in increased liver toxicity and fibrosis (England et al 2006).
To date no guidelines exist as to the most appropriate non-therapeutic clinical m anagem ent 
o f children coinfected with HIV and HCV. The current guidelines from BIIIVA on 
HIV/HCV coinfection in adults suggest that, given the shared transm ission route o f both 
infections and the im plications o f coinfection on treatm ent in com parison to HIV infection 
alone, it is necessary to screen all HIV infected individuals for HCV infection (Nelson et al 
2005). Once coinfection has been established, the guidelines recom m end carrying out a 
variety o f  liver function tests in addition to HCV genotyping and HCV RNA viral load 
testing.
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2. AIM S AND M ETH O DS
2.1 Rationale for this w ork
HCV and HIV infection in children has been well docum ented in term s o f MTCT and 
progression o f vertically acquired infection (See sections 1.2, 1.4, 1.6 and 1.7). However, 
research in the context o f  parenteral infection is limited and it remains unknown w hether 
disease progression differs in children infected in utero or intra-partum  com pared with 
those acquiring infection later in infancy or childhood. Limited evidence does however 
suggest that there are some differences in the initial disease progression o f  children infected 
with HIV early or later in infancy, possibly due to infection during early im mune 
m aturation (Rouet et al 2003, Shearer et al 1997, Newell et al 2004). In light o f  these 
potential differences it is possible that parenterally infected children, who are receiving care 
based on evidence from  studies o f  vertically infected children, are not receiving optimal 
clinical m anagem ent. As the num ber o f children with parenteral infection is likely to 
continue to increase w orldw ide, improved knowledge o f paediatric HCV and HIV acquired 
by different routes and at different ages will allow treatm ent and m anagem ent to be tailored 
to a more individual level. The issues o f increasing prevalence/diagnosis o f parenterally 
acquired HIV and HCV infection and the lack o f guidelines inform ing their managem ent 
are exacerbated by the lack o f  data available on parenterally HIV or HCV infected children. 
This is largely due to the difficulties in screening or diagnosing children who may have 
been parenterally infected years previously, m eaning that biological and clinical follow-up 
information is minim al, and also due to the inadequate surveillance or data collection 
systems in resource lim ited countries where the majority o f  parenteral HIV and HCV 
infections now occur.
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In addition to HIV and HCV infection acquired singly, evidence on all aspects o f  paediatric 
HIV/HCV coinfection is limited but specifically regarding HIV and HCV disease 
progression in the context o f coinfection. As the effects o f  coinfection become more 
apparent in adult populations (Bonacini and Puoti 2000, Braitstein et al 2004, Sulkowski et 
al 2005), it is im portant to understand the impact o f HIV/HCV coinfection in a paediatric 
setting in order to inform clinical management and treatment. Additionally, investigating 
paediatric HIV/HCV coinfection according to mode o f  acquisition o f  infection (vertical or 
parenteral) will advance current knowledge in this area and add to the understanding o f the 
effect o f  differentially acquired HIV and HCV on disease progression.
As a result o f the lim ited knowledge on paediatric HIV/HCV coinfection, there are 
currently no guidelines for the clinical m anagem ent o f  this group o f children. The only 
guidelines available to clinicians are on the managem ent and treatm ent o f HIV or HCV 
singly infected children (Sharland et al 2005, EPHN 2005b) or on adult HIV/HCV 
coinfection (Nelson et al 2005) and for this reason coinfected children may not be receiving 
the optimal clinical care. Surveying current policies and practices o f European clinicians 
with regards the m anagem ent and treatment o f HIV/HCV coinfected children allows an 
assessm ent o f how these difficulties are overcom e and helps em phasise the need for 
specific guidelines for the clinical m anagem ent o f this group.
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2.2 Scientific hypothesis
a) There are differences in the biological and clinical profile o f HIV and/or HCV 
infected children according to whether they became infected vertically, via mother- 
to-child transm ission, or parenterally via contact with infected blood or blood 
products. Given the tim ing o f vertical infection during early im mune maturation, it 
is plausible that vertically infected children may respond less well to the infection 
and their subsequent disease progression my be worse.
b) The biological and clinical profile o f HIV/HCV coinfected children differs from 
that o f singly HIV or HCV infected children. An accelerated HIV disease 
progression has been observed in some adult studies com paring HIV/HCV 
coinfected individuals to those with HIV only. The extent to which differences exist 
in paediatric populations remains unknown.
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2.3 Aims and O bjectives
Aim
To investigate the effect o f mode o f  acquisition o f infection (vertical vs parenteral) on
markers o f  infection and disease progression in HCV infected, HIV infected and HIV/HCV
coinfected children.
Objectives
1. To establish age and sex specific references ranges for ALT levels in children to
better identify children with elevated ALT levels in clinical practice.
2. To com pare biological markers o f HCV infection in parenterally and vertically
infected children to clarify whether routinely collected clinical data differ by mode 
o f acquisition o f  infection.
3. To describe the natural history, allowing for treatm ent, and disease progression in
parenterally HIV infected children and assess the pattern in light o f published 
material relating to vertically HIV infected children.
4. To determ ine im m unological, virological and clinical profiles o f HIV/HCV
coinfected children, to identify and describe predictors o f  disease progression and 
quantify differences by mode o f acquisition o f  infection.
5. To investigate current European policies and practices for the clinical managem ent
and treatm ent o f  children coinfected with HIV and HCV to assess the need for 
clinical consensus and developm ent o f treatm ent and m anagem ent guidelines 
specific to this group.
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2.4 Data sources
2.4.1 European Paediatric HCV Network (EPHN)
The European Paediatric HCV N etwork was established in 1999 at a time when little was 
known about paediatric HCV. The Network specifically aim ed to estim ate HCV M TCT 
rates and timings, identify factors associated with increased risk and thus inform possible 
interventions to reduce M TCT and to elucidate the natural history o f  paediatric HCV 
infection. This European cohort study was therefore established to prospectively collect 
data from clinicians in 30 centres in ten European countries (UK, Italy, Spain, The 
Netherlands, Ireland, Sweden, Greece, Norway, Germany and Belgium). Enrolm ent o f 
m other-child pairs was based on the identification o f women diagnosed as HCV infected 
before or during pregnancy and the follow-up o f their children, or o f  children HCV 
seropositive within one m onth o f  birth for whom maternal infection could be confirmed. 
Clinicians com pleted paper study forms (Appendix 5) after routine clinical visits and sent 
these to the coordinating centre at the UCL Institute o f Child Health, London, UK. Data 
from these forms were entered into a M icrosoft Access database and checks were made for 
com pleteness, logicality and quality o f data. All mother-child pairs were given a unique 
numeric identifier and all data were anonym ously linked with no nam es appearing on any 
study forms or the study database. Data collection ceased in 2006 at which point 2272 
mother-child pairs had been enrolled and 247 HCV infected children followed-up (EPHN 
2005a, EPHN 2005c).
The inform ation collected at different stages in the follow-up process are described in Table 
2.1. M aternal inform ation was collected at enrolm ent, usually during pregnancy, on mode
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o f acquisition o f IICV infection, history o f injecting drug use and HIV infection status. 
Maternal laboratory tests carried out during pregnancy and at delivery for anti-HCV 
antibody, qualitative and quantitative HCV RNA PCR and ALT levels were routinely 
collected and additionally inform ation on HCV genotype and HCV and/or HIV treatm ent 
were recorded. After delivery, information was collected on mode o f  delivery, duration o f 
labour, any obstetric interventions, and birth weight, gestational age, gender and neonatal 
ART HIV therapy if  applicable. Paediatric follow-up was recom m ended at birth, 6 weeks, 
3, 6, 9, 12, 18 and 24 m onths and then every 6 months if  the child was HCV infected and 
annually if  they were uninfected. At each follow-up visit clinical exam ination data were 
collected on the ch ild ’s height, weight and HIV infection status as well as clinical 
symptoms in nine categories (growth failure, hepatomegaly, splenom egaly, nephropathy, 
cardio-pulm onary, skin disorders, haematological disorders, auto-im m une diseases and 
others). Data were also collected on Hepatitis A and B im munisations, ultrasound 
exam inations, liver biopsy results, genotype and HCV treatment. In addition to clinical 
exam ination, local laboratory testing o f blood samples for anti-HCV antibody, qualitative 
and quantitative HCV RNA PCR, ALT, haem oglobin, white blood cells, lymphocytes, 
neutrophils and im m unoglobulin was carried out. Liver biopsies were perform ed according 
to local practise and interpreted by the local pathologist (Table 2.1).
The data from children enrolled in the EPHN are utilised in Chapters three, four and five 
(Figure 2.1).
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Figure 2.1 Data sources and their use in this thesis
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Table 2.1 EPHN data collection
EPHN study form________________Information collected________________________________
Maternal enrolment EPHN study ID number
information Maternal date of birth
Most likely mode of acquisition o f HCV infection 
Reason for HCV testing 
Maternal use of intravenous drugs 
Maternal HIV infection status 
Previous reporting to EPHN study 
Maternal clinical and EPHN study ID number
laboratory information during HCV test results in pregnancy and delivery
ELISA 
RIBA
PCR-RNA (pos/neg)
RNA (copies per ml)
ALT 
Genotype
Treatment during pregnancy or delivery for HCV or HIV 
Stored serum 
EPHN study ID number 
Delivery date 
Mode o f delivery 
Duration o f labour 
Obstetric interventions 
Neonatal information 
Birth weight 
Gestational age 
Gender
ART to reduce HIV transmission 
Paediatric follow-up: clinical EPHN study ID number
examinations Child date o f birth
Weight 
Height
HIV infection status 
Clinical manifestations
Growth failure Cardio-pulmonary
Skin disorders Splenomegaly
Haematological disorders 
Ever breast-fed 
Age stopped 
Vaccinated against Hepatitis A / Hepatitis B 
Hepatic ultrasound results 
Liver biopsy results 
HCV treatment 
Paediatric follow-up: HCV RNA PCR tests
Laboratory test information HCV antibody tests
ALT levels
Samples stored (Guthrie card / serum / plasma)
Other tests
Haemoglobin IgG, IgM, IgA, IgE
Lymphocytes Platelets
Total bilirubin Albumin
Genotype 
Autoantibody tests
Hepatomegaly 
Nephropathy 
Auto-immune disease
White blood cells 
Coagulation screen 
Alpha fetoprotein
pregnancy and delivery
Delivery information
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2.4.2 European C ollaborative Study (ECS)
The European Collaborative Study (ECS) was set up in 1986 at a time when very little was 
known about the rate o f  HIV MTCT, risk factors for transm ission or the natural history o f 
vertically-acquired HIV infection. W ith funding from the UK M edical Research Council 
and the European Com m ission, a m ulti-centre cohort study was established with sites 
across W estern Europe, to address these research questions. In 1998 the cohort extended 
into Central Europe, with two centres in Poland, and in 2000, to Ukraine. The ECS now 
covers ten European countries, with continuing enrolm ent and follow-up in 25 clinical 
centres from Spain, Italy, the United Kingdom, Germany, Belgium, Sweden, N etherlands, 
Denmark, Poland and Ukraine. More than 8000 mother-child pairs had been enrolled in the 
study by January 2008.
Routinely collected inform ation is recorded at enrolm ent and follow-up visits by clinicians 
and docum ented on paper forms (Appendix 6) which are sent to the UCL Institute o f Child 
Health, London, UK for data entry and analysis. All data is anonym ously linked and each 
m other-child pair in the study is given a unique numeric identifier at enrolm ent and this is 
used in all data collection and analysis, no names are written on study forms or recorded in 
the ECS database. (ECS 2001).
Children born to w om en identified as HIV infected before or during pregnancy or at 
delivery are followed up according to a standard protocol collecting detailed clinical and 
laboratory information. The follow-up schedule includes clinical and laboratory data 
collection at birth, 3 and 6 weeks, 3, 4.5 and 6 months then every 3 m onths until 2 years o f  
age. Subsequently HIV infected children are exam ined at least twice at year.
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At enrolm ent maternal inform ation on country o f birth, ethnic group, obstetric history, 
transm ission risk group, current clinical status and HIV treatm ent during pregnancy is 
recorded. Additionally, data from maternal laboratory investigation during pregnancy and 
at delivery are recorded and include HIV DNA PCR, HIV RNA PCR, anti-HIV antibody 
and CD4 cell count tests. Perinatal inform ation on antiretroviral therapy adm inistered 
during labour or at delivery, mode o f delivery, duration o f  labour, perinatal problems and 
infant feeding method is collected at, or shortly after, delivery. Detailed paediatric data on 
clinical abnorm alities along with developmental assessm ents, antiretroviral therapy 
adm inistered, im m unisations given and maternal health are then collected at each follow-up 
visit where blood sam ples are also tested for anti-HIV antibody, HIV RNA PCR, 
im m unoglobulin, CD4 and CD8 cell count, lymphocyte and neutrophils. Testing is carried 
out locally and the assays used are recorded. Data collection at each point during enrolm ent 
and follow-up can be seen in Table 2.2.
The data from children enrolled in the ECS are utilised in Chapter six (Figure 2.1).
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Table 2.2 ECS data collection
ECS study forms Information collected
Perinatal information ECS ID number Child’s data of birth Sex
Gestational age Birth weight Mode of feeding
Obstetrician details Antiretroviral therapy during labour/delivery
Mode of delivery Duration of labour OFC
Time from rupture of membranes to deliver Perinatal problems Living with parents or adopted
Maternal information at delivery ECS ID number Mother’s date o f birth Country of birth
Marital status Ethnic group Obstetric history
Likely mode of acquisition of HIV infection 
Details o f treatment during pregnancy
Date of first positive HIV test Current clinical status
Maternal laboratory ECS ID number HIV RNA PCR (collected since 1994) HIV DNA PCR
investigations during pregnancy Total lymphocytes CD4 cell count (collected since 1992) CD8 cell count
and at delivery IgG
P24 Ag
IgA
HIV Elisa
IgM
Paediatric medical examinations: ECS ID number Weight Height
3 and 6 weeks, 3, 4.5 and 6 OFC Recurrent fever Bacterial infection
months Communicable disease Skin infection Non-infectious skin eruption
Palpable lymph nodes Chronic paratoid swelling Oral Candida
Upper respiratory tract infection Lower respiratory tract infection Opportunistic infection
Hepatomegaly splenomegaly Neurological abnormality Developmental assessment
Loss of developmental milestones Neonatal ART details HIV treatment details
Hospital admissions 
Breastfeeding
Immunisations 
Health o f mother
Child care
Paediatric medial examinations: ECS ID number Weight Height
9, 12, IS and 24 months and older Head circumference Paediatrician details HIV infection status
Child care Preschool/Schooling Treatment
Communicable diseases Oral Candida Hospital admissions
Renal abnormalities Gastro-intestinal abnormalities Hepatic abnormalities
Paediatric laboratory test results
Cardio-vascular abnormalities 
Malignancy abnormalities 
ECS ID number
Central nervous system abnormalities Respiratory abnormalities
HIV ELISA HIV DNA PCR 
T8 T4 (collected since 
IgA IgM 
Neutrophil Platelet 
Toxo IgG Latex Tetanus IgG
HIV RNA PCR (collected since 1994) 
1992) IgG
Absolute lymphocyte 
Haemoglobin 
CMV IgG
2.4.3 UK National HCV Register
The UK National HCV Register collects information on children known to be infected with 
HCV in the UK (Harris et al 2000). The majority o f these children have been identified as 
part o f several surveillance and research initiatives, including the UK Departm ent o f Health 
“ Lookback" study (D epartm ent o f Health 1995) in 1995 identifying individuals, including 
children, who received blood products from HCV infected donors and the E3ritish Paediatric 
Surveillance Unit study to assess the prevalence o f HCV in UK children during 1997 and 
1998 (Gibb et al 2000). To date there are approxim ately 246 individuals enrolled in the 
Register who were children at infection, most (76%) o f whom acquired infection 
parenterally although as follow-up continues the balance shifts and the majority o f new 
paediatric enrolm ents are vertically infected children (personal com m unication Dr Helen 
Harris, 2007).
The UK National HCV Register is based on active surveillance m ethods whereby clinicians 
following-up HCV infected children record routinely collected data on study forms on an 
annual basis and send the forms (Appendix 7) to the Register coordinating centre at the 
Health Protection Agency, London, UK. Data are recorded on clinical signs o f liver 
disease, any other m edical conditions, HCV RNA PCR and anti-HCV antibody test results, 
HCV genotype, liver function results such as ALT levels, liver biopsy results, hospital 
treatm ent and adm issions (Table 2.3). Data from the UK National HCV Register is linked 
to national UK cancer and death registers to accurately monitor any major clinical disease 
progressions. All data w ithin the Register is anonym ously linked using unique identifiers 
for each individual and no names are recorded on the study forms or database. For the
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purposes o f this thesis, a database o f  HCV infected children which was a subset o f the 
larger Register database was provided by the Health Protection Agency. Liver biopsies 
were carried out locally and additionally biopsy samples were sent to the Register 
coordinating centre at the Health Protection Agency in London for independent scoring 
(Harris el al 2000).
The data from children enrolled in the UK National HCV Register are utilised in Chapter 
four (Figure 2.1).
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Current clinical status 
Test results
Antiviral drug treatment
Current management
Follow-up form 
Patient details 
Current clinical status
Test results
Antiviral drug treatment
Current management
Date of birth 
Ethnic group 
Country of birth 
GP details
Risk factors for HCV acquisition
Other chronic viral infection
Other significant medical conditions
Signs and symptoms o f liver disease
Hepatitis B test results
Date o f first positive HCV PCR test
HCV PCR test results
HCV genotype
Liver function test results
Livery biopsy results
HCV treatment details
Response to treatment
Antiviral drug trial participation
Hospital admissions or outpatient care details
Alcohol intake at first diagnosis
Current alcohol intake
Register ID number 
Is patient alive
Signs or symptoms of liver disease
Other significant medical conditions
HCV PCR test results
HCV antibody test results
HCV genotype
Liver function test results
Haematology test results
Liver biopsy results
HCV treatment details
Response to treatment
Antiviral drug trial participation
Hospital admissions or outpatient care details
Current alcohol intake
2.4.4 Libyan Cohort Follow-up Study
The Libyan Cohort Follow-up Study was established in 1999 in a collaborative 
between the Benghazi Infectious Disease and Immunity Center and two Italic 
centres (Bambino Gesii Children’s Hospital, Rome and L.Sacco Hospital, Mi
6 8
agreement was in response to a nosocomial outbreak o f HIV infection at Al-Fateh 
C hildren 's Hospital, Benghazi, Libya whereby approxim ately 400 children became infected 
with HIV and many became coinfected with HCV. Follow-up exam inations take place at 
clinical centres in M ilan and Rome and began soon after children were exposed 
in 1998/1999 and continues to date although enrolm ent rem ains static (Yerly et al 2001, 
V isco-Comandini 2002). Paediatric HIV infection was confirm ed by HIV serological and 
virological analysis and vertical transm ission was excluded by carrying out HIV serology 
and virology on parents o f  HIV infected children (Yerly et al 2001).
Data are collected at biannual routine follow-up exam inations and entered into a M icrosoft 
Access database. Data collected include quantitative HIV RNA PCR and quantitative and 
qualitative HCV RNA PCR test results, ALT levels and CD4 cell counts among other 
detailed data on clinical sym ptom s o f disease and HIV and HCV treatm ent administered. 
More detail on the data collected at enrolment and follow-up visits can be found in Table 
2.4.
The data from children enrolled in the Libyan Cohort Follow-up Study are utilised in 
Chapters five and six (Figure 2.1).
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Table 2.4 Libyan Cohort Follow-up Study data collection
Libyan Cohort Follow-up 
Study forms
Information collected
Enrolment Study ID number 
Sex
Date o f birth
Place o f residence
Date of first positive HIV test
Date of first visit to Benghazi hospital
Number of visits to Benghazi hospital during 1997 and 1998
Diagnosis Other medical conditions and diagnosis dates
Aids defining illnesses AIDS defining illnesses and diagnosis dates
Antiretroviral therapy Antiretroviral therapy drugs, start and stop dates
Follow-up Study ID number
Hospital admissions
CDC stage
Weight
Height
BMI
Evidence of fever 
Evidence o f diarrhoea 
Evidence of Candida 
Evidence o f failure to thrive
HIV RNA viral load HCV infection status HCV RNA viral load
AST ALT Creatinine
Cholesterol Triglycerides Bilirubin total
White blood cell count PTL Hb
Lymphocyte count Neutrophils CD4 %
CD4 copies/ml CD8 % CD8 copies/ml
2.5 Biases
By using HIV and HCV data from four different cohorts there are possible biases which 
could occur from the differing design and data collection m ethods and also from the 
children that they collect data on, e.g. children who are vertically versus parenterally 
infected. All four cohorts analysed as part o f this thesis prospectively collected data which 
was reported to study coordinating centres by clinicians following routine exam inations at 
participating clinical centres according to a set protocol. All cohorts collected similar data 
from these routine exam inations on virological, im m unological, clinical and treatm ent 
profiles o f  HIV and/or HCV coinfected children. The sim ilar design and data collection
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methods o f the cohorts means that biases resulting from com bining data from different 
sources are minimised before any data analysis takes place (Appendices 5, 6 and 7) .
The children enrolled in the four cohorts differ predom inantly by their mode o f acquisition 
o f  infection; vertically versus parenterally. Vertically infected children are from birth 
cohorts, with data collected from birth and regularly thereafter in children who were only 
later confirm ed as infected and therefore there was no selection bias based on disease 
progression or m aternal factors or treatm ent and all vertically infected children were 
included (EPHN 2005a, ECS 2002). Parenterally infected children are from two different 
sorts o f cohorts. Those children from the UK National HCV Register were identified 
largely based on exposure to a known contaminated source and therefore selection and 
enrolm ent into the cohort was not related to disease progression as may have been the case 
had they been identified after referral to specialist services for abnormal liver function tests. 
Children from the Libyan Cohort Follow-up Study were identified in relation to exposure to 
a known contam inated source and therefore similarly, their enrolm ent was not biased by 
selection o f particular groups or children with more advanced disease progression.
In the UK National HCV Register analysed in this thesis, enrolm ent in the study and 
consequently the start o f  follow-up inform ation was often a num ber o f years after infection 
occurred. There is therefore also the possibility that some children exposed to contaminated 
blood or blood products and consequently infected with HCV, who would otherwise have 
been enrolled in the Register, cleared the virus prior to testing and therefore were never 
diagnosed as infected. The result o f  this would be to underestim ate the level o f HCV virus
71
clearance in this cohort and possibly to overestimate disease progression if those who did 
not clear the virus were those most likely to progress to HCV-related disease. Children 
enrolled in the Libyan Cohort Follow-up Study were diagnosed much sooner after HIV or 
HCV infection than those in the UK Register as the source o f  infection was identified 
within two years o f the first possible infection. As a result, parenterally infected children 
from this cohort have inform ation available much sooner after infection reducing any bias 
related to late diagnosis. As a result, this group o f parenterally infected children are a very 
unique group to study.
A nother possible source o f bias may be the timing o f m easurem ents from these children 
which are available from the time o f infection (birth) for vertically infected children from 
the ECS and EPHN cohorts, whereas parenterally infected children are not followed up 
from the point o f  infection and therefore there are fewer and som etim es no measurements 
during early infection.
The biases anticipated by the use o f  these different cohorts and the differences between the 
inform ation available for children enrolled in them will be dealt with in either the analysis 
or the interpretation o f  the results. Some specific biases such as the age at which infection 
occurred or the age at which m easurem ents were taken, relative to the age at infection, can 
be adjusted for using specific statistical techniques which are discussed in individual 
chapters throughout this thesis. O ther biases, in terms o f  the context in which the data was 
collected and any possible biases in terms o f selection or late diagnosis will be considered 
at the interpretation stage o f  the data in the Discussion Chapter o f this thesis.
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2.6 Definitions
2.6.1 HCV infection
For the purposes o f inclusion in analyses for this thesis, vertically HCV infected children 
were defined as those with a positive HCV antibody result at or after 18 months o f age 
and/or two consecutive positive HCV RNA PCR test results at any age who were born to 
mothers with HCV infection confirm ed before or during pregnancy (EPHN 2005a). 
Parenterally HCV infected children were those infected before 18 years o f age who tested 
positive to HCV antibodies with a known parenteral risk factor for infection, exclusion o f 
vertical acquisition o f  infection and for whom follow-up inform ation was available before 
18 years o f age.
2.6.2 HIV infection
Vertical HIV infection was established by the detection o f  HIV in at least two blood 
samples taken on separate occasions, and/or the persistence o f HIV antibody beyond 18 
months o f  age in children whose m others had docum ented HIV infection in pregnancy or at 
delivery (ECS 2002). Parenteral HIV infection was defined by serological and virological 
confirm ation o f  HIV and exclusion o f  mother-to-child transm ission by laboratory exclusion 
o f  HIV in m others o f  infected children. The date o f HIV infection in parenterally infected 
children from the Libyan Cohort Follow-up Study was determ ined using the m idpoint 
between 1st January 1998 (the first possible date o f infection) and the date o f their first 
positive HIV test or, if  this was unavailable, the m idpoint (1st January 1999) o f the period 
that infection was known to have occurred -  January 1998 to Decem ber 1999. As
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nosocomial infection was isolated to a specific period o f time the tim ing o f possible 
infection can be estim ated with sufficient accuracy.
2.7 Data analysis
The data m anagem ent o f  all four cohort studies was carried out using M icrosoft Access 
databases and statistical analyses were performed using STATA software version 9.0 (Stata 
Corporation, Texas, USA) and SAS software (v9.01, SAS Institute, Cary, North Carolina, 
USA). Data cleaning was carried out before the use o f data from all databases and checks 
on data quality, logistic quality and completeness o f data were perform ed in M icrosoft 
Access prior to statistical analysis. The specific statistical analysis m ethods for each piece 
o f  work can be found at the beginning o f  each individual Chapter.
Information specifically for analysis in this thesis were provided by the cohort coordinators 
in the form o f  abbreviated datasets and permission was granted for their use in all the 
analyses presented. A dditionally, advice on the use o f the data was provided by the cohort 
coordinators.
2.8 Role o f the researcher
The data analysed in the following chapters were provided by a variety o f  study teams and 
therefore I will clarify my role in the research carried out for this thesis.
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Data on vertically HCV infected children from the EPHN presented in Chapters 3, 4 and 6 
were provided by the EPHN coordinating team at the UCL Institute o f Child Health, 
London, UK in the form o f a M icrosoft Access database. I had personally carried out some 
data entry on this project in order to carry out some previous analyses not forming part o f 
this thesis (EPHN 2005d, EPHN 2005e) and had access to the original study forms to check 
any queries which arose as part o f  the data cleaning process. Data on parenterally HCV 
infected children for the analyses presented in Chapter 4 were provided by the Health 
Protection Agency, London, UK in the form o f a M icrosoft Access dataset. The 
interpretation o f  this dataset and queries arising from the analysis were carried out with the 
assistance o f  the UK N ational HCV Register study coordinator at the HPA, Dr Helen 
Harris. The aims and objectives o f  the analyses were agreed with my supervisors Professor 
M arie-Louise Newell and Dr Claire Thorne and additionally Dr Lucy Pem brey contributed 
to the planning o f  these analyses in her role as EPHN coordinator. The methodological and 
technical developm ent o f  the analyses along with the interpretation o f results for this thesis 
were my own responsibility.
The data on vertically HIV infected children from the European Collaborative Study 
analysed as part o f Chapters 5 and 6 were provided by the ECS coordinating team at the 
UCL Institute o f Child Health, London, UK in the form o f a M icrosoft Access database. I 
had carried out some data entry for the ECS and had access to the original study forms and 
clinician contacts for any queries w hich arose from the data cleaning process. The aims and 
objectives o f the analyses were developed with my supervisors Professor M arie-Louise 
Newell and Dr Claire Thorne who were also the lead members o f  the ECS team. The
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methodological and technical developm ent o f the analyses along with the interpretation o f 
results for this thesis were my own responsibility.
Data on children from the Libyan Cohort Follow-up Study analysed as part o f Chapters 5 
and 6 were provided by Dr Guido Castelli-Gattinara, Bambino Gesu C hildren’s Hospital, 
Rome, Italy and Dr Alessandra Vigano, L. Sacco Hospital, Milan, Italy in the form o f two 
M icrosoft Access databases. I carried out data cleaning and interpretation o f  the databases 
in consultation with Dr Castelli-Gattinara and Dr Vigano and then the aims and objectives 
o f the analyses were developed with my supervisors Professor M arie-Louise Newell and Dr 
Claire Thorne. The methodological and technical development o f the analyses along with 
the interpretation o f  results for this thesis were my own responsibility.
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3. AGE AND SEX RELATED REFERENCE RANGES OF ALANINE  
A M INO TRA NSFERASE (ALT) LEVELS IN CHILDREN
3.1 Introduction
Definitions o f  normal or abnormal alanine am inotransferase (ALT) levels have been largely 
based on reference ranges provided by laboratories carrying out the ALT tests (Piton et al 
1998). The populations from which these reference ranges have been extrapolated are 
undefined and are likely to vary widely. There is some doubt about the validity o f ALT as a 
marker o f  liver disease, especially in the case o f chronic HCV infection where patients with 
normal ALT levels have been found to have minimal to mild liver abnorm alities (Prati et al 
2002). M any paediatric studies refer to normal or elevated A LT levels, often as twice the 
upper limit o f  norm al, but few provide details o f the specific cu t-o ff values or the 
populations and m ethods by w hich these were defined. To date no studies have investigated 
the accuracy o f  these ranges in children which consequently remain unqualified.
3.2 M ethods specific to this chapter
The reference group for the calculation o f ALT reference ranges was children born to HCV 
infected m others enrolled in the EPHN but who were confirm ed as HCV uninfected 
themselves on the basis o f a negative HCV antibody test after 18 m onths o f age and/or at 
least two negative H CV-RNA PCR tests and fewer than two positive PCR tests before 18 
months. Additionally, children with no positive PCR test results who were antibody 
negative between 9 and 18 m onths were considered to be HCV uninfected. ALT testing
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was performed locally from birth (EPHN 2005a). All HCV uninfected children with at least 
one ALT m easurem ent recorded during the first five years o f  follow-up after birth were 
included in this analysis.
3.2.1 Statistical analysis
Univariable and m ultivariable linear regression analyses were used to identify factors 
associated with variations in ALT levels while accounting for w ithin-child repeated 
measures and betw een child differences that could not be m easured, e.g. the use o f data 
from different clinical centres, using a maximum likelihood random effects estim ator on the 
intercept. Linear regression adjusted for age at ALT m easurem ent (categorised into five 
groups: 6-m onthly groups until 2 years o f age and those over 2 years o f  age to account for 
the larger num ber o f  m easurem ents and wider variation in ALT levels in the first two years 
o f life), gender and w eight (expressed as a standard deviation z-score representing the 
deviation from the m edian o f  the reference group previously used to calculate the UK 1990 
Growth Standards) (Cole et a l 1998, EPHN 2005d). A djusting for weight in linear 
regression allowed adjustm ent for appropriate size-for-age w ithout using BMI which is a 
less appropriate m easure in younger children (Pietrobelli et al 1998).
Centiles for ALT levels over age were calculated using maximum penalized likelihood 
methods and LMS software (LM S 1.22, Institute o f Child Health, London) (Cole and Green 
1992). M odels accurately representing the ALT centiles were developed separately for 
males and females, using appropriate equivalent degrees o f  freedom for each o f  the three 
curves making up the model -  median, coefficient o f  variation and skewness. For the
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purposes o f this analysis, age at ALT measurem ent was transform ed to better reflect the 
non-m onotonic distribution o f ALT over age by stretching the age scale at younger ages 
where there were many m easurements and shrinking it at older ages where there were fewer 
measurements. This was done using splines fitted on a pow er-transform ed scale which were 
then redrawn on the original scale (LMS Handbook, LMS 1.22, Institute o f  Child Health, 
London).
3.3 Results
A total o f 1293 HCV uninfected children, 709 (55%) male and 579 (45% ) female (5 had no 
sex recorded), had at least one ALT measurement during 5 years o f follow-up from birth 
with 5011 ALT m easurem ents available overall (median 3 observations per child, range 1 
to 10). M edian A LT level per child was 24 U/l (range 6-117 U/l). The m edian age at ALT 
m easurem ent was 6 m onths (range 0 -  4.9 years) with 3811 observations (76.1%) in the 
first 12 m onths o f life from 1255 children, 1020 (20.4%) between 12 and 24 months from 
721 children and 180 (3.6% ) after 24 months o f age from 133 children (Table 3.1). The 
distribution o f  ALT m easurem ent over age can be seen in Figure 3.1. Baseline 
characteristics were sim ilar regardless o f  the com bination o f tests used to exclude HCV 
infection. The rare high ALT values in uninfected children seen in Figure 3.1 were not 
indicative o f continuously high values for specific children but were one-off events 
predom inantly in the first six m onths o f life when ALT levels are known to peak (EPHN 
2005c). There is no evidence that they were indicative o f any liver assault in these children 
based on concurrent clinical exam inations and reporting o f  any clinical abnorm alities o f 
any kind. A recent survey with a 96% response rate confirm ed that only 4% o f children
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enrolled in the EPHN were non-white but individual level data on ethnicity were not 
available (personal com m unication Dr Lucy Pembrey, N ovem ber 2007).
Table 3.1 Key characteristics o f 1293 children used to calculate ALT reference ranges
Children used to calculate ALT reference 
ranges(n=1293)
Sex
Male (%) 709 (55%)
Female (%) 579 (48%)
M issing 5
M edian num ber o f A LT m easurem ents 3 (1-10)
during follow-up (range)
Num ber o f  ALT m easurem ents at specific
ages
Before 12 months o f  age (no. o f children) 3811 (1255)
12 to 24 m onths o f  age (no. o f  children) 1020 (721)
After 24 months o f age (no. o f  children) 180 (133)
M edian age at ALT m easurem ent (range) 6 months (1 m onth -  4.9 years)
Year o f birth
Before 1999 88 children
1999 to 2002 842 children
After 2002 363 children
M edian ALT m easurem ent per child 24 U/l (6-117 U/l)
(range)
8 0
Figure 3.1 Distribution of ALT measurements in HCV uninfected, healthy children 
under five years of age.
Age (months)
3.3.1 Factors associated with changes in ALT levels
Linear regression analysis assessed the association between ALT levels and age at ALT 
measurement, sex and age-adjusted weight z-score (Table 3.2). ALT level decreased 
significantly with increasing age (non-parametric test for trend, z=-15.1, p<0.001) and ALT 
levels in all age categories were significantly lower in comparison to measurements taken 
in the first six months in both univariable and multivariable linear regression. For example, 
in multivariable analysis, there was a mean decrease in ALT levels o f 11.6 U/l in those 
measurements taken after 24 months o f age compared to those taken before 6 months o f 
age (Table 3.2). Female children had significantly lower ALT levels during follow-up than 
male children and this association remained significant in multivariable analysis with a
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mean decrease in ALT levels o f 1.5 U/l in female com pared to male children (Table 3.2). 
ALT levels significantly increased with increasing weight z-scores at univariable and 
multivariable levels (Table 3.2). W hen the weight z-scores were categorised to represent 
those children with a weight z-score o f two or more standard deviations above the median 
(comparable with the 95th centiles for weight) there was no significant association between 
being above the 95th centile o f  weight for age and ALT level, coefficient -0.308 p=0.863.
Table 3.2 Linear regression o f factors affecting ALT levels in healthy children
Univariable analysis M ultivariable analysis *
Mean change in 
ALT level
p-value M ean change 
ALT level
in p-value
Age at ALT m easurem ent
Less than 6 m onths (n= l 183) 1.00 1.00
6 to 12 m onths (n=908) -1.766 <0.001 -2.501 <0.001
12 to 18 m onths (n=627) -4.339 <0.001 -5.280 <0.001
18 to 24 m onths (n=279) -7.654 <0.001 -8.842 <0.001
Greater than 24 m onths -10.241 <0.001 -11.554 <0.001
(n=130)
Sex
Male (n=709) 1.00 1.00
Female (n=579) -1.569 0.005 -1.499 0.036
Age-adjusted w eight z-score 1.107 0.001 1.065 0.001
(per standard deviation)
( n = l188)
* Adjusting for all variables shown
3.3.2 Age and sex specific centiles for ALT levels
Centiles o f ALT levels over age showed the maximum 95th centile over five years was at 
three months o f age in males (ALT 58.9U/1) and one month in females (ALT 55.7U/1). This
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upper value o f  the reference range decreased with increasing age and was lowest at two 
years in males (ALT 34.8 UI/L) and five years in females (ALT 28.4 Ul/L). Up to five 
years o f age, the 95th centile for ALT levels was consistently higher in males than in
t hfemales (Table 3.3). The 50 centile for ALT levels over age in males and females shows a 
peak in ALT levels during the first six months o f  life and a gradual decrease in ALT 
thereafter (Figure 3.2). This pattern is consistent with those found in HCV infected children 
where ALT levels have been shown to peak in the first 2 years o f  life and decrease 
thereafter (EPHN 2005a, Resti et al 2003).
3.3.3 Interpretation o f ALT level centiles
The ALT level centiles represent the distribution o f ALT levels in the reference population,
th . »uwhere the 50 centile is the m edian ALT level at each age. The 95 centile for each age is 
the point at w hich only 5% o f  the population will have larger ALT levels and therefore this 
is the centile com m only chosen to represent the upper limit o f “normaU.
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Table 3.3 Reference values for Alanine am inotransferase levels for males and females
at selected ages
Age Sex
ALT levels (UI/I)
Centiles
5 10 50 90 95
Birth Male 7.45 9.19 19.78 44.47 56.43
Female 6.78 8.75 20.36 44.09 54.26
1 month Male 11.27 13.33 24.69 47.73 58.03
Female 10.56 12.79 24.73 46.71 55.71
3 months M ale 13.97 16.11 27.47 49.32 58.87
Fem ale 12.96 15.16 26.36 45.73 53.44
6 months Male 14.66 16.67 27.10 46.77 55.32
Fem ale 13.52 15.52 25.28 41.24 47.40
12 months M ale 13.11 14.71 22.89 38.04 44.59
Fem ale 12.10 13.83 22.07 34.87 39.63
18 months M ale 11.80 13.16 20.00 32.55 37.97
Fem ale 10.77 12.39 19.87 30.89 34.83
2 years M ale 11.29 12.53 18.73 30.00 34.84
Fem ale 9.73 11.61 18.37 28.18 31.53
5 years M ale 11.67 13.01 19.91 33.18 39.16
Fem ale 8.02 10.13 17.88 26.00 28.35
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Figure 3.2 Centiles for ALT levels in a) males and b) females over age.
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3.4 Key points
• ALT levels in a population o f HCV uninfected, healthy children significantly decreased 
with increasing age after a peak in the first six months o f  life.
• ALT levels were significantly and consistently higher in males than females up to five 
years o f age and also peaked earlier in girls.
• ALT levels in children increased significantly with increasing weight-for-age but no 
statistically significant increase in ALT levels in children with weight-for-age above the 
95th centile com pared with those below the 95th centile was found.
• From the pattern o f  A LT levels over age, it would be more appropriate to use above and 
below 18 m onths o f  age as the cu t-off for differing reference ranges rather than above 
and below 12 months as has been used previously.
•  Calculation o f  A LT centiles showed that an ALT level o f  greater than 60U/1 in boys and 
55U/1 in girls should be regarded as elevated in the first 18 months o f  life while in 
children older than 18 months the upper limits o f normal ALT levels are lower; 40U/1 in 
boys and 35U/1 in girls.
• Reference ranges in children younger than five years o f  age calculated from a 
population o f healthy HCV uninfected children with low likelihood o f liver-related
8 6
abnormalities appear to be lower than previously reported.
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4. THE IM PACT OF M ODE OF ACQ UISITIO N ON BIO LO G ICAL M ARKERS OF 
HEPATITIS C VIRUS INFECTION
4.1 Introduction
Information on the im pact o f  mode o f acquisition o f paediatric HCV infection on biological 
markers o f infection, including HCV viraem ia and ALT levels, used to assess disease 
progression in the absence o f liver biopsy, is limited. In a recent European study, 44% o f 
240 vertically HCV infected children followed-up for a median for 4.2 years, were found to 
have consistently positive HCV RNA PCR test results, while 7% were found to have 
consistently negative HCV RNA PCR results despite positive antibody (EPHN 2005a). A 
com parative figure for parenterally infected children is not available, but in a small study 
com paring clinical outcom es in 16 vertically and 15 post-transfusion infected children, viral 
clearance, although undefined, was 13% in vertically infected and 27%  in parenterally 
infected children but the difference was not statistically significant likely due to the small 
numbers o f  children in each group (Rerksuppaphol et al 2004).
It is plausible that given the infection o f vertically infected children during early immune 
maturation, or the possible adaptation o f  the immune system o f the vertically infected 
children following early exposure in utero, the natural history and disease progression in 
parenterally infected children acquiring HCV later in childhood might differ from that o f 
their vertically infected counterparts. To inform the managem ent o f parenterally HCV 
infected children worldwide, and in the light o f continued outbreaks and diagnoses o f new 
cases, it is vital to understand any differences between this group and vertically infected 
children, upon whom the m ajority o f  paediatric HCV guidelines are based.
4.2 M ethods specific to this chapter
For the purposes o f this chapter, a dataset o f vertically HCV infected children from the 
European Paediatric HCV Network and a dataset o f parenterally HCV infected children 
from the UK National HCV Register were analysed (See section 2.3.1 and section 2.3.3).
4.2.1. Definitions
A recent study from 54 children enrolled in the EPHN suggested that between one third and 
a half o f vertically HCV infected children acquired infection in utero and half acquired 
infection late intrauterine or peripartum. Although in a few children postnatal acquisition 
could not be ruled out (M ok et al 2005). However, it was not feasible to accurately estimate 
the timing o f  infection before delivery for the purposes o f the analyses in this chapter and 
so here infection was assum ed to have occurred at birth in vertically HCV infected 
children. The estim ated date o f  HCV infection in the parenterally infected study population 
was the date o f  transfusion or receipt o f blood products for the 76 (60% ) children where 
this was known. Fifty (40% ) children were transfused outside the UK or received multiple 
transfusions during childhood, and thus the date o f  infection could not be accurately 
estimated. These 50 children were consequently excluded from specific analyses which 
involved knowing the exact age at infection, for example, com paring factors in those 
infected before and after 12 m onths o f  age. Clearance o f HCV viraem ia was defined as 
having occurred in children with confirmed HCV infection whose last two consecutive 
HCV RNA PCR test results were negative, irrespective o f antibody status. A sustained 
virological response (SVR) to HCV treatm ent was defined by a negative HCV RNA PCR 
test six months or more after the cessation o f treatment (Poynard 2003). ALT levels greater
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than 60U/1 in boys and 55U/1 in girls are regarded as elevated in the first 18 months o f life 
while in children older than 18 months the upper limits o f normal ALT levels are 40U/1 in 
boys and 35U/1 in girls (See Chapter 3).
4.2.2 Statistical analysis
Comparisons between parenterally and vertically infected children were carried out using 
Chi-squared or z-tests when com paring proportions or Mann W hitney ranksum tests when 
com paring medians (K irkwood and Sterne 2003). Logistic regression identified factors 
associated with ALT, PCR and hepatomegaly summary variables. Children with two or 
more RNA PCR test results, for whom 75% or more o f these PCR results were positive, 
were defined as being consistently HCV viraemic and similarly, children with 75% or more 
ALT z-scores greater than 2 standard deviations (SD) (equivalent to the 95th centile on the 
reference range), were defined as having consistently elevated ALT z-scores, assuming that 
they had at least two A LT levels recorded during follow-up.
4.3 Results
Data on 395 HCV infected children were available from the datasets provided by the EPHN 
and UK National HCV Register. This included 269 vertically infected and 126 parenterally 
infected children. Seventy-six (60%) parenterally infected children had a known date o f 
infection and the median age at infection for this group was 19 m onths o f age. Follow-up in 
vertically infected children was more intensive; and the larger num ber o f  median follow-up 
visits in the vertically infected group is likely a reflection o f the different study protocols
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with the EPHN recom m ending follow-up approxim ately every six months and the UK 
National HCV Register carrying out annual follow-up (EPHN 2005a, Harris et al 2000).
The male to female sex ratio in the vertically infected children was approxim ately 1:2
reflecting the increased likelihood o f vertical HCV infection in girls com pared to boys
(EPHN 2005c). Conversely, the male to female sex ration in the parenterally infected
children was approxim ately 2:1, p<0.001 (Table 4.1). HCV genotype was recorded for 165
(42%) children, 115/269 (43%) vertically and 50/126 (40%) parenterally infected. No
significant differences were found in HCV genotype profiles by mode o f acquisition when
' 2looking at each genotype individually (% =4.85, p=0.301) or genotype 1 in comparison to 
any other genotype (x2=E99, p=0.158) (Table 4.1).
Ten vertically infected children and 39 parenterally infected children received anti-HCV 
therapy during follow-up. N ine (90% ) vertically infected children received IFN-alpha with 
the remaining vertically infected child receiving IFN-alpha in com bination with Ribavirin. 
Eighteen (46%) parenterally infected children received IFN-alpha and 12 (30%) received 
IFN-alpha with Ribavirin. The remaining nine (23%) parenterally infected children 
received Pegylated IFN alpha with Ribavirin. Parenterally infected children were 
significantly more likely to have received HCV treatment than vertically infected children 
(Table 4.1) and the m edian age at the start o f treatm ent was 5.7 years (range 2.3-11.7 years) 
for the vertically infected and 11 years (range 1.9-17.3 years) for the parenterally infected. 
There were no significant differences in the proportion o f vertically and parenterally 
infected children achieving a SVR following treatment (Table 4.1). Seventeen (44%)
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parenterally infected children who received HCV treatment had genotype information 
available (ten children had genotype 1, one had genotype 2 and six had genotype 3). Only 
two vertically infected children who received HCV treatm ent had genotype information 
available (one had genotype 1 and the other had genotype 2). A higher proportion o f  
children with genotype 3 achieved a SVR (66.7% (4/6)) than children with genotype 1 
(18.2% (2/11), F isher’s exact p-value=0.073.
Parenterally HCV infected children with a known date o f infection began follow-up at an 
earlier age than those with no known infection date and had a longer duration o f follow-up 
but the two parenterally infected groups did not differ in terms o f  their gender, HCV 
genotype or treatm ent profile (Table 4.2).
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Table 4.1 Key characteristics and follow-up profiles of vertically and parenterally
HCV infected children
Mode of acquisition 
Vertically infected Parenterally infected
n=269 (%) n= 126 (%)
Comparison
(jf/z-test or Mann 
Whitney)
Sex
Male 96 (38.9) 69 (63.9) X2— 18.91, p<0.001
Female
Missing
151 (61.1) 
22
39 (36.1)
Median age at infection Birth 19.13 months (n=76) 
(range 2.1 days-13.5 yrs)
N/A
Known date of infection
Yes 269* 76 (60.3) N/A
No 0 50 (39.7)
Median age at start of follow-up Birth 12.2 yrs
(range 12.0months- 
17.9yrs)
N/A
Median number of follow-up 
test dates
4 (range 1 -25) 2 (range 1-10) Mann Whitney=l 1.74
p<0.001
median duration of follow-up 2.8 yrs 2.5 yrs Mann Whitney=2.59,
(range 1 month-17.9yrs) (range 1 month-10.Oyrs) p=0.010
HCV Genotype
1 55 (47.8) 29 (58) % -4.845, p=0.304
2 18(15.7) 5(10)
3 31 (27.0) 13 (26)
4 11 ( 9.6) 2 ( 4 )
5 0 1 ( 2 )
Missing 154 76
T reated
No 259 (96.3) 87 (69.0) X2=58.57, pO.001
Yes 10 ( 3.7) 39(31.0)
Response to treatment
No response 5 (50.0) 15 (38.5) X  =1 -037, p=0.595
Sustained virological response 3 (30.0) 15 (38.5)
Unknown 5 (20.0) 9(23.1)
* All vertically HCV infected children were assumed to have been infected at birth
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Table 4.2 Difference between parenterally HCV infected children with and without
known dates o f infection
Parenterally infected children 
Known infection date Unknown infection date
n= 7 6 (%) n = 5 0 (%)
Comparison
(%2/z-test or Mann 
Whitney)
Sex
Male 48 (63.2) 34 (68.0) r= 0 .3 1 ,  p=0.577
Female 28 (36.8) 16(32.0)
Median age at infection (range) 19.13 months 
(2.1 days-13.5 yrs)
N/A
Median age at start of follow-up 10.5 yrs 14.0 yrs Mann Whitney=4.42,
(range) (12 months -  17.9 yrs) (4.6 yrs -  17.9 yrs) p<0.001
Median number of follow-up 
test dates (range)
3 (1-10) 2(1-7) Mann Whitney=-5.04,
p<0.001
median duration of follow-up 4.3 yrs 6.1 months Mann Whitney=-4.89,
(range) (1 month-10.1 yrs) (1 month-6.4 yrs) p<0.001
HCV Genotype
1 26 (57.8) 3 (60.0) X =1-31, p=0.859
2 5(11.1) 0
3 11 (24.4) 2 (40.0)
4 2 (4.4) 0
5 1 (2.2) 0
Missing 31 45
T reated
No 53 (69.7) 34 (68.0) X2=0.04, 0.837
Yes 23 (30.3) 16(32.0)
Response to treatment
No response 5 (21.7) 10(62.5) X =7.04, p=0.0.030
Sustained virological response 12(52.2) 3 (18.3)
Unknown 6(26.1) 3 (18.3)
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4.3.1 Clinical signs and sym ptom s of HCV infection
Parenterally infected children were significantly more likely to have hepatomegaly 
reported at least once during follow-up with hepatomegaly events occurring in 22/126 
(17.5%) parenterally infected children in com parison to 27/269 (10.0%) vertically infected 
children (z=-2.097, p=0.036). Among the 49 children with hepatomegaly events, 
hepatomegaly occurred at both a longer time after infection and an older age in parenterally 
infected children in com parison to vertically infected children; median time since infection
10.2 years (range 8.4yrs-15.1yrs) and 4.8 years (range 3.6days-15yrs) respectively, z=- 
3.814, p<0.001, and m edian age at first hepatomegaly event 12.0 years (range 6.8yrs- 
17.4yrs) and 4.3 years (range 3.6days -15yrs) respectively, z=-5.106, p<0.001.
Liver biopsy was carried out on a total o f 27/269 (10.0%) vertically infected children and 
73/126 (57.9% ) parenterally infected children. Similar proportions o f  vertically and 
parenterally infected children showed signs o f  chronic hepatitis, 82% and 67% respectively 
(z=1.468, p=0.142). Three o f  27 (11%) biopsied vertically infected children and 29/73 
(40%) biopsied parenterally infected children had more than one biopsy during follow-up, 
number o f  biopsies ranged from two to four. Genotype information was available for 12/27 
(44%) biopsied vertically infected children and o f these 12, four children had genotype 1, 
two had genotype 2, five had genotype 3 and one had genotype 4. Similarly, genotype 
information was available for 29/73 (40%) o f  biopsied parenterally infected children and o f 
these 29, 16 had genotype 1, three had genotype 2, nine had genotype 3 and one had 
genotype 4. Children who received anti-HCV therapy com prised 22% (6/27) o f  vertically 
infected and 40%  (29/73) o f parenterally infected children who were biopsied.
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4.3.2 HCV RNA PCR
Qualitative HCV RNA PCR was measured for 262 (of 269) vertically infected and 116 (of 
126) parenterally infected children, o f whom 250 and 68 respectively had at least two PCR 
results recorded overall. O f these 250 vertically infected and 68 parenterally infected 
children, 21 (9%) and 37 (32%) respectively had two PCR test results recorded, 30 (12%) 
and 21 (8%) respectively had three PCR tests recorded, 43 (17%) and 10 (9%) respectively 
had four PCR tests recorded and 156 (62%) vertically infected children and no parenterally 
infected children had five or more PCR test results recorded during follow-up. Among the 
children with two or more PCR tests, a higher proportion o f  parenterally infected children 
had PCR results which were all positive than vertically infected children, 34/68 (50.0%) 
and 101/250 (40.4% ) respectively, this difference was o f borderline statistical significance, 
z= -1.420, p=0.079. A pproxim ately 60% o f both vertically and parenterally infected 
children were consistently viraemic (75% or more HCV RNA PCR test results positive); 
145/250 (58.0%) and 37/68 (54.4% ) respectively, z=0.532, p=0.595.
Logistic regression was used to identify any factors associated with being consistently 
HCV viraemic in 300 children (232 vertically infected and 68 parenterally infected) who 
had inform ation available on all the variables in Table 4.3. In univariable and multivariable 
regression, the odds o f  being consistently HCV viraemic was significantly associated with 
having consistently elevated ALT z-scores and children who were consistently viraemic 
were over 10 times as likely to have consistently elevated ALT z-scores than those who 
were not consistently viraemic (Table 4.3). Overall, the adjusted odds ratios were similar to 
the unadjusted odds ratios for all the variables included in the logistic regression, this is not
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surprising given the lack o f associations between consistent viraem ia and most o f the 
variables under consideration in univariable analysis. Although not significantly so, being 
female, parenterally infected or receiving anti-HCV therapy reduced the odds o f being 
consistently HCV viraemic. In contrast, ever having evidence o f hepatom egaly increased 
the odds o f being consistently HCV viraemic but again, not significantly so.
Due to the small num ber o f children with genotype information, this variable was not part 
o f the logistic regression model in Table 4.3 to maximise the num ber o f children included. 
Univariable logistic regression was carried out on the subset o f 125 children with genotype 
information available separately; the odds o f being consistently viraemic was higher in 
children with HCV genotype 1 versus any other genotype but this association did not reach 
statistical significance (unadjusted OR=1.94 (95% Cl 0.92-4.08, p=0.082 (n=125)).
Clearance o f  HCV viraem ia was seen in similar proportions o f vertically and parenterally 
infected children, 30% (74/250) and 34% (23/68) respectively (z=-0.633, p=0.527). The 
median time from infection to clearance was 1.3 years (range 3 months -  10.4 years) in 
vertically infected children and 7.5 years (range 3.7 years -  13.5 years) in parenterally 
infected children.
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Table 4.3 Logistic regression o f factors associated with having a positive HCV RNA
PCR result on 75% or m ore o f tests during follow-up (n=300)
Univariable logistic M ultivariable logistic
regression regression*
OR (95% Cl)_______ p-value A P R  (95% Cl) p-value
Sex
Male (n=128) 
Female (n=172)
1.00
0.97 (0.61-1.55) 0.912
1.00
0.88 (0.54-1.44) 0.615
M ode o f acquisition
Vertical (n=232) 
Parenteral (n=68)
1.00
0.89 (0.52-1.53) 0.670
1.00
1.137 (0.59-2.20) 0.703
Evidence o f hepatom egaly
No (n=260)
Yes (n=40)
1.00
1.50 (0.75-3.00) 0.255
1.00
1.20 (0.55-2.65) 0.646
Ever treated
No (n=284) 
Yes (n=34)
1.00
0.65 (0.32-1.32) 0.232
1.00
0.67 (0.29-1.55) 0.349
Proportion o f ALT z-scores 
above 2SD
Less than 75% (n=263)
75% or greater (n=37)
1.00
10.58 (3.17-35.31) <0.001
1.00
10.28 (3.03-34.85) <0.001
* M ultivariable regression adjusting for all other factors in the table.
4.3.3 ALT levels
A total o f  1404 ALT observations were recorded (range 2-1213 U/I) from 218 vertically 
infected and 91 parenterally infected children. O f these, 14 (6.4%) vertically infected and 
52 (57.1%) parenterally infected children had one ALT level recorded, 24 (11.0%) and 21 
(23.1%) respectively had two ALT levels recorded, 27 (12.4%) and 10 (11.0%) respectively 
had three ALT levels recorded, 24 (11.0%) and 8 (8.8%) respectively had four ALT levels
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recorded and 129 (59.2% ) vertically infected children and no parenterally infected children 
had five or more ALT levels recorded during follow-up.
At least one elevated ALT level was recorded from 137 (62.8%) vertically infected and 53 
(58.2%) parenterally infected children during follow-up (z=0.577, p=0.564). Significantly 
fewer vertically infected than parenterally infected children had persistently elevated ALT 
levels, 33/218 (15.1% ) and 36/91 (39.6%) respectively (z=-4.715, p<0.001). Age at 
infection was associated with having persistently elevated ALT levels, with 18.2% (45/247) 
o f children infected before 12 months o f age, regardless o f  mode o f  acquisition, having 
persistently elevated ALT results com pared to 41.7% (10/24) o f  children infected after 12 
months o f age, z=-2.733, p=0.006. However, among 53 parenterally infected children, there 
was no difference in the proportion o f children infected before and after 12 months o f age 
with persistently elevated ALTs, 12/29 (41.4%) and 10/24 (41.7% ) respectively, z=-0.02, 
p=982.
Age-adjusted ALT standard deviation z-scores were calculated for each ALT measurement 
in reference to a standard population o f  HCV uninfected children bom  to HCV infected 
mothers. The m ean A LT z-score for vertically infected children was 2.049 (SD 2.059) and 
for parenterally infected children was 1.541 (SD 1.783), t=2.949, p=0.03 (Figure 4.1). The 
mean ALT z-score in 247 children infected before 12 months o f  age (2.033, SD 2.033) was 
also significantly higher than the mean ALT z-score in the 24 children infected after 12 
months o f age (1.387 SD 1.652), t = l .887, p=0.030. Among 53 parenterally infected 
children, there was no difference by age at infection in terms o f  mean ALT z-score; mean
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ALT z-score 1.64 (SD 1.37) in those infected before 12 months o f age and mean ALT z- 
score 1.63 (SD1.66) in those infected after 12 months o f age, t=0.010, p=0.992.
Figure 4.1 ALT z-score over time since infection in vertically and parenterally 
infected children.
vertically infected
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0 24 120 180 0 24 60
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Running mean smoother calculating smoothed values for each data point
Fifty-one children had consistently elevated ALT z-scores (defined as having 75% or more 
ALT z-scores 2 SD or above in those children with 2 or more ALT results recorded); 
43/204 (21.1%) vertically infected children and 8/39 (20.5%) parenterally infected children. 
Children who had ever had evidence o f  hepatomegaly were over three times as likely to 
have consistently elevated ALT z-scores in multivariable logistic regression. Additionally,
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those who were consistently HCV viraemic were over 12 times as likely to also have 
consistently elevated ALT z-scores in comparison to those who were not consistently 
viraemic. Although not significantly so, parenterally infected children were more likely to 
have consistently elevated ALT z-scores than vertically infected children in univariable, but 
not multivariable analysis (Table 4.4)
In univariable logistic regression including the 122 children with ALT z-score and 
genotype inform ation, the odds o f having consistently elevated ALT levels was higher in 
children with HCV genotype 1 versus other genotypes but this association did not reach 
statistical significance (unadjusted OR 2.23, p=0.072 (n= 122)).
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Table 4.4 Logistic regression of factors associated with having 75% or more ALT z-
scores greater than 2 SD (n=205)
Univariable logistic M ultivariable logistic
regression regression*
OR (95% Cl) p-value AOR (95% Cl) p-value
Sex
Male (n=87) 
Female (n=l 18)
1.00
1.34 (0.68-2.64) 0.394
1.00
1.43 (0.67-3.04) 0.358
Mode o f acquisition
Vertical (n = l75) 
Parenteral (n=30)
1.00
1.31 (0.54-3.18) 0.614
1.00
0.83 (0.26-2.61) 0.748
Evidence o f hepatom egaly
No (n=174)
Yes (n=31)
1.00
4.33 (1.94-9.67) <0.001
1.00
3.07 (1.25-7.52) 0.014
Ever treated
No (n=187) 
Yes (n=T8)
1.00
1.37 (0.46-4.07) 0.571
1.00
1.13 (0.28-4.53) 0.863
Proportion o f HCV RNA  
PCR results positive
Less than 75% (n=82)
75% or greater (n=123)
1.00
14.15 (4.22-42.51) <0.001
1.00
12.69 (3.73-43.17) <0.001
* M ultivariable logistic regression adjusting for all other variables in table.
Fifteen children were consistently HCV viraemic, had consistently elevated ALT z-scores 
and evidence o f hepatom egaly from a total o f 295 children with no missing information on 
any o f these variables. The proportion o f  children with two or more o f these three markers 
o f infection was sim ilar in parenterally (15/84, 17.9%) and vertically infected children 
(45/211, 21.3%), % =-0.67, 0.504 and also similar in those infected before 12 months o f age 
and after 12 m onths o f  age (52/239, 21.8% and 3/24, 14.3% respectively), x2= 1-13, 
p=0.288. W hen only the 52 parenterally infected children with date o f infection information
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and no missing inform ation on the three markers o f infection were exam ined, similar 
proportions o f those infected before and after 12 months o f  age were found to have two or 
more markers o f infection (7/28, 25.0% and 3/24, 10.7% respectively), x2= 1-30, p=0.254. 
Similar proportions o f children receiving anti-HCV therapy (9/36, 25%) and those 
receiving none (51/259, 19.7%) had two or more markers o f infection, x2==0-55, p=0.458 
and similarly there was no statistically significant difference between the number o f 
children with genotype 1 who had two or more markers o f  infection (21/73, 28.8%) and 
those with any other genotype (13/75 17.3%), x2=2.73, p=0.098 (Table 4.5).
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Table 4.5 C haracteristics o f children with two or more m arkers o f infection 
(consistently viraem ic, consistently elevated ALT z-scores, evidence o f hepatom egaly)
Num ber o f children with two Comparison  
or m
i% i
ore markers o f infection ( / 2, p-value)
Mode of acquisition
Vertically infected (n:
Parenterally infected (n=84) 15 (17.9%)
= 211) 45(21 .3% ) x2="0-67, p=0.504
Age at infection
Younger than 12 m onths (n=23 9) 52 (21.8%) x2=l -13, p=0.288
Older than 12 m onths (n=24) 3 (14.3%)
Age at infection -  only parenterally 
infected
Younger than 12 m onths (n=28) 7 (25.0%) X2=1.30, p=0.254
Older than 12 m onths (n=24) 3 (10.7%)
T reated
Not treated (n=259) 51(19.7% ) X2=0.55, p=0.458
Treated (n=36) 9 (25.0%)
Genotype
Genotype
Any other genotype (n=75) 13 (17.3%)
 1 (n=73) 21 (28.8%) X2=2.71, p=0.098
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Table 4.6 Summary o f differences between parenterally and vertically HCV infected 
children
Factor of interest Difference between parenterally and
____________________________________________ vertically HCV infected children_________
Sex
Anti-HCV therapy 
HCV genotype
Hepatom egaly events during follow-up
Persistently positive HCV viraemia
Consistently positive HCV viraem ia 
Persistently elevated A LT levels
Consistently elevated A LT levels
Two or more biological markers o f  HCV 
infection
Significantly more parenterally infected
boys and vertically infected girls
Significantly more parenterally infected
received treatm ent
No difference
Significantly more hepatom egaly events in 
parenterally infected
More parenterally infected with persistent 
viraemia, borderline significance
No difference
Significantly more parenterally infected
with persistently elevated ALT levels
No difference
No difference
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4.4 Key Points
• The analyses in this chapter represent the largest investigation o f  the impact o f mode o f 
acquisition o f infection on biological markers o f HCV infection in vertically and 
parenterally infected children to date.
• Vertically and parenterally HCV infected children differed in term s o f some key 
characteristics including the male: female ratio and the proportion o f children receiving 
anti-HCV therapy.
• Children who had consistently elevated ALT z-scores were more than 10 times as likely 
to also be consistently viraemic than those without consistently elevated ALT z-scores.
• Parenterally infected children had a higher odds o f being consistently viraemic than 
vertically infected children but not significantly so.
• No differences were found in the HCV genotype profiles o f vertically and parenterally 
infected children but a higher proportion o f children with genotype 3 achieved a 
sustained virological response to anti-HCV therapy in com parison to children with 
other HCV genotypes. Additionally, in univariable logistic regression, children with 
genotype 1 were more likely to be consistently HCV viraemic and have consistently 
elevated ALT z-scores than those with any other genotype but these associations
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remained o f borderline significance, perhaps due to the small numbers available for 
analysis.
• Children who had ever had evidence o f hepatomegaly were over three times as likely to
have consistently elevated ALT z-scores compared to those with no evidence o f
hepatomegaly.
• Children who were consistently HCV viraemic were over 12 times as likely to have 
consistently elevated ALT z-scores as those who were not consistently viraemic.
• In m ultivariable logistic regression analysis, parenterally HCV infected children were 
less likely to have consistently elevated ALT z-scores but not significantly so.
• Similar proportions o f  parenterally and vertically HCV infected children had evidence 
o f two or more m arkers o f  infection (consistent viraemia, consistently elevated ALT z- 
scores and evidence o f  hepatom egaly) and similar proportions o f those infected before 
and after 12 m onths o f  age had two or markers o f infection.
• Children who were genotype 1 were more likely to have two or more markers o f
infection than those with any other genotype but this association only reached
borderline statistical significance, perhaps due to the small numbers available for 
analysis.
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5. NATURAL AND TREATED HISTORY OF HIV INFECTION IN 
PARENTERALLY INFECTED CHILDREN
5.1 Introduction
The natural and treated history o f paediatric HIV in vertically infected children has been 
well docum ented (Blanche et al 1997, ECS 2004, ECS 2001, Thorne et al 2002, Pliner et al 
1998, Palumbo et al 1998, Dunn et al 2003, Prendergast et al 2007, Little et al 2007). 
However, less is known about HIV disease characteristics and progression in children who 
acquire HIV parenterally via receipt o f infected blood or blood products or contact with 
contaminated hospital instruments. This group o f children is relatively small due to the 
im plem entation o f  blood donor screening and universal sterilisation procedures in most 
developed countries in the early 1990s but there remain groups o f  children infected in this 
way and new infections continue to occur globally, often with large numbers o f children 
infected from a single source (Prati 2006, Morris 2006, V isco-Com andini et al 2002, Yerly 
et al 2001, Popova et al 1999, Hersh et al 1993). These children are unique both in terms o f 
their route o f acquisition o f  infection and the fact that they often have significant 
comorbidities, given the circum stances under which HIV infection occurred. Popova et al 
presented inform ation on 124 nosocom ially infected children from Russia o f whom 33 
(26%) had died 9 years after diagnosis. They report that in the first year o f  life, HIV 
infection in these children could rapidly progress to AIDS due to their background o f often 
severe disease prior to contracting HIV (Popova et al 1999). Despite continued outbreaks o f 
parenterally acquired HIV infection globally, few studies have quantified the natural history
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of children infected in this way and specifically the impact o f age at infection remains 
unqualified.
Differences in the natural history and disease progression o f HIV infected individuals by 
mode o f  and age at acquisition have been dem onstrated in adults, although overall results 
are conflicting. Recent large studies have identified no difference in disease progression 
among homosexuals in com parison to heterosexuals contrary to early research suggesting 
faster progression in the former (Carre et al 1994, Prins and Veugelers 1997, Rezza 1998). 
It is less clear whether differences found between progression in drug users and those 
acquiring infection via sexual transm ission are genuinely a result o f differing disease risk or 
are confounded by the high prevalence o f other-cause m ortality in infecting drugs users, 
their poorer adherence to therapy and their worse access to HAART (Langford et al 2007, 
Babiker et al 2003). A study o f UK haemophiliacs infected with HIV showed a higher 
survival rate 10 years after seroconversion, a longer time from infection to AIDS diagnosis 
and a longer survival after AIDS diagnosis in patients seroconverting before 15 years o f age 
compared to those seroconverting at older age groups up to 55 years o f age (Darby et al 
1996). More recently, data from over 13000 parenterally HIV infected individuals were 
analysed and the estim ated survival o f  individuals infected before 14 years o f age was 
greater than that am ong individuals infected at older ages, although the high number o f 
those infected before 14 years o f  age surviving to the end o f the follow-up period limited 
the estimation o f survival rates for this group (Collaborative Group on AIDS incubation 
and HIV survival 2000). Similarly, age at initiation o f HAART was found to be inversely
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associated with the magnitude and speed o f CD4 cell count recovery in a recent 
retrospective analysis o f 187 HIV infected patients (M icheloud et al 2008).
On the basis o f  adult data, it may therefore be hypothesised that the earlier a child is 
infected the slower the progression to severe disease. However, it is biologically plausible 
that those infected from M TCT or early in infancy may elicit a faster and more severe 
disease progression as a result o f an under-developed im mune system at the time o f 
infection. Several studies have partially investigated this by com paring disease progression 
in vertically infected children acquiring infection in utero with those acquiring infection 
intrapartum and/or post-partum  via breastfeeding. One study dem onstrated that children 
who were presum ed infected intrapartum, on the basis o f repeated early PCR tests, had a 
significantly lower mean initial viral load after infection and a more gentle decrease in viral 
load than those who were infected through breastfeeding. However in adjusted analysis, 
timing o f infection was not associated with risk o f progression to AIDS or death (Rouet et 
al 2003). Similarly, Shearer et al dem onstrated differences in initial peak HIV RNA viral 
load in those vertically infected early (n=7) or late (n=43) (initial peak HIV RNA viral load
780,000 and 243,000 respectively) but this difference disappeared shortly after birth and 
both groups subsequently responded to the virus in a similar way (Shearer et al 1997). In 
contrast, in a study o f vertically HIV infected children in sub-Saharan Africa, mortality was 
significantly lower in children who were postnatally infected, predominantly via 
breastfeeding, and those infected perinatally or intra-partum (Newell et al 2004).
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Using data from a large prospective cohort study, this analysis describes the short/medium- 
term natural and treated history and disease progression in parenterally HIV infected 
children. This chapter aims to docum ent this progression and facilitates its comparison to 
existing literature on vertically HIV infected children to assess differences by mode o f 
acquisition.
5.2 M ethods specific to this chapter
The dataset o f parenterally HIV infected children utilised for analyses in this Chapter were 
from the larger cohort o f  parenterally HIV and HIV/HCV infected children from the Libyan 
Follow-up Cohort Study (See section 2.3.4). Date o f infection was estim ated using the 
midpoint between the first positive HIV test and the earliest date at which infection was 
known to be possible, 1st January 1998. If the date o f the first positive HIV test was 
unavailable, date o f infection was assumed to be the 1st o f January 1999 as this was the 
midpoint o f the two year interval, 1st January 1998 to 31st Decem ber 1999, during which 
infection was known to have occurred. An undetectable viral load (UVL) is defined as the 
lower cut-off o f  the HIV RNA PCR assay.
5.2.1 Statistical analysis
HIV RNA viral load, CD4 count and progression to CDC immunological stage 3 and 
clinical stages B or C (CDC 1994) were used to indicate HIV-related progression in this 
analysis. Kaplan M eier survival analysis estimated the proportion o f  children progressing to 
moderate or severe clinical signs or severe immunosuppression over time and formal
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com parisons were made using log-rank tests (Bland and Altman 1998). CDC clinical 
categories were based on clinician reporting, while CDC immunological categories were 
designated on the basis o f  CD4 cell counts and age at measurem ent (CDC 1994).
Standard linear mixed effect (LM E) regression was used to exam ine HIV RNA viral load 
since infection, accounting for baseline CD4 count in the form o f  CDC immunological 
categories 1 vs 2/3. The final model included a random effect term for the intercept. The 
linear missed effect regression was performed using SAS software (v9.01, SAS Institute, 
Cary, North Carolina, USA).
5.3 Results
There was a total o f  243 parenterally HIV infected children in the cohort and their follow- 
up profile, including age at entry to the cohort and age at infection are presented in Table
5.1. For 195 children (80% ), date o f infection was estimated to be the midpoint between 1st 
January 1998 and their first positive HIV test. For the rem aining 48 children, date o f 
infection was assum ed to be the 1st January 1999. Follow-up began in all children within 
four years o f  infection, w ith 168 children (69%) first followed up within 12 months o f 
presumed infection. The m edian num ber o f  follow-up visits was three, with ten children 
only having one follow-up visit and 212 (87%) having three or more visits.
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Table 5.1 Follow-up profile o f parenterally HIV infected children
Parenterally HIV infected children (n=243)
Sex
Male (%) 138 (58%)
Female (%) 101 (42%)
Missing 4
Median age at infection (range) 21.8 months (14 days - 15.8 years)
Median age follow-up start (range) 3.3 years (27 days - 17.2 years)
Median duration of follow-up (range) 2.1 years (1 month -  4.9 years)
M edian time from infection to 8.2 months (range 14 days -  4.0 yrs)
follow-up start (range)
Median follow-up visits (range) 3(1-11)
5.3.1 HIV RNA viral load
Eight hundred and eighty-nine HIV RNA viral load measurements were available from 236 
parenterally HIV infected children with the median number o f m easurements per child 
three (range 1 - 1 0 )  (Figure 5.1). Twenty children (8%) only had one HIV RNA viral load 
m easurement recorded during follow-up while 191 children (81%) had three or more 
measurements. In the linear mixed effect model, HIV RNA viral load was associated with 
time since infection, baseline CDC immunological stage, receiving treatment and gender 
but not with the age at infection. The mean HIV RNA viral load within 12 months o f 
infection, adjusting for all the above factors, was 4.76 logio cp/ml (95% Cl 4.35 -  5.17 
logio cp/ml), from 153 HIV RNA measurements during this time. M ean HIV RNA level 
between 12 and 24 months after infection was significantly lower than in the first year after
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infection, 4.25 logic cp/ml (95% Cl 3.64 -  4.86 logio cp/ml). Mean HIV RNA viral load 
continued to decrease with increasing time since infection and the mean HIV RNA viral 
load between two and three years after infection was 3.78 logio cp/ml (95% Cl 3.18 -  4.37 
logio cp/ml). The viral load remained similar between three and four years after infection at
3.77 logio cp/ml (95% Cl 3.14 -4 .3 9  logio cp/ml) and decreased further after four years o f 
infection but observations during this period were fewer and therefore the estimate is not as 
robust.
As expected, children with a baseline CDC immunological category o f two or three had a 
significantly higher m ean HIV RNA viral load than those with baseline category one, mean 
HIV RNA viral load in those with moderate or severe im m unosuppression 5.11 logio cp/ml 
(95% Cl 4.45 -  5.77 logio cp/ml, p=0.007). Children who received ART had a significantly 
lower HIV RNA viral load than those untreated, mean HIV RNA viral load in those treated 
was 0.74 logio cp/ml lower than in those untreated, p<0.001 and girls had a lower HIV 
RNA viral load than boys, mean HIV RNA viral load in girls 0.23 logio cp/ml lower than 
boys, p=0.061.
114
Figure 5.1 Unadjusted logio HIV RNA viral load in 236 parenterally HIV infected
children (889 measurements)
24 36 48
Time since infection (months)
bandwidth = .8
Running mean smoother calculating smoothed values for each data point
5.3.2 Treatment
No children received post-exposure prophylaxis following infection as diagnosis occurred 
too late after infection for this to be appropriate. Twenty-six (11%) parenterally infected 
children received antiretroviral therapy after confirmation o f infection; 18 (69%) received 
highly active antiretroviral therapy (HAART) and eight dual therapy (Table 5.2). Eight 
(44%) o f the 18 children given HAART received a combination o f zidovudine, 3TC and 
nevirapine while 39% (7/18) received a combination o f zidovudine, 3TC and Nelfinavir. 
Seven o f the eight patients on dual therapy received Combivir (zidovudine and 3TC) while
115
one received zidovudine and zalcitabine. Among these 26 children, median time since 
infection at initiation o f treatment was 15 months (range 3.4 months -  3.0 years) and the 
median age at treatment initiation was 3.2 years (range 6.8 m onths-14.2 years). Children 
treated with HAART had a longer time from infection to initiation o f treatment in 
comparison to those treated with dual therapy, z=1.83, p=0.067. There were no differences 
in the age at initiation o f  treatment between those treated with dual therapy and those 
receiving HAART, z=0.61, p=0.541
At the time o f treatm ent initiation, or at the follow-up exam ination directly preceding 
initiation o f  treatment, 11 children (46%) were CDC im munological stage 1 (no 
im m unosuppression), nine (38%) were stage 2 (moderate im m unosuppression) and four 
were stage 3 (severe immunosuppression). Only three children additionally had any 
evidence o f  clinical sym ptom s at or before treatment initiation.
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Table 5.2 Treatm ent and disease progression in parenterally infected children
Parenterally HIV infected children 
(n=243)
Ever treated
No 217(89% )
Yes 26(11% )
Type of treatm ent (n=26)
Dual therapy 8(31% )
HAART 18(69% )
M aximum CDC im m unological stage
during follow-up
1 118(49% )
2 98 (41%)
3 24(10% )
missing 3
M aximum CDC clinical stage during
follow-up
N 29 (43%)
A 30 (45%)
B 4 (6%)
C 4 (6%)
missing 176
5.3.2.1 Response to treatment
Fourteen treated children (54%) had HIV RNA viral load measurements recorded before 
and after treatment. O f these 14 children, ten (71%) achieved an UVL between four and 1 8 
months after initiation o f treatment. The median HIV RNA viral load at initiation of 
treatment was 4.76 logio cp/ml (range 3.04-5.70 logio cp/ml) and decreased to a median of
1.77 logio cp/ml four to 18 months after initiation o f treatment. The median age at initiation 
in those who achieved an UVL was lower than in those who did not achieve an
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undetectable viral load, 2.9 years (range 1.5 years -  7.2 years) compared to 6.5 years (range
6.8 months -  11.8 years), but not significantly so (M ann W hitney=0.14. p=0.888).
5.3.3 Clinical signs and symptoms of HIV-related disease
Sixty-seven (28%) children had information on CDC clinical category and 29 (43%) and 30 
(45%) o f these children had no or mild clinical symptoms respectively throughout follow- 
up. Only eight (12%) children progressed to moderate or severe clinical symptoms during 
follow-up (Table 5.2) (Figure 5.2). Kaplan M eier survival analysis estim ated that 2% o f 
children will have progressed to moderate or severe AIDS defining symptom s 12 months 
after infection and 3% 36 months after infection (Figure 5.3).
118
CD
C 
Im
m
un
ol
og
ic
al
 
C
at
eg
or
ie
s
Figure 5.2 Centres for Disease Control immunological and clinical status of parenterally HIV infected children
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O f the eight children who progressed to moderate or severe clinical symptoms, six received 
HAART. Forty-one o f  43 children with CDC clinical stage information who received no 
treatment, had no or mild clinical symptoms. 11 children with no or mild clinical symptoms 
received HAART.
5.3.4 Progression to severe immunosuppression
Two hundred and forty children (99%) had CD4 cell count information which could be 
converted to CDC immunological categories. O f these 240 parenterally infected children, 
49%, 41% and 10% progressed to CDC immunological category 1, 2, and 3 respectively
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(Table 5.2) (Figure 5.2). Twelve months after infection, an estimated 2% o f children will 
have progressed to severe immunosuppression (defined as CDC immunological category 3) 
and three years after infection an estimated 8% will have progressed to severe 
immunosuppression (Figure 5.4). O f those 24 children who had progressed to severe 
immunosuppression by their most recent follow-up visit, an estimated 25% had done so by 
12 months o f  age and an estimated 75% three years after infection (Figure 5.5).
Figure 5.4 Progression to severe immunosuppression in parenterally HIV infected 
children
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Figure 5.5 Time to severe immunosupression in parenterally HIV infected children 
progressing to this stage by their most recent follow-up visit
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Four o f the 24 (16.7%) children progressing to severe immunosuppression received 
HAART during follow-up while one child received dual therapy and the rest received no
therapy.
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5.3.5 Factors associated with progression to severe im m unosuppression or moderate 
or severe AIDS-defining symptoms
In multivariable Cox proportional hazard analysis, progression to either moderate or severe 
im munosuppression or severe AIDS-defining symptoms (or both) was not associated with 
gender or age at infection but children receiving treatment were more likely to progress to 
either o f these stages during follow-up Hazard ratio 4.42 (95% Cl 1.90-10.26, p=0.001 
(Table 5.3).
Table 5.2 Univariable and multivariable Cox proportional Hazard regression of  
factors associated with progression to moderate to severe im m unosuppression and/or
progression to severe AIDS-defining symptoms (n=238).
Univariable analysis 
Hazard ratio p-value 
(95% Cl)
M ultivariable analysis* 
Hazard ratio p-value 
(95% Cl)
Sex
Male (n=137) 
Female (n=101)
1.00
0.94 (0.45-1.96) 0.865
1.00
1.08-2.28) 0.842
Age at infection
Younger than 22 m onths (n=l 11) 
Older than 22 m onths (n=127)
1.00
0.54 (0.25-1.14) 0.107
1.00
0.57 (0.27-1.22) 0.151
Received antiretroviral therapy
No (n=212)
Y es(n=26)
1.00
4.63 (2.00-10.69) <0.001
1.00
4.42(1.90-10.26) 0.001
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5.4 Key Points
• The mean viral load in parenterally HIV-only infected children after adjustment for 
baseline CDC immunological category, age at infection (before or after the median o f 2 
months), sex and whether children received treatm ent or not, was 4.76 logio cp/ml 
within 12 months o f infection. The mean HIV RNA viral load significantly decreased in 
subsequent years following infection and began to level out between two and three 
years after infection.
• Twenty-six o f  243 (11%) children received ART; 18 received HAART and eight dual 
therapy. ART was initiated at a median o f 15 months after HIV infection and at a 
median age o f  3.2 years.
• Ten o f fourteen children (79%) who were treated had an undetectable HIV RNA viral 
load 4 to 18 m onths after treatment initiation. The mean decrease in viral load four to 
18 months after infection was 3.04 logio cp/ml and more children treated with HAART 
achieved an undetectable viral load than those treated with dual therapy.
• During a m axim um  o f 4.9 years o f follow-up, 88% (59/67) o f parenterally HIV-only 
infected children had no or mild clinical symptoms with 12% (8/67) having moderate or 
severe clinical symptoms.
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• An estimated 2% o f parenterally infected children will have progressed to moderate or 
severe clinical symptoms 12 months after infection and an estimated 3% will have 
progressed to moderate or severe clinical symptoms 36 months after infection.
• During follow-up, 49% o f children had no im m unosuppression, 41% had moderate 
immunosuppression and 10% had severe immunosuppression.
• Twelve months after infection, an estimated 2% o f children will have progressed to 
severe im m unosuppression and 36 months after infection an estimated 8% will have 
progressed to severe immunosuppression.
• O f the 24 children progressing to severe immunosuppression, an estimated 25% did so 
within 12 m onths o f infection and an estimated 75% within 36 months o f infection.
• There was no association between gender or age at infection in those children 
progressing to m oderate or severe AIDS-defining symptoms and/or severe 
im m unosuppression during follow-up.
• Children who received treatment during follow-up were much more likely to have 
progressed to moderate or severe AID-defining symptoms and/or severe 
im munosuppression, likely reflecting confounding by indication and the initiation o f 
treatment in children with worse disease progression.
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6. HIV AND HCV COINFECTION: BIOLOGICAL M ARKERS IN 
PARENTERALLY AND VERTICALLY INFECTED CHILDREN
6.1 Introduction
HIV/HCV coinfection and its effect on disease progression has become a more prominent 
issue in recent years due to the longer life-expectancy o f HIV infected individuals and the 
subsequent increase in the effects o f comorbidities. The extent to which HIV/HCV 
coinfection and HIV treatm ent impact on morbidity and mortality in children remains 
unknown and optim um  clinical management and treatment for this group consequently 
remains uncertain (England et al 2006). To inform the m anagem ent o f coinfected children 
it is necessary that as much evidence on the natural and treated history o f coinfection is 
gathered and to achieve this research in all areas o f paediatric HIV/HCV coinfection must 
be prioritised.
It is unclear w hether HIV or HCV disease progression in coinfected children differs by 
mode o f acquisition and whether vertical infection during early immune development may 
lead to more severe or more rapid disease progression. If there are substantial differences in 
disease progression by mode o f acquisition, evidence-based management o f coinfected 
children should be tailored accordingly.
Using databases from three established and ongoing prospective cohort studies this chapter 
compares im munological, virological and clinical profiles o f  HIV/HCV coinfected children
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to describe and identify predictors o f disease progression and determine whether there are 
differences by mode o f acquisition.
6.2 M ethods specific to this chapter
Children vertically coinfected with HIV and HCV were identified from the European 
Collaborative Study (ECS) and the European Paediatric HCV Network (EPHN) (ECS 
2002, EPHN 2005a). Parenterally HIV/HCV coinfected children were identified from the 
Libyan Follow-up Study (Yerly et al 2001). Date o f infection in vertically infected children 
was assumed to be equivalent to date o f birth. Given the evidence on timing o f infection in 
mother-to-child transm ission (See section 1.6) it is possible that infection occurred before 
birth but repeated PCRs in the first few days o f life were unavailable and so it was not 
possible to formally allocate children into timing o f infection groups. The date o f HIV 
infection in parenterally infected children from the Libyan Cohort Follow-up Study was 
determined using the m idpoint between 1st January 1998 (the first possible date o f 
infection) and the date o f  their first positive HIV test or, if  this was unavailable, the 
midpoint (1st January 1999) o f  the period that infection was known to have occurred -  
January 1998 to January 1999. It is feasible that HIV and HCV infection occurred at 
different times in those children who had multiple exposures, however, as the window of 
possible infection is relatively short (approxim ately two years) assuming that both 
infections occurred concurrently shouldn’t lead to any substantial over- or under-estimates 
with regards timing o f  infection.
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6.2.1 Statistical Analyses
ALT levels were converted to standard deviation (SD) z-scores to account for variations 
over age. This involved calculating ALT age-related standards using penalized maximum 
likelihood and LMS software, with HCV and HIV uninfected children from the EPHN as 
the reference group (Bunders et al 2005, Cole and Green 1992). ALT measurements from 
the HIV/HCV coinfected children were then compared to these standards to give age- 
standardised z-scores m easuring the SD from the reference population. ALT z-scores above 
and below zero respectively indicate ALT levels above or below the reference median ALT 
level for that specific age. Elevated ALT levels were defined as greater than 2 SDs above 
the reference population for each age, corresponding to a value above the 95th centile o f the 
standard population.
Similar methods were used to calculate age and sex adjusted CD4 cell count SD z-scores 
for HIV/HCV coinfected children in comparison to a standard population o f  HIV and HCV 
uninfected children from the ECS [Bunders et al 2005].
Comparisons between parenterally and vertically coinfected groups were carried out using 
Mann W hitney rank sum, Chi squared or Student t-tests as appropriate. Univariable and 
multivariable linear regression with a random effects estimator on the intercept determined 
the factors associated with ALT z-scores and CD4 count z-scores, accounting for within- 
child repeated measures.
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Kaplan M eier survival analysis was used to estimate the proportion o f  parenterally and 
vertically coinfected children progressing to moderate or severe AIDS defining symptoms 
or immunosuppression over time since infection, with censoring occurring at the date a 
child first progresses to either CDC clinical stage B or C or CDC immunological stage 2 or 
3. If progression to this stage did not occur then a child is censored at the date o f their most 
recent follow-up visit. In addition, a further analysis was carried out among the sub-group 
o f children who progressed to CDC clinical stage B or C or CDC immunological stage 2 or 
3, to estimate the time taken for progression to occur from infection, again using Kaplan 
Meier survival analysis. Statistical comparisons between survival times in different groups 
were made using log-rank tests (Bland and Altman 1998).
Where indicated, follow-up data were limited to within 6.4 years o f infection as this was 
the maximum duration o f  infection in parenterally coinfected children. Restricting the 
analysis in this way m ade the parenterally and vertically coinfected groups more equal in 
terms o f  the length o f  follow-up.
6.3 Results
Data on 160 parenterally and 32 vertically HIV/HCV coinfected children were analysed. 
Vertically coinfected children were infected between 1986 and 2001 with follow-up 
between 1986 and 2005. Parenterally coinfected children were all infected during 1998 and 
1999 and follow-up occurred between 1999 and 2004. Significantly more vertically 
infected than parenterally infected children were male; vertically infected children had 
significantly more follow-up visits and a significantly longer duration o f follow-up (Table
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6.1). Significantly more vertically infected than parenterally infected children received 
antiretroviral treatment for HIV disease during follow-up and significantly more vertically 
than parenterally infected children were given HAART compared to dual therapy (Table
6 . 1).
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Table 6.1 Summary o f follow-up and HIV treatment in parenterally and vertically HIV/HCV coinfected children
Parenteral coinfected (n= 160) Vertical coinfected (n=32) Comparison (x or Ranksum)
Sex
Male 97 (62.2%) 11 (39.3%) X  =5.13, p=0.023
Female 59 (37.8%) 17(60.7% )
Missing 4 4
Median age at infection 1.3 years
(range lmonth-15.9yrs)
At birth N/A
Median age at start o f follow-up 3.2 years
(range 1 m onth-17.3 yrs)
Follow-up started at birth N/A
Median follow-up visits 4 visits (range 1-8) 11 visits (range 1-133) z=-6.251, p<0.001
Median duration of follow-up 1.8 years
(range 1 month -4.9 yrs)
4.6 years
(range 1 m onth-19.0 yrs)
z=-3.434, p<0.001
ART during follow-up
Not treated 127 (79.4%) 20 (62.5%) X  4.232, p=0.040
T reated 33 (20.6%) 12(37.5% )
Type of ART
Dual therapy 13 (39.4%) 1 (8.3%) X  3.961,p=0.047
HAART 20 (60.6%) 11 (91.7%)
Median age at initiation of ART 35.2 months
(range 14.2 m onths-14.8 yrs)
54.2 months
(range 7.5 m onths-14.3 yrs)
z= -1.360, p=0.174
Median duration of ART at last follow-up 1.3 yrs (1 month-5.0 years) 8.1 yrs (5.2 m onths-14.4 yrs) z=-3.44, pO.OOl
6.3.4 Treatm ent
No child received HCV treatment during follow-up. O f 45 (23%) coinfected children 
receiving HIV treatment, significantly more vertically than parenterally coinfected children 
were treated and most received HAART (Table 6.1). Eight (26%) children treated with 
HAART received a com bination o f Nelfinavir, Zidovudine and 3TC, Seven (23%) received 
a com bination o f Nevirapine, Zidovudine and 3TC, three (10%) received Nevirapine, 
Nelfinavir and D4T and a further three (10%) received Efavirenz, Tenofovir and 3TC. All 
children being treated with dual therapy received Zidovudine and 3TC.
HIV RNA viral load was available both before and six to 12 months after treatment 
initiation for ten o f  the 45 treated children, o f whom seven were parenterally coinfected and 
three were vertically coinfected. Nine children were treated with HAART and one with 
dual therapy. At initiation, m edian HIV RNA viral load was 4.32 logio copies/ml (range 
1.69-6.32 logio copies/m l) and six to 12 months after initiation, median HIV RNA viral 
load was 4.30 logio copies/m l (range 1.69-5.43 logio copies/ml). Six children showed a 
good virological response to treatm ent with a median decrease in HIV RNA viral load o f 
1.88 logio copies/ml (range 0.28-3.56 logio copies/ml). The median age at initiation o f 
treatment was higher in those children who exhibited an increase in viral load in response 
to treatment com pared to those who exhibited a decrease in viral load, median age at 
initiation 9.5 years (range 3.0 years -  14.3 years) compared to 3.6 years (range 2.0 years -
4.8 years), p=0.88.
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6.3.1 ALT levels
Five hundred and twenty-eight ALT m easurements were available from 156 parenterally 
coinfected children and 230 from 21 vertically coinfected children (Table 6.2) The 11 
vertically coinfected children with no ALT measurements during follow-up were enrolled 
in the studies earlier with dates o f birth ranging from 1987 to 1994 while those 21 who did 
have ALT m easurements were born between 1986 and 2001. This suggests a change in the 
m anagement o f these children to include more ALT testing. The median measurements per 
child were three (range 1-7) and six (range 1-116) in the parenterally and vertically 
coinfected groups respectively. M ean ALT z-score was significantly higher in vertically 
than parenterally coinfected children, but when the analysis was restricted to measurements 
taken within 6.4 years o f infection the difference was not statistically significant (Table
6.2), implying that this difference was a result o f ALT levels collected beyond 6.4 years o f 
infection where no com parable values from parenterally coinfected children were available. 
No significant differences were found in the proportion o f parenterally and vertically 
infected children with either one or more elevated ALT levels or all elevated ALT levels 
(Table 6.2).
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Table 6.2 ALT levels in parenterally and vertically HIV/HCV coinfected children.
Parenteral acquisition
(n=160)
Vertical acquisition (n=32) 
[comparison with parenteral group]
Vertical acquisition limited to 6.4 
yrs duration of infection (n=32) 
[comparison with parenteral group]
Median ALT level (UI/L) 38 (range 10-285) 
(n= 758 obs)
Mean ALT z-score
(n= 758 obs)
At least 1 elevated ALT 
(>2SD above normal)
All ALTs elevated 
(>2SD above normal)
2.30 (SD 1.70) 
115(73.7% )
53 (34.0%)
49 (range 17-218) 
[z=-1.910, p=0.056]
3.32 (SD 1.76) 
[t=-2.52,p=0.013]
17(81.0% ) 
[z=-0.739, p=0.460]
11 (52.4%)
[z=-1.647, p=0.100]
52 (range 20-144) 
[z=-1.489, p=0.137]
2.32 (SD 1.09) 
[t=0.005, p=0.996]
7 (77.8%)
[z=-0.272, p=0.242]
3(14.3% )
[z=0.043, p=0.966]
Linear regression analysis included 124 parenterally coinfected children with information 
available on all variables. These children did not differ from the whole group o f 
parenterally coinfected children with respect to any variable (Table 6.3). There was an 
increase in ALT z-score o f borderline statistical significance among parenterally coinfected 
children receiving HIV treatm ent and a significant decrease in ALT z-score with increasing 
duration o f  infection (Table 6.4). Both associations remained after adjusting for gender, age 
at infection, CD4 cell count z-score, HIV RNA viral load and HCV RNA viral load. For 
example, ALT z-scores were a mean o f 0.831 standard deviations higher in treated children 
in com parison to untreated children. Additionally, in m ultivariable analysis, ALT z-score 
significantly increased in parenterally coinfected children with increasing age at infection, 
increasing HCV RNA viral load and in those who received HIV treatm ent compared with 
those who were untreated (Table 6.4). In 21 vertically coinfected children with information 
on all the variables included in the linear regression model, ALT z-score was significantly 
increased in children on HIV therapy and ALT z-score was significantly increased with 
duration o f  infection. Both associations remained in bivariable analysis (Table 6.4). 
Uni variable analysis also showed a significant decrease in ALT z-score with increased CD4 
count z-score in contrast to the parenteral group. There were too few vertically coinfected 
children with ALT levels recorded to carry out multivariable linear regression.
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Table 6.3 Parenterally HIV/HCV coinfected children not included in multivariable
analysis
Parenterally HIV/HCV coinfected 
children not included in multivariable 
analysis n=36
Sex
Male 16(50% )
Female 16(50% )
missing 4
Median age at infection 1.8 years (range 1 m onth-13.7 yrs)
Median duration of infection 10.7 months (1 month-3.8 yrs)
HIV treatm ent
No 24 (66.7%)
Yes 12(33.3% )
Mean CD4 cell count z-score -0.216 (SD 1.20)
Mean ALT z-score 2.751 (SD 1.42)
M edian HIV RNA viral load (loglO 4.03 (range 2.21-5.28)
cp/ml)
Median HCV RNA viral load (loglO 5.55 (range 2.48-6.38)
cp/ml)
136
Table 6.4 Factors affecting ALT z-score in parenterally and vertically coinfected children.
Parenterally coinfected (n=124)
Univariable analysis Multivariable analysis
Coefficient (95% C l), Coefficient (95% C l),
p-value_________________ p-value_______________
Vertically coinfected (n=21)
Univariable analysis Bivariable analysis
Coefficient (95% C l), Coefficient (95% C l),
p-value_________________ p-value______________
Sex
Male
Female
0.00
-0.027 (-0.712-0.658), 
p= 0.938
0.00
-0.109 (-0.769-0.542), 
p=0.747
0.00
-1.012 (-2.651-0.626),
p=0.226
N/A
HIV treatment
No 0.00 0.00 0.00 0.00
Yes 0.674 (0.180-1.529),
p=0.122
0.831 (-0.021-1.683), 
p=0.056
2.50(1.824-3.167),
p<0.001
1.226 (0.460-1.992),
p=0.002
Duration o f infection (per one -0.028 (-0.047 - -0.009), -0.022 (-0.042 - - 0.019(0.014-0.023), 0.014(0.009-0.019),
monthly increase) p=0.004 0.003),p=0.026 p<0.001 p<0.001
Age at infection (per one 
monthly increase)
0.006 (-0.001-0.012), 
p=0.098
0.008 (-0.002-0.015), 
p=0.013
Collinear N/A
CD4 cell count z-score (per 
standard deviation increase)
-0.083 (-0.257-0.091), 
p=0.348
-0.022 (-0.154-0.198), 
p=0.807
-0.225 (-0.433 - -0.018), 
p=0.033
N/A
HIV RNA viral load 
(per loglO increase)
0.078 (-0.093-0.248), 
p=0.372
0.069 (-0.110-0.249), 
p=0.449
0.072 (-0.656-0.799), 
p=0.847
N/A
HCV RNA viral load 
(per loglO increase)
0.256 (0.111-0.401),
p=0.001
0.242 (0.096-0.387),
p=0.001
0.270 (-0.116-0.656), 
p=0.171
N/A
6.3.2 CD4 cell count
Nine hundred and six CD4 cell counts from 158 parenterally and 15 vertically coinfected 
children were analysed. CD4 cell count SD z-scores were similar in both groups but lower 
than in the uninfected but HIV-exposed standard comparison group used to calculate the z- 
scores (See section 2.5) (Table 6.5). The median lowest recorded CD4 cell count during 
follow-up was significantly lower in vertically compared with parenterally coinfected 
children and this significant difference remained when limiting duration o f infection to 6.4 
years (Table 6.5). M edian age at lowest CD4 cell count was 4.3 years (range 5.9 m onths-18 
years) after a m edian time since infection o f 2.6 years in the parenterally coinfected 
children com pared to a median age at lowest CD4 cell count o f 7.3 years (range 1.1 years-
15.4 years) in vertically coinfected children.
Univariable and m ultivariable linear regression analyses were carried out separately for the 
parenterally and vertically coinfected groups to investigate factors associated with CD4 cell 
count z-scores. In parenterally coinfected children, CD4 cell count z-score was significantly 
increased with longer duration o f  infection, but only univariably (Table 6.6). CD4 cell 
count z-score decreased significantly with increasing HIV RNA viral load both univariably 
and m ultivariably (Table 6.6). In vertically coinfected children mean CD4 cell count z- 
score was significantly lower in children receiving HIV treatm ent than in those untreated 
and this association was strengthened by adjustment for duration o f infection in bivariable 
analysis such that there was a mean decrease in CD4 z-score o f  1.54 standard deviations in 
treated children com pared with untreated children (Table 6.6). In bivariable analysis, there 
was a significant increase in CD4 z-score with increasing duration o f infection but the
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change in mean CD4 z-score was minimal despite the association being statistically 
significant (Table 6.6). There were too few vertically coinfected children with CD4 counts 
information to allow m ultivariable linear regression on this group.
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Table 6.5 CD4 cell counts in parenterally and vertically HIV/HCV coinfected children (n=173)
Parenteral
acquisition
(n=158)
Vertical acquisition (n-15) 
[comparison with parenteral 
group*]
Vertical acquisition limited to 6.4 
yrs duration of infection (n=15) 
[comparison with parenteral group*]
Median CD4 cell count 
(cells/mm3)
(n=906 observations)
1018 (range 150-9423) 787 (range 260-3495) 
[z-1.478, p=0.139]
1060 (range 480-3495) 
[z=-0.239, p=0.811]
Mean CD4 cell count z-score
(n=889 observations*)
-0.570 (SD 1.285) -0.607 (SD 1.188) 
[t=-0.104, p=0.917]
-0.943 (SD 1.281) 
[t=0.608, p=0.544]
Median nadir CD4 cell count 
(cells/mm3)
(n=173 children)
729 (range 62-2284) 368 (range 30-1850) 
[z=2.913, p=0.004]
368 (range 30-1850) 
[z=2.9139, p=0.004]
*Mann Whitney rank sum comparison o f medians or Student t-test comparison o f means
+ CD4 cell count z-scores not calculated for those children with missing gender
Table 6.6 Factors affecting CD4 cell count z-score in parenterally and vertically coinfected children.
Parenterally coinfected (n=124)
Univariable analysis Multivariable analysis* 
Coefficient (95% C l), p- Coefficient (95% C l), p- 
value value
Vertically coinfected (n=15) 
Univariable analysis 
Coefficient (95% C l), p- 
value
Bivariable
Coefficient (95% C l), p- 
value
Sex
Male 0.00 0.00 0.00
Female -0.134 (-0.636-0.367),
p=0.600
-0.046 (-0.468-0.560),
p=0.861
1.307 (0.189-2.426),
p-0.022
N/A
HIV treatment
No 0.00 0.00 0.00 0.00
Yes -0.060 (-0.574-0.694), 
p=0.853
-0.362 (-1.015-0.292), 
p=0.278
-0.984 (-1.520- -0.447),
p<0.001
-1.536 (-2.191--
0.881 ),p<0.001
Duration o f infection (per 
one monthly increase)
0.020 (0.006-0.034), p=0 .004 0.011 (-0.002-0.025), 
p=0.092
0.0002 (-0.004-0.004), 
p=0.905
0.006 (-0.002- -0.011), 
p-0.005
Age at infection (per one 
monthly increase)
-0.003 (-0.007-0.002), p= 
0.307
-0.005 (-0.010-0.001), 
p=0.078
Collinear N/A
ALT z-score (per one 
standard deviation 
increase)
-0.045 (-0.137-0.047), 
p=0.336
-0.004 (-0.084-0.092), 
p-0 .934
-0.434 (-0.777 - -0.090), 
p=0.013
N/A
HIV RNA viral load 
(per loglO increase)
-0.338 (-0.451— 0.224),
p<0.001
-0.329 (-0.446— 0.212),
p<0.001
-0.131 (-0.342-0.080), 
p=0.225
N/A
HCV RNA viral load 
(per loglO increase)
-0.100 (-0.207-0.007),
p=0.068
-0.073 (-0.176-0.030), 
p=0.863
0.001 (-0.053-0.056), 
p=0.446
N/A
* adjusting for all other variables
6.3.3 HIV and HCV RNA viral load
HIV RNA viral load was recorded 529 times from 142 parenterally and 196 times from 14 
vertically coinfected children. Although there was no significant difference in median HIV 
RNA viral load by mode o f  acquisition (Table 6.7), in a sub-analysis o f measurements 
taken within 6.4 years o f  infection, median HIV RNA viral load was higher in vertically 
than parenterally coinfected children, although not significantly so (Table 6.7). HCV RNA 
viral load was recorded 290 times from 139 parenterally and 50 tim es from 17 vertically 
coinfected children and was non-significantly higher in vertically than parenterally 
coinfected children (Table 6.7).
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Table 6.7 HIV RNA and HCV RNA viral loads in parenterally and vertically HIV/HCV coinfected children (n=156)
Parenteral acquisition
(n=142)
Vertical acquisition (n=14) 
[comparison with parenteral group]
Vertical acquisition limited to 6.4 
yrs duration of infection (n=14) 
[comparison with parenteral group]
Baseline HIV RNA viral load 
(loglO cp/ml) (n=142)
4.48 (1.40-6.30) 4.52 (range 1.90-5.74) 4.52 (range 1.90-5.74)
Median HIV RNA viral load 
(loglO cp/ml) (n=725 obs)
3.79 (range 1.40-5.87) 3.46 (1.70-5.54) 
[z=0.465, p=0.642]
4.62 (1.93-5.54) 
[z=-1.390, p=0.165]
Baseline HCV RNA viral load 
(loglO cp/ml) (n=T4)
5.40 (0.00-7.92) 5.46 (2.30-7.24) 5.46 (2.30-7.24)
Median HCV RNA viral load 
(loglO cp/ml) (n=340 obs)
5.35 (range 0.00-7.92) 5.76 (2.30-7.25) 
[z=-0.603, p=0.549]
Too few observations
6.3.5 Progression to moderate or severe immunosuppression
6.3.5.1 Proportion progressing to moderate or severe immunosuppression
CDC immunological stage was available for 172 children, 157 parenterally and 15 
vertically coinfected. Ninety six children, 86 parenterally and 10 vertically coinfected, 
progressed to moderate or severe immunosuppression during follow-up (CDC 
immunological stage 2 or 3). From survival analysis, one year after infection, an estimated 
4% o f parenterally and 20% o f vertically coinfected children will have progressed to 
moderate or severe immunosuppression, increasing to an estimated 48% and 34% 
respectively three years after infection (Figure 6.1). The overall difference during follow-up 
was not statistically significant, p=0.448.
Figure 6.1 Progression to moderate or severe immunosuppression in HIV/HCV 
coinfected children
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Forty-four o f 172 children with immunological stage information were receiving HIV 
treatment, 32 parenterally and 12 vertically coinfected. A higher proportion o f children who 
received HIV treatm ent (68%) progressed to moderate or severe im munosuppression during 
follow-up in com parison to those who did not receive treatm ent (60%), p=0.090, likely 
reflecting confounding by indication. Significantly more children treated with dual therapy 
versus HAART progressed to moderate or severe im m unosuppression, p=0.049, with an 
estimated 40% and 26% o f children treated with dual therapy and HAART respectively 
progressing to moderate or severe im munosuppression 36 m onths after infection.
6.3.5.2 Time taken for progression to moderate or severe im munosuppression to occur
Time from infection to progression to moderate or severe im munosuppression among the 
96 children who progressed, showed that 12 months after infection progression was 
substantially slower in parenterally coinfected children, an estim ated 6% compared with 
30% o f vertically coinfected children. However, an estimated 84% o f parenterally and 50% 
o f vertically coinfected children progressed to moderate or severe immunosuppression 
within three years o f  infection. Overall, parenterally coinfected children progressed to 
moderate or severe im m unosuppression significantly faster than vertically coinfected 
children, p^O.046 (Figure 6.2).
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Figure 6.2 Time taken for progression to moderate or severe immunosuppression to
occur in parenterally and vertically HIV/HCV coinfected children
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In parenterally and vertically coinfected children, there were no significant differences in 
the time it took children to progress to moderate or severe immunosupression among those 
receiving HIV treatm ent and those untreated (p=0.122), or between those receiving 
HAART and those receiving dual therapy (p=0.223).
6.3.5.3Proportion progressing to moderate or severe immunosuppression -  age at infection 
Progression to moderate or severe immunosupression in vertically coinfected children was 
compared with parenterally coinfected children infected before and after age one. Twelve 
months after infection, an estimated 20% o f vertically coinfected children, an estimated 5% 
o f parenterally coinfected children infected in the first year o f life and an estimated 29%
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infected after the first year o f life will have progressed to moderate or severe 
immunosuppression. Thirty-six months after infection an estimated 34% o f vertically 
coinfected children will have progressed to moderate or severe immunosupression. In 
contrast, an estim ated 54% o f parenterally coinfected children infected in the first year of 
life will have progressed to moderate or severe im munosuppression 36 months after 
infection, p=0.166 and an estim ated 44% o f parenterally infected children infected after the 
first year o f life will have progressed to this stage 36 months after infection, p=0.030.
6.3.5.4 Time taken for progression to moderate or severe immunosuppression to occur -  
age at infection
In the 96 children progressing to moderate or severe im munosuppression, an estimated 87% 
of parenterally coinfected children infected after the first year o f  life had progressed 36 
months after infection com pared with an estimated 80% o f those infected within the first 
year o f life, p=0.850. Progression after 36 months was not significantly slower in vertically 
than parenterally coinfected children infected during the first year o f  life, p=0.100.
6.3.6 Progression to m oderate or severe A IDS-defining symptoms
6.3.6.1 Proportion progressing to moderate or severe AID - defining symptoms
Information on CDC clinical category during follow-up was available for 43 coinfected 
children. Ten children progressed to moderate or severe AIDS-defining symptoms. An 
estimated 7% o f  the 43 children progressed to this stage 12 months after infection, 5% 
parenterally coinfected and 20% vertically coinfected. Three years after infection, an
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estimated 19% o f coinfected children with progression information available, will have 
progressed to moderate or severe AIDS-defining symptoms, 16% parenterally and 40% 
vertically coinfected, p=0.245. Two children (1 parenterally and 1 vertically) were 
receiving HIV treatment.
6.3.6.2 Time taken fo r progression to moderate or severe AID S-defining symptoms to occur
O f the ten children who progressed to moderate or severe AIDS-defining symptoms, an 
estimated 30% had done so 12 months after infection and an estim ated 80% by 36 months. 
Overall, there was no difference in the time to progression to m oderate or severe AIDS- 
defining sym ptom s by mode o f acquisition, p=0.582.
6.3.6.3Proportion progressing to moderate or severe AID S-defining symptoms -  age at 
infection
An estimated 26% o f children parenterally coinfected after the first year o f life will have 
progressed to m oderate or severe AIDS-defining symptoms 36 months after infection 
compared to an estim ated 15% o f children parenterally coinfected before 12 months o f age 
and 40% o f vertically coinfected children, with no significant differences between the latter 
two groups, p=0.684 or the two parenterally coinfected groups, p=0.498. Too few children 
progressed to m oderate or severe AIDS-defining symptoms during follow-up to assess 
differences in the speed o f  progression in groups infected at different ages or receiving 
different treatment.
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6.4 Key points
• Vertically and parenterally HIV/HCV coinfected children differed in terms o f some 
key population characteristics including duration o f follow-up, proportion receiving 
ART for HIV disease and the type o f  ART being given.
• ALT z-score significantly increased with increasing duration o f infection in both 
parenterally and vertically coinfected groups.
• ALT z-score was significantly higher among those children receiving ART for HIV 
disease in com parison to those untreated in both parenterally and vertically coinfected 
children.
• In vertically coinfected children, CD4 cell count z-score was significantly lower in 
those receiving ART than in those untreated. This association was not present in 
parenterally coinfected children.
• Six out o f ten children had a decrease in HIV RNA viral load following initiation o f 
antiretroviral treatm ent and this was similar in both parenterally and vertically 
coinfected groups.
• Three children achieved undetectable HIV RNA viral load after treatment; all were 
parenterally coinfected and treated with HAART.
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• No difference was found in the proportions o f  vertically and parenterally coinfected 
children progressing to moderate or severe immunosuppression, but among those who 
did reach this stage, parenterally coinfected children did so faster.
• Few children progressed to moderate or severe AIDS-defining symptoms during 
follow-up and no differences were found in the proportions o f vertically and 
parenterally coinfected children doing so.
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7. POLICIES AND PRACTICES FOR THE CLINICAL M ANAGEM ENT OF 
CHIDREN DIAGNOSED W ITH BOTH HIV AND HCV IN EUROPE
7.1 Introduction
To date no guidelines exist as to the most appropriate clinical m anagement o f children 
coinfected with HIV and HCV. The current guidelines from the British HIV Association 
and the Center for Disease Control on HIV/HCV coinfection in adults suggest that given 
the shared transm ission route o f both infections and the im plications o f coinfection on 
treatment in com parison to HIV infection alone, it is necessary to screen all HIV infected 
individuals for HCV infection (Nelson et al 2005, CDC 2004). Once coinfection has been 
established, the adult guidelines from BHIVA recommend carrying out a variety o f  liver 
function tests in addition to HCV genotyping and HCV RNA viral load testing. Liver 
biopsy can be used to asses the extent or the presence o f  any liver damage but uncertainty 
remains as to w hether the benefits o f this invasive procedure outweigh the costs, 
specifically in m ore vulnerable groups (Nelson et al 2005).
From a treatm ent perspective the current guidelines for HIV/HCV coinfection in adults 
vary depending on the stage at which HIV and or HCV is diagnosed. If patients are 
identified before HIV therapy is indicated or when CD4 cell count is greater than 500 
cells/ml, then HCV treatm ent should be considered in order that a better response to HIV 
therapy might be elicited once necessary (as HCV treatment is a one-off six-month course it 
is anticipated that the infection could be eliminated before HIV progression indicated 
treatment) (Nelson et al 2005). If  coinfection is diagnosed at a point where the patient
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requires, or is currently receiving, HIV therapy or CD4 cell count is less than 500 cells/ml, 
then this treatm ent should be optimised in terms o f increasing CD4 cell count before HCV 
treatment is considered (Nelson et al 2005, CDC 2004). Adding to the complexity o f 
treatment in HIV/HCV coinfected individuals is the evidence that HAART is associated 
with a reduced likelihood o f  liver fibrosis and related disease progression in coinfected 
adults, implying that delaying treatment in coinfected patients could be detrimental in terms 
o f both HIV and HCV disease progression (Quirishi et al 2003). The treatment o f 
HIV/HCV coinfected children is made more complex still by the limited number o f HIV 
drugs available for use in paediatric treatment, making it even harder to find paediatric 
ART that does not exhibit hepatotoxic properties (England et al 2006). The extent to which 
these issues identified as im portant in adult populations are relevant to HIV/HCV 
coinfected children rem ains unknown and thus no consensus on the treatment or 
management o f  coinfected children exists.
7.2 M ethods specific to this chapter
A semi-structured questionnaire survey was developed to ascertain details about current 
European m anagem ent and treatm ent o f HIV/HCV coinfected children in the context o f 
policies and practices for the treatm ent and m anagement o f HIV or HCV-only infected 
children. The survey was piloted on two clinicians who were asked to complete the 
questionnaire and provide feedback on ease o f completion, content validity and whether 
any areas o f specific clinical interest had been overlooked. The survey comprised the 
following sections; Background information, Policy for management o f HIV/HCV 
coinfected children, M anagem ent o f  HIV/HCV coinfected children, Treatment o f HIV-only
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infected children, Treatm ent o f HCV-only infected children and Treatment o f HIV/HCV 
coinfected children (Appendix 8). The survey sections included a combination o f closed 
and open ended questions in an attempt to gain as much inform ation as possible about each 
area. Following revisions based on the pilot feedback, the survey was distributed in July 
2006 via email to clinicians from eight European countries participating in either the 
European Collaborative Study o f HIV-infected pregnant women and their children and/or 
the European Paediatric HCV Network o f children born to HCV-infected mothers (ECS 
2001, EPHN 2005a). Rem inders were emailed to clinicians who had not responded four 
weeks after the original survey was circulated, together with another copy o f the 
questionnaire. Clinicians were asked to respond even if  they had no experience o f treatment 
and or m anagem ent o f  HIV/HCV coinfected children. As the number o f HIV/HCV 
coinfected children seen by each clinician was assumed to be small, questionnaires were 
sent to all centres in the ECS and EPHN studies regardless o f  whether they were known to 
manage coinfected children in an effort to maximise the inform ation on coinfected children 
collected. As a result o f  this more unselective distribution o f  questionnaires, only 16 
responses were received from a total o f  38 questionnaires distributed but it is likely that the 
majority o f non-responders had no experience o f managing HIV/HCV coinfected children 
and therefore deem ed the questionnaire irrelevant.
7.2.1 Data analysis
For the purposes o f describing the results o f this survey, the denom inator will be the 
number o f clinicians who com pleted any given question and this denominator may 
therefore differ for different questions.
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7.3 Results
Survey responses were received from clinicians from 16 clinical centres in Italy, Spain, 
Sweden, UK, Belgium, Denmark, Poland and Germany (Figure 7.1). These clinicians were 
currently caring for a total o f  44 HIV/HCV coinfected children (Appendix 4). Four centres 
(Bologna, Pavia, Edinburgh and London) were not currently following any coinfected 
children and had no experience o f  doing so in the past. Therefore, clinicians from these four 
centres did not com plete the majority o f the questionnaire.
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Figure 7.1 Centres surveyed on the management and treatment of HIV/HCV
coinfected children
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7.3.1 Background information
Forty-four HIV/HCV coinfected children were currently being managed by the 16 
clinicians contributing information to this survey. These 44 children ranged in age from 
three to 25 years old (the older patients having been managed by these clinicians since they 
were children) and 42 o f the children were vertically infected while two were parenterally
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infected. All the children were being followed up at university hospitals or tertiary referral 
centres and the respondents were all consultant paediatricians.
Twelve clinicians (all those answering this question) stated that they test for coinfection in 
children born to HIV/HCV coinfected mothers. Nine (75%) also test for HCV infection in 
all HIV infected children and two (17%) test for HIV infection in all HCV infected 
children. The latter two circumstances are more suited to the managem ent o f parenterally 
infected children which is less common but the statements are likely a reflection o f general 
clinical practice and principle. Five clinicians gave additional inform ation on other 
circumstances which would lead them to test for HIV or HCV infection in children. These 
circumstances were raised transaminase levels with an unknown cause or the presence o f 
other laboratory indicators o f infection, receipt o f intravenous im munoglobulin, history o f 
needle stick injury or sexual abuse, emigration from Africa or haem ophilia.
7.3.2 W ritten policies for the m anagem ent and treatm ent o f H IV/H CV coinfected  
children
Only one centre (in Italy) had a written policy for the m anagem ent and treatment o f 
HIV/HCV coinfected children although one other centre (in Spain) was in the process o f 
developing such a docum ent. In most other centres who com pleted this section o f the 
questionnaire, (8/11, 72%), decisions regarding the care o f coinfected children were taken 
at the hospital or departmental levels with only three out o f 11 centres relying on regional 
or national decision-making, although without the aid o f  written guidelines it is unclear
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how decision-making on a regional or national level was com municated to specific clinical 
centres.
In five centres, the schedule for the management o f HIV/HCV coinfected children was 
more frequent in children who were being treated for either HIV or HCV than those not 
treated. Two centres did not change their management schedule if  children were being 
treated. One centre altered the management o f coinfected children based on their age; 
specifically, HCV treatm ent would be delayed in younger coinfected children, but seven 
centres said that their m anagement schedule was unaffected by the age o f the child, the 
duration o f infection or the mode o f acquisition o f infection.
The one centre with a w ritten policy for the management o f HIV/HCV coinfected children 
recom mended a schedule o f  laboratory testing which included HCV RNA PCR testing 
every three m onths, IgA, IgM and IgG testing and hepatic ultrasound every six months and 
testing for cryoglobulins and a wide range o f autoantibodies annually. This policy was 
written in the context o f  extra m onitoring requirements for HIV infected children with 
HCV infection and therefore details o f the HIV m onitoring itself were not provided.
7.3.3 Laboratory testing
In addition to standard laboratory tests for monitoring HIV disease carried out in 
accordance with current guidelines (Helbert and Breuer 2000) 50% o f 12 centres also 
performed HCV RNA PCR tests at least annually and 50% o f  12 centres carried out ALT 
and AST tests at least every six months in coinfected children. Liver biopsy was rarely
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performed unless HCV treatm ent was due to begin but liver ultrasound was performed on 
coinfected children in five out o f 12 centres at least annually. Ten o f eleven centres (91%) 
performed HCV genotyping on all HIV/HCV coinfected children and seven o f nine centres 
(89%) monitored for evidence o f hepatotoxicity in coinfected children receiving ART for 
HIV disease. This m onitoring for hepatotoxicity predom inantly took the form o f ALT and 
AST testing approxim ately every three months.
7.3.4 Treatm ent of H IV/H CV coinfected children
Four centres (M ilan, W arsaw, M adrid and Turin) followed a com bination o f CDC (CDC 
1994), PENTA (Sharland et al 2004) and National guidelines for the treatm ent o f HIV only 
infected children. Two centres (Padua and Barcelona) followed a com bination o f CDC and 
PENTA guidelines and four centres (Valencia, Brussels, Stockholm and Hamburg) relied 
upon National guidelines only. One centre (Copenhagen) adhered to PENTA guidelines 
only. Five centres had experience o f treating HCV only infected children, o f which four had 
never done so outside the context o f a treatment trial.
Only one centre had ever treated coinfected children for HIV and HCV infections 
concurrently but four o f seven other centres stated that they would consider treating both 
infections at the same time if  a child met the criteria for both treatm ent o f HIV and HCV at 
the same point in time. In the situation o f an HIV/HCV coinfection diagnosis later in 
childhood, three out o f seven centres responding stated that they would preferably treat 
HCV infection before initiating HIV therapy as suggested in the adult guidelines.
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7.5 Key Points
• This survey represents a unique investigation o f European clinical management 
practices for the care o f HIV/HCV coinfected children by surveying clinicians actively 
involved in two o f the largest paediatric HIV and HCV cohorts in Europe.
• In the absence o f  guidelines for the clinical m anagem ent o f  children coinfected with 
HIV and HCV, practices in the European centres surveyed vary widely in terms o f 
testing high risk groups for HIV/HCV coinfection, w hether the hospital has a written 
policy for the m anagem ent o f  treatment o f coinfected children and what laboratory 
investigations were performed on children with coinfection in comparison to those with 
HIV infection only.
• Although a total o f  44 HIV/HCV coinfected children were being cared for in the 
surveyed centres, individual centres see relatively few coinfected children and therefore 
a lack o f experience in the management o f this group and the lack o f evidence-based 
policy may be a barrier to achieving optimal care and treatment.
• This survey highlights the im portance o f  research focussed on HIV/HCV coinfected 
children to inform guidelines for their best possible care.
• The development o f  such guidelines can only be achieved with consensus among 
clinicians on the optimal m anagement o f HIV/HCV coinfected children.
159
8. DISCUSSION AND CONCLUSIONS
8.1 Introduction
In this thesis a diverse range o f topics related to paediatric HIV and HCV infection have 
been investigated and in doing so much needed inform ation on the wider areas o f natural 
history and disease progression and on more specific areas o f coinfection, disease 
monitoring m ethodologies and the impact o f  mode o f acquisition o f infection has been 
provided.
Given the asymptomatic nature o f  paediatric HCV infection there is a need for accurate 
biological markers o f infection to m onitor progression. One o f  the main markers used in the 
management o f HCV, especially in children, is ALT levels and in this thesis the first 
reference ranges for normal ALT levels in young children stratified by sex and age and 
based on an appropriate, defined reference population are provided. This work from 
Chapter three suggests that an ALT level o f 60 U/l or greater in boys and 55 U/l or greater 
in girls under 18 m onths o f age and an ALT level o f 40U/1 or greater in boys and 35 U/l or 
greater in girls over 18 m onths o f  age should be regarded as elevated. The fact that these 
ALT levels are lower than previously reported or used in a clinical or research setting 
(Behrman 2003, EPHN 2005a), may explain why children with what were assumed to be 
normal ALT levels have been found to have mild or moderate liver abnormalities and may 
consequently have im plications for the referral o f children with elevated ALT levels to 
specialist hepatic services and the management and monitoring o f HCV infected children.
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The impact o f  mode o f acquisition of HIV or HCV infection on disease progression was 
the focus o f Chapters four, five and six. Parenterally HCV-only infected children were one 
and a half times more likely to have evidence o f  hepatomegaly during a similar duration of 
follow-up than vertically HCV-only infected children but no differences were found 
between mode o f acquisition groups in the genotype profile, proportion with consistent 
viraemia, proportion with consistently elevated ALT levels or the proportion with evidence 
o f two or more markers o f infection. These results provide evidence on the natural and 
treated history o f parenterally acquired HCV infection which is lacking in the literature and 
also suggest predom inantly similar characteristics in term s o f biological markers of 
infection between mode o f acquisition groups. This is a vital tool in informing the 
management and treatm ent o f parenterally HCV infected children and confirms the likely 
appropriateness o f  guidelines, developed on the basis o f inform ation from vertically HCV- 
only infected children, for their parenterally infected counterparts.
The disease progression o f vertically HIV-only infected children is well described in the 
literature and the results presented in this thesis show for the first time, patterns o f HIV 
RNA viral load in parenterally HIV-only infected children similar to those seen in 
vertically infected children, with HIV RNA viral load decreasing with increasing time since 
infection. In parenterally infected children, HIV RNA viral load increased by 0.35 logio 
cp/ml with decreasing im mune competency, as expected. In the 11% o f parenterally HIV 
infected children treated, response to A RT was high with 71% achieving an UVL four to 18 
months after initiation. This is higher than the response to treatm ent in some studies o f 
vertically HIV infected children (ECS 2006) and may be higher still given the small 
numbers o f parenterally infected children receiving treatment and the even smaller number,
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6%, with information on response to treatment. During a maximum o f five years follow-up, 
88% o f parenterally HIV-only infected children had no or mild clinical symptoms and 12% 
had moderate or severe clinical symptoms. Three years after infection, only 3% of children 
were estimated to have progressed to moderate o f severe clinical symptoms. Similarly, only 
10% o f parenterally HIV-only infected children progressed to severe immunosuppression 
during follow-up with 8% having done so three years after infection. Given the lack o f 
ART in this group o f children, their disease progression thus appears to be slower than that 
o f vertically HIV-only infected children reported in the literature (Gray 2001). The natural 
and treated history o f  parenterally acquired HIV infection has not been described in such a 
large group o f children previously and this thesis therefore provides insight into the most 
appropriate clinical m anagem ent and treatment o f this group. The relative lack o f ART in 
comparison to what has been the norm for vertically infected children for the last decade 
provides a rare look at true natural history and dem onstrates that even without therapy, this 
group o f children are predom inantly well with no or mild clinical symptoms or evidence o f 
im munosuppression, as was found for the parenterally HCV infected children. These results 
support delayed initiation o f  treatm ent in this group and may fuel the debate on delayed 
treatment in vertically infected children although further research in this area would be 
necessary.
Both vertically and parenterally HIV/HCV coinfected children exhibited an increase in 
ALT z-score with increasing duration o f  infection and in those treated versus untreated. 
There is the possibility that this increase in ALT z-score in treated children is confounded 
by treatment indication; it is plausible that children requiring HIV treatment will be those 
with worse HIV progression and consequently may have worse HCV progression and
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consequently higher ALT levels. It may also be possible that the hepatotoxicity o f the ART 
regimes being given are manifesting in increased ALT levels. No vertically coinfected 
children achieved an undetectable HIV RNA viral load following HIV treatment in 
comparison to 50% o f  parenterally coinfected children. Additionally parenterally HIV/HCV 
coinfected children progressed to severe im munosuppression faster than vertically infected 
children. There were no differences in the proportions o f  vertically and parenterally 
HIV/HCV coinfected children with severe im m unosuppression o f  clinical symptoms. 
Information on all aspects o f paediatric HIV/HCV coinfection is lacking despite recent 
increases in the importance o f coinfection in adult populations. This thesis provides the 
most detailed description o f parenterally coinfected children to date and in the context of 
mode of acquisition o f infection dem onstrates possible detrim ental effects o f ART on ALT 
levels and the possible need for differential m anagem ent o f  children infected via different 
routes. Additionally, this work helps clarify differences between coinfected and singly 
infected children as differences between parenterally and vertically infected children seem 
to be more evident in coinfected children than singly HIV or HCV infected children. This 
may be a result o f the interaction o f the HIV and HCV viruses which perhaps are more 
detrimental for HIV disease progression in parenterally coinfected children due to the 
source o f their infection. It is possible that infection transm itted through donor blood or 
which remains on un-sterilised equipment may have a higher level o f  virus and therefore 
the effects o f infection in this way may be more than from mothers who by nature o f the 
fact that they are pregnant are a reasonably well group. This difference may not be seen in 
singly parenterally and vertically infected children purely due to the bodies possible 
increased ability to respond to single infection compared to coinfection
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The issue o f the management o f HIV/HCV coinfected children in the context o f the lack o f 
paediatric guidelines specifically for this group is explored in Chapter seven o f this thesis 
by the survey o f current practices and policies for care o f these children by European 
clinicians. The fact that only one centre had a working policy for the care o f coinfected 
children and that in general the management practices varied widely in terms o f testing high 
risk groups for coinfection, which laboratory tests to carry out in com parison to those 
performed on HIV-only and HCV-only infected children and the opinions on optimal 
treatment for this group em phasise the importance o f research in this area to inform clinical 
guidelines. The lack o f coinfected children seen at individual centres further underlines the 
need for clinical consensus among those caring for HIV/HCV coinfected children in order 
to identify the optim um  m anagem ent and treatment for this group.
8.2 Context of results
The abundance o f  inform ation on vertically acquired paediatric HIV and HCV infection has 
created evidence-based know ledge on M TCT o f these viruses and the natural and treated 
history o f infected children and has led to paediatric treatments diminishing the effects o f 
infection and, in the case o f HIV, interventions vastly reducing vertical transmission. This 
body o f inform ation also means that the majority o f  HIV or HCV infected children are 
managed and treated according to clinical guidelines developed on the basis o f  evidence 
from large cohorts o f  vertically infected children. However, it remains unknown whether 
children who are parenterally HIV or HCV infected via exposure to contaminated blood or 
blood products follow a sim ilar natural and treated history as their vertically infected 
counterparts and therefore, w hether managing and treating parenterally infected children
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according to guidelines for vertically infected children is appropriate. In light o f potential 
differences in children infected early or late in childhood, it is possible that parenterally 
infected children, who are receiving care based on evidence from vertically infected 
children, are not receiving optimal clinical management. Additionally, there may be 
differences in disease progression by age at infection in parenterally infected children 
which have further im plications for the management o f this group. As well as informing 
clinical management, clarification o f these issues will provide more detailed information 
for families in term s o f the prognosis o f an infected child and for health services with 
regards planning for the burden o f infection given the ever evolving HIV and HCV 
epidemics globally.
As the num bers o f parenterally HIV or HCV infected children increase, or their reporting 
and diagnostic identification increases, specifically in less developed countries, it becomes 
progressively m ore im portant to understand disease progression in these children and 
determine differences to the vertically infected population.
This thesis goes some way to informing knowledge regarding these potential differences 
and provides an evidence base upon which clinical decisions regarding parenterally HIV or 
HCV infected children can be confidently made, further research in specific areas can be 
carried out and ultimately, guidelines can be expanded to include topics relevant to 
parenterally HIV or HCV infected children or developed specifically in relation to this 
group alone if  necessary. Additionally, this thesis addresses some issues inextricably linked 
to the more general area o f  paediatric HIV or HCV infection in terms o f  methodologies for 
analysing specific types o f  data, the development and im provement o f some disease
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progression m onitoring tools and the more qualitative assessm ent o f clinical practices. As a 
whole, this thesis expands on existing evidence and indicates where further research in 
more under-studied but increasingly important areas o f paediatric HIV and HCV infection 
is needed, particularly as the paediatric epidemics continue to present challenges for the 
care o f infected children.
8.3 M onitoring o f disease progression in HCV infected children
M onitoring progression o f paediatric HCV infection and associated diseases or 
abnormalities via the identification o f clinical symptoms o f disease is difficult and often 
inappropriate due largely to the asymptomatic nature o f  the infection and the presentation 
o f symptom s often several decades after infection, despite early establishm ent o f chronicity 
and lasting abnorm alities. Consequently, the use o f biological markers that can be related to 
disease outcomes, which can help to predict disease progression in HCV infected children 
and can help m onitor treatm ent response are ever more valuable.
For these biological m arkers to be o f use in a clinical setting, it is vital to optimise the way 
in which they are used. One exam ple o f a m arker about which conflicting views and 
evidence o f usefulness exist is ALT levels which serve as a marker o f  liver-related 
abnormalities in HCV infected individuals. Moreover, there is some doubt about the 
validity o f ALT as a m arker o f  liver disease, especially in the case o f chronic HCV 
infection where patients with normal ALT levels have been found to have minimal to mild 
liver abnormalities (Prati et al 2002). As has recently been suggested for adult studies, this 
may be partly explained by the current definitions o f normal or abnormal ALT levels based
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on data from undefined populations. In Chapter 3 I investigated the extent to which this was 
true for paediatric ALT levels and identified more accurate reference ranges for ALT levels 
in children.
8.3.1 Age and sex related reference ranges of ALT levels in children
I analysed data on serum ALT levels from a large group o f  healthy, HCV uninfected 
children and described ALT levels during a maximum o f  five years follow-up from birth, 
subsequently presenting ALT centiles and reference ranges for early childhood for the first 
time stratified by sex and updating previous studies (Lockitch et al 1988, Siest et al 1975, 
Behrman et al 2003). The study population from which these references were calculated 
were children born to HCV infected mothers but who were them selves uninfected with 
HCV. There is no evidence to suggest that ALT levels are affected by maternal HCV 
infection status in HCV uninfected children, although this cannot be totally excluded, and 
there is also no evidence to suggest that HCV exposure in utero affects the health o f 
uninfected children, especially given the lack o f anti-HCV therapy during pregnancy, but 
information and follow-up o f  HCV exposed but uninfected infants is short and 
underreported in the literature (EPHN 2005d, M ast et al 2005). Additionally, these children 
had been followed up from birth according to a standard protocol with intense reporting o f 
clinical signs and sym ptom s o f disease, both liver-related and otherwise, and there is 
nothing to suggest that children in this group were more morbid than the general 
population. Thus, any increases in ALT level as a result o f  underlying morbidity are likely 
to be representative o f the general paediatric population and not because this group had a 
higher prevalence o f  any liver-related abnormalities. This is further supported by the lack o f
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consistently elevated ALT levels in any individual child. M oreover, this group o f children 
was followed from birth and there are thus no children included in the uninfected group 
who were HCV infected but spontaneously cleared the virus. As a result, these children 
represent the largest group o f  HCV uninfected children with no underlying disease and 
regular ALT measurements, between birth and age five years, carried out within the 
standardised protocol o f  a cohort study. As ALT levels are not generally available for 
healthy children, it is unlikely that a more representative group o f  children would be 
available.
Although the few outlying ALT levels are one-off events and do not coincide with clinical 
events, there is the possibility that they are a result o f infection with other viruses, for 
example non-A, non-B or non-C hepatitis viruses or possibly SEN-V which can 
temporarily elevate ALT levels w ithout evidence o f concurrent clinical manifestations. 
There is also the possibility that children who cleared the virus very early in life, before 
their first HCV RNA test result, were diagnosed as uninfected when actually they are 
clearers and therefore possibly have higher residual ALT levels. It is not possible to isolate 
the reason for these outlying high ALT levels, simply to minimise the possibility that they 
occurred as a result o f  any underlying liver disease, which has been achieved. Additionally, 
as these outliers account for less than 1% o f all ALT measurements available, it is unlikely 
that their presence has influenced the resulting ALT centiles and reference ranges.
ALT assays were carried out at local hospital laboratories according to standardised study 
protocol but inter-laboratory assay variation is possible. However, variations in assays are 
likely to be random or lab-based rather than child-based, and not associated with age, sex or
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weight (Pembrey et al 2003). Furthermore, as these centiles are intended to be used as 
population based reference ranges, calculating them based on ALT assays from a number o f 
laboratories and with potential inter-laboratory variations minimises any bias which might 
arise from specific techniques had only one laboratory been used, making these reference 
ranges more generalisable to the broad paediatric population and in particular o f relevance 
for vertically and parenterally HCV infected children. A dditionally, there is the possibility 
that different laboratory machines were being used to analyse samples for ALT levels, 
again causing inter-laboratory variation. However, there are a limited number o f machines 
in use throughout Europe and similarly to the possible variation in assays, any differences 
in the results obtained using different machines are likely to be random and not child-based 
and not associated with age, sex or weight.
The analyses presented in Chapter three showed that ALT levels significantly decrease with 
increasing age after a peak in the first six months o f life and that mean ALT levels in boys 
are 1.5 U/l higher than in girls up to five years o f  age. A dditionally this investigation 
demonstrated an increase in mean ALT levels o f  1.1 U/l w ith each increase in weight-for- 
age standard deviation. Despite this, weight-for-age above the 95th centile compared with 
below the 95th centile was not associated with an increase in ALT levels leaving no 
clinically relevant measure o f weight which could be applied to the ALT centiles. The 
small number o f children with weight-for-age above the 95th centile (23 children in total) 
most likely limited the power to detect a difference in ALT levels between groups. 
However, in children under five years o f  age, weight will vary less than in older children or 
adolescents and therefore the effect o f weight-for-age on ALT levels here is likely to be 
smaller than in studies including older children and adolescents (Quiros-Tejeira et al 2007,
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Bedogni et al 2004). Previous studies have investigated the effect on ALT levels o f sex and 
weight in children and adolescents, however, none have presented sex and age specific 
ALT centiles.
The finding that ALT levels were higher in boys than in girls under five years o f age 
strengthens the evidence that similar sex differences in adult studies are at least in part due 
to biological mechanisms and not purely due to environm ental factors as has been 
suggested (Piton et al 1998). Higher ALT levels in males have been previously reported to 
some extent in children but not at such young ages (Lockitch et al 1988) and so this 
investigation provides the first evidence o f such a difference in children younger than five 
years old and confirms the similarity o f ALT differences by sex found in adult studies. 
Previous reports o f appropriate upper limits o f ALT levels in children suggested that ALT 
levels greater than 40U/1 should be considered as elevated (M oham adnejad et al 2003, 
Behrman et al 2003). There are also a number o f other studies which used a variety o f 
values, such as greater than 55U/1 or greater than 80U/1, representing the upper limit o f 
normal ALT reference ranges but these rarely refer to the population from which the 
reference range originated or they refer to previous studies which have used inappropriate 
populations for com parison purposes (Lockitch et al 1988, Siest et al 1975). The 
investigation presented here endorses the need for different cut-offs for different ages, as 
recommended by previous studies, but provides a more detailed, age-specific account o f 
these variations. Some previous studies have suggested that ALT cut-offs should differ in 
those younger and older than 12 months o f age (EPHN 2005a, Berhman et al 2003), 
however, the patterns o f ALT levels we present indicate that 18 months would be a more 
appropriate age at which to offer a clinically-relevant cut-off in term s o f ALT level centiles
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as this is the point at which Figure 1 shows ALT to level o ff indicating the end of the peak 
seen early in life. The results from this investigation therefore recommend that an ALT 
level o f greater than 60U/1 in boys and 55U/1 in girls should be regarded as elevated in the 
first 18 months o f  life while in older children the upper limits o f normal ALT levels are 
lower: 40U/1 in boys and 35U/1 in girls. W hile the difference o f 5U/1 between boys and girls 
is small, it is a crucial difference if  defined cut-offs are being used to identify elevated ALT 
levels because o f the im plications o f an elevated ALT level in terms o f further investigation 
and possible treatment.
It is important for appropriate clinical care that patients’ ALT levels are correctly classified 
as normal or elevated. The im plications o f revising paediatric ALT reference ranges, i.e. the 
lowering o f upper limits, requires careful consideration given to the potential increase in 
children with elevated ALT levels being referred to hepatology services. The benefits o f a 
revised (i.e. reduced) upper limit o f normal in terms o f  identifying liver abnormalities 
which would otherwise go undetected may be small in com parison to the extra costs, both 
economic and psychological, for health services, patients and families. However, this 
finding that ALT levels in children vary significantly by sex is an important consideration 
and clinicians should be aware o f these differences when categorising ALT levels as 
normal or elevated.
The frequency with w hich ALT is used as a m arker o f liver abnormalities, in clinical and 
research settings, highlights the importance o f using reference ranges for normality which 
are appropriate for the specific population under investigation, rather than relying on 
arbitrarily assigned reference ranges which do not account for differences by age or sex.
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This study represents the largest, most detailed and, to date, the only investigation o f the 
appropriateness o f ALT reference ranges in children under five years o f age and 
consequently provides an evidence base for the identification o f elevated ALT levels in 
children under five years o f  age.
8.4 Challenges in the investigation o f mode o f acquisition o f parenteral and vertical 
HIV and/or HCV infection in children
There are three major com ponents to unravelling the issue o f  w hether mode o f acquisition 
impacts on the biological and clinical markers o f paediatric HIV and HCV which 
complicates comparison o f parenterally and vertically infected groups in general and which 
have proved challenging throughout this thesis: 1) accurately estimating the date o f 
infection in parenterally infected children, 2) dealing with differing ages at infection 
between parenterally and vertically infected groups and within parenterally infected groups 
and 3) accounting for the different durations o f infection when measurements are recorded. 
These, in com bination with the differences in the tim ing o f  com m encem ent o f follow-up, 
the schedule o f these follow-up exam inations, exacerbated by the exclusive analysis o f 
vertically infected children from birth cohorts where inform ation during primary infection 
is collected, and the often different population characteristics o f children who acquired 
infection parenterally in comparison to vertically made deciphering whether differences 
between these groups were truly due to mode o f acquisition o f  infection increasingly 
complex.
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8.4.1 Accurately estim ating the timing o f infection
In the case o f many parenterally infected children, it is difficult to record a definitive source 
and timing o f HIV or HCV infection due to multiple exposure, exposure many years before 
diagnosis o f infection or inadequate recording o f medical procedures. To compare the 
natural/treated history and disease progression o f  parenterally infected children with that in 
vertically infected children requires information on the tim ing o f  infection as the effect o f 
age on many markers o f  HIV and HCV infection and subsequent prognosis is substantial 
and may additionally be related to age at infection.
In this thesis, the uncertainty surrounding date o f infection has been dealt with in different 
ways for the two parenterally infected cohorts. Children in the UK National HCV Register 
had been identified prim arily from retrospective studies specifically aiming to identify 
children who received blood or blood products from a source w hich has since been 
confirmed as contam inated (Departm ent o f  Health 1995, Gibb et al 2000). The medical 
records for these children were com prehensive and for many children (approximately 60%) 
the date o f infection was accurately estimated as the date at which a blood transfusion or 
other medical procedure occurred. However, for 40% o f  children in the Register it was 
impossible to accurately estimate the timing o f infection from medical notes, predominantly 
because these children received multiple transfusions. For these children, and for others 
with no known date o f  infection because they were exposed while living abroad and 
medical notes are not available or incomplete, the infection date either has to be regarded as 
missing, and the im plications in terms o f reduced sample size and possible bias dealt with, 
or has to be estimated. For the purposes o f this thesis I explored estimating the date o f 
infection using two methods. Firstly, using the mid point o f an interval during which
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infection is known to have occurred is a common statistical methods but posed problematic 
when applied to the HCV only infected children in Chapter four. The only point at which 
the children were known to be negative was birth and the only point at which they were 
known to be infected was when they were reported to the Register or diagnosed within 
specific retrospective studies (Department o f Health 1995, Gibb et al 2000). For many 
children the interval between these two events represented a period o f many years (as many 
as 17 years for the oldest child) and this was deemed too wide to make the use o f mid 
points appropriate. Secondly, I explored the possibility o f using interval censoring (as with 
Turnbull analysis (Alioum et al 2003, EPHN 2005e)) to model a likely infection date based 
on the distribution o f infection dates from those children who did have a known date o f 
infection. However, as the children without a known infection date seemed to be random in 
terms o f their differences to those who did have a known infection date there were no 
covariates indicative o f a missing infection date and so this methods was not possible. As a 
result, analyses in Chapter four were limited to only include those with a known date o f 
infection where this piece o f  inform ation was a vital com ponent o f  the specific analysis 
being carried out, i.e. a denom inator o f  76. Results may therefore be less generalisable or 
have less ability to dem onstrate statistically significant results, although 76 is still a large 
number o f parenterally HCV infected children in com parison to other studies. There are 
however, many analyses in Chapter four where a known date o f  infection was not necessary 
and data from the whole group o f children were utilised, e.g. the analysis o f factors 
associated with being consistently viraemic, having consistently elevated ALT levels or two 
or more markers o f  infection. M oreover a univariable com parison o f key characteristics of 
those with and without a known date o f infection showed no differences in the terms o f
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gender, HCV genotype or treatm ent profiles and confirm ed that dates o f infection were 
most likely missing at random.
The parenterally HIV and HIV/HCV infected children from the Libyan Cohort Follow-up 
Study posed different problem s in terms o f their dates o f  infection. For this cohort the 
window o f possible infection was very short -  the nosocomial source was reasonably 
defined - and so infection was known to have occurred during 1998 and 1999. This is in 
contrast to the children in the UK National HCV Register where exposure was via multiple 
sources in the UK and abroad. Some children had a defined date at which a procedure was 
carried out and infection was known to have occurred but again, for many children, 
multiple exposures occurred and an infection date was undefined. However, unlike the 
parenterally HCV infected children from the UK National HCV Register, the children from 
the Libyan cohort were all infected during a period o f  two years and additionally a large 
number have the date o f  their first positive HIV test recorded. It was therefore decided to 
estimate the date o f infection in these children using the m idpoint between the earliest date 
at which infection could have occurred (1st January 1998) and the date o f the child’s first 
positive HIV test result. For those children where no date o f first positive HIV test was 
recorded, the m idpoint during the two year interval o f  possible infection (1st January 1999) 
was taken as the date o f  infection. In this way, the accuracy o f the estimated dates o f 
infection were ensured and all analyses in Chapters five and six could utilise all data from 
the parenterally HIV and HIV/HCV coinfected children.
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8.4.2 Analytical challenges relating to different ages at infection
One o f the greatest challenges in the comparison o f parenterally and vertically HIV or HCV 
infected groups was trying to separate differences due to mode o f acquisition from those 
attributable to differing ages at infection. Accounting for different ages at infection was 
therefore a vital part o f assessm ent o f differences by mode o f acquisition in this thesis. The 
most straightforward way to do this was to stratify by different ages at infection whereby 
all the vertically infected children were included in the youngest age group along with those 
parenterally infected children who acquired infection early in childhood. The more children 
being analysed and the greater spread o f infection ages, the more specific these age groups 
could be. Specifically, the most im portant com parison was between vertically infected 
children and those parenterally infected children who were infected early in infancy as this 
allowed a comparison o f mode at acquisition while lim iting the confounding effects o f age 
at infection. For the purposes o f this thesis, the distribution o f  the date o f infection were 
such that parenterally infected children were categorised as those infected before and after 
12 months o f age so that a sufficient number o f children were included in each category to 
allow meaningful analyses. By com paring clinical and biological markers o f HIV or HCV 
infection in parenterally and vertically infected children and then making the same 
comparison according to age at infection (before or after 12 months o f age), it was possible 
to tease out w hether and to what extent mode o f acquisition or age at infection or both were 
influential in the nature o f  specific markers o f infection.
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8.3.3 Accounting for differing durations of infection at the time o f measurements
In trying to account for differences in age at infection, it was dem onstrated that 
measurements taken from parenterally infected children were often more sparse 
immediately after infection than they were for vertically infected children. This was due to 
the fact that inform ation was not collected from parenterally infected children from the 
point o f  infection because diagnosis was made on the basis o f symptom s leading to HCV or 
HIV testing or due to retrospective testing o f children exposed to a contaminated source as 
was the case for children subsequently enrolled in the UK National HCV Register and the 
Libyan Cohort Follow -up study. This delay between acquisition and diagnosis o f infection 
meant that follow -up data and biological/clinical inform ation for children in both these 
cohorts but especially for those enrolled in the UK Register for whom retrospective testing 
occurred after a longer duration o f infection, was unavailable during this period o f 
undiagnosed, prim ary infection.
There were a num ber o f  solutions to these problem s w hich needed to be tailored to the 
analysis being perform ed but for the purposes o f  this thesis it was first necessary to make 
sure that com parisons betw een parenterally and vertically infected groups were accounting 
for different ages at w hich m easurem ents were taken. This was done by calculating age- 
standardised z-scores for variables that vary with age, specifically, ALT levels and CD4 
cell counts, so that an A LT z-score represented the same raw A LT level regardless o f  the 
age at which it was m easured (See section 6.2.1). However, this only goes part o f the way 
to accounting for differences in the distribution o f m easurements; to illustrate, for a 
measurement taken at three years, for a vertically infected child this would be three years 
after infection but for a parenterally infected child this m ight have been taken a matter o f
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months after infection. This has im plications for the resultant m easurem ents taken from 
vertically infected children during primary infection where some markers o f infection, 
specifically viral load, are known to be high for this short period o f time. This is especially 
relevant for the vertically infected children included in this thesis who gre all enrolled in 
birth cohorts m eaning m easurem ents are available from birth. To avoid the use o f 
measurem ent-specific data when z-scores were not appropriate or did not fully account for 
biases in term s o f duration o f  infection, summary variables were created to form a measure 
o f the proportion o f  test results per child which met specific criteria. There is the possibility 
that children w ith more m easurem ents available, had a higher proportion o f  measurements 
that met specific criteria but these children had not necessarily been infected for a longer 
duration.
8.4.4 Incorporating differences in population characteristics
There were m any differences between parenterally and vertically HCV and/o HIV infected 
groups in term s o f  key population characteristics. Specifically, the setting o f parenteral and 
vertical HIV cohorts w ere very different as all parenterally HIV infected children were 
Libyan and were infected from  a defined hospital source. Additionally, by nature o f the 
way in which parenterally infected children acquired their infection, they were in general a 
more morbid group at the tim e o f  infection and possibly rem ained so throughout follow-up. 
This is problem atic if  the sym ptom s or biological markers associated with these 
comorbidities are sim ilar to, or have an effect on, those symptom s or markers o f  HIV or 
HCV infection. A ccounting for these in specific analyses was complex and the numbers o f 
children with individual com orbidities were small. Therefore the issue o f comorbidities was
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dealt with at the time o f  interpretation o f results, bearing in mind the feasibility o f any 
differences in the presence or levels o f biological markers o f HIV or HCV infection being 
influenced by the excess o f  com orbidities in the parenterally infected group.
Analysis o f  these cohorts o f parenterally infected children highlight ju st some o f the 
difficulties in analysing data from this group and provide guidance on how these difficulties 
can be overcom e or accounted for. Obviously, in addition to these particular areas, there are 
individual challenges specific to each analysis which are dealt with in this discussion 
chapter under the subject-specific headings.
8.5 Paediatric HCV infection
In Chapter four, the im pact o f  mode o f  acquisition on biological markers o f HCV infection 
in the largest com parison o f  vertically and parenterally infected children to date was 
investigated. A significantly higher mean ALT z-score in vertically versus parenterally 
infected and a significantly higher m ean ALT z-score in children infected before 12 months 
o f age com pared with those infected later, regardless o f  mode o f acquisition, was found. 
This latter association did not rem ain when only parenterally infected children were 
investigated which m ay be due to the small num bers (29 infected before 12 months o f  age 
and 24 infected after 12 m onths o f  age) but may also indicate that the differences between 
parenterally and vertically infected groups are not com pletely explained by age at infection 
but may be related more directly to the mode o f acquisition o f infection itself.
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Comparing biological markers o f  HCV infection in vertically and parenterally infected 
children is problem atic in light o f  the often substantial differences in populations in terms 
o f age at infection, age at study entry, treatm ent profile, likelihood o f clearance o f viraemia 
or genotype. In the children from the cohorts studied in Chapter four, four times as many 
parenterally than vertically infected children received HCV treatm ent; this may be due to 
more severe disease in parenterally infected children due to their age or mode o f 
acquisition, as suggested by the finding here o f  an increased proportion with two or more 
markers o f disease progression. A lternatively their older age at diagnosis (median age 19 
months) may make them more eligible for treatment; anti-HCV therapy is contraindicated 
in children under three years o f age, therefore vertically infected children who were 
followed from birth, will have started on a regim e o f clinical m onitoring without treatment 
and if  they remain asym ptom atic at three years o f age clinicians and parents may be 
reluctant to treat. A nti-HCV  therapy has substantial side-effects and many clinicians only 
treat in circumstances w here clinical sym ptom s com pel them  to do so. Although HCV 
therapy is well adhered to  in the paediatric population the unpleasant side-effects and the 
potential impact on grow th m ake the decision to treat a com plex one (Fischler 2007). There 
could also be bias in term s o f  the individual clinic or national treatm ent policies, especially 
given the continually evolving nature o f  inform ation on paediatric HCV treatm ent and the 
ongoing debate about w hen to initiate treatm ent (EPHN 2005c).
This debate on when to initiate treatm ent is partly fuelled by knowledge that some children 
spontaneously clear viraem ia w ithout treatment. In this study there was no effect o f mode 
of acquisition on clearance o f  viraem ia, 30% and 34% cleared the virus in vertically and 
parenterally infected children respectively, in contrast to some previous studies
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(Rerksuppaphol et al 2004). However, parenterally infected children in the UK National 
HCV Register were not followed up from the time o f  infection and possibly a large number 
o f those who cleared viraem ia did so before diagnosis or study entry. Therefore, any 
estimate o f clearance here and elsewhere, likely underestim ates the true proportion clearing 
viraemia in parenterally infected groups and it was therefore considered inappropriate to 
compare clearance in vertically and parenterally infected children. O f note, however, is the 
high clearance rates in parenterally infected groups reported in some studies (Vogt et al 
1999, O ’Riordan et al 1998, M atsuoka et al 1994) which w ould presum ably be even higher 
if  those who cleared viraem ia prior to diagnosis could be included. Similarly, in Chapter 
four, it is assumed that some parenterally HCV infected children cleared the virus prior to 
diagnosis the rate would be substantially higher than in the vertically infected group. It may 
therefore be the case that parenterally infected children are m ore likely to clear the virus 
than vertically infected children. It is likely that this can be substantiated as follow-up from 
infection in parenterally infected children is so difficult.
Quantitative levels o f HCV RNA viral load could not be exam ined in this thesis as they 
were only available for the children from the EPHN and not those from the UK National 
HCV Register. As the natural history o f  children enrolled in the EPHN is already well 
described, any analysis o f  viral load here was restricted to quantitative measurements.
No differences were found in the HCV genotype profiles o f vertically and parenterally 
infected children in contrast to Jara et al who found genotype lb  more frequently in 
children with transfusion-acquired HCV and genotype 3 more frequently in vertically 
infected children from seven European countries (Jara et al 2003). It is possible that the
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differences in the years at which infection occurred, infection in the studies investigated in 
Chapter four having occurred more recently than in Jara et aV s study, may reflect changes 
in the genotype profile o f the HCV epidemic in Europe as suggested recently (Bortolotti 
2007). A higher proportion o f children with genotype 3 achieved a SVR to anti-HCV 
therapy, as has been reported from a num ber o f  other paediatric studies (Bortolotti 2005). 
Additionally, in univariable logistic regression, children with genotype 1 were more likely 
to have consistently elevated ALT levels and consistently positive HCV RNA PCR results, 
although the associations did not reach statistical significance likely due to small numbers. 
This finding does how ever support those o f  Harris et al who suggested that type 1 
infections may be more aggressive than types 2 or 3 (Harris et al 2007) and those o f a 
previous EPHN study w hich found that intrauterine vertical transm ission was more likely 
to occur from mothers with genotype 1 (M ok et al 2005). As no differences in the genotype 
profile o f vertically and parenterally infected children were found here, it is unlikely that 
any differences in biological or clinical markers o f  HCV infection between groups can be 
attributed to the possible differences in HCV progression by genotype. In the analyses 
presented in Chapter 4, only 39% o f  those children receiving anti-HCV therapy had 
genotype inform ation recorded w hich may be underreporting, especially in the vertically 
infected group, but could also be a genuine lack o f genotype testing prior to treatment 
initiation, which is m ore likely in the parenterally infected group where data collection is 
more complete. These results confirm  the im portance o f  genotype testing in all children 
regardless o f  treatm ent status, to individualise m onitoring and provide information for 
patients and families in term s o f  prognosis and likely treatm ent outcome. They also 
demonstrate the need for m anagem ent and treatm ent guidelines to stress the importance o f 
this which this analysis suggests is not being carried out in practice.
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The investigation carried out in Chapter four reduced biases by accounting for treatment, 
genotype, age at infection and study entry, to a m inim um  and dem onstrated the persistence 
o f some differences by mode o f acquisition o f infection regardless o f  age at infection or age 
at which measurements were taken. In m ultivariable logistic regression no association 
between consistently raised ALT z-scores and mode o f  acquisition was found, although the 
odds ratio remained below  one, indicating higher ALT z-scores in vertically infected 
children. This could be due to a lack o f  power as only 29 parenterally infected and 47 
vertically infected children had ALT z-scores consistently above 2 SD. ALT levels have 
been shown to peak in the first two years o f life in vertically infected children (Tovo et al 
2000, Palomba et al 1996, Paccagnini et al 1995) and to adjust for this peak and any other 
differences resulting from age at m easurem ent, ALT z-scores were used. This ensured that 
the bias resulting from the fact that by nature o f the age distribution, ALT levels recorded 
during this peak would be m ore com m on in vertically infected children. However, the 
finding o f increased ALT z-scores in vertically infected children adjusted for age is similar 
to an Australian study in which significantly higher geom etric m ean ALT levels in 16 
vertically versus 15 parenterally infected children in the first five years o f life were found, 
again after accounting for the early peak in ALT levels (Rerksuppaphol et al 2004).
Significant positive associations were found between consistently high ALT z-scores and 
both consistent HCV RNA viraem ia and ever having evidence o f hepatomegaly. There was 
also a higher odds o f  having consistently positive HCV RNA PCRs in children ever having 
evidence o f hepatom egaly but not significantly so. The associations between these three 
markers o f  HCV-related disease progression support previous studies indicating that they
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may define a group o f children with evidence o f  chronic progressive HCV or who are at 
increased risk o f  rapid or more severe progression (EPHN 2005a). In this analysis, similar 
proportions o f parenterally and vertically infected children had evidence o f two or more of 
these markers o f  infection. Similarly, no difference was found in the proportion with two or 
more markers and age at infection, in either all children or ju s t the parenterally infected 
group. This lack o f association with mode o f or age at acquisition may have been due to 
combining the markers o f  infection into this summary variable and also the small number 
(15 children) o f parenterally and vertically infected children with evidence o f two or more 
markers o f infection.
The prevalence o f com orbidities in parenterally infected children in this and other 
populations is high given the nature o f  their infection during receipt o f  medical treatment 
(Popova et al 1999) and this may have been influential in term s o f  the child’s ability to 
mount an initial or continued im m une response to HCV infection. In contrast, vertically 
infected children, although acquiring infection during im m une development, may benefit 
from persistence o f  maternal antibodies, although it has been suggested that vertical 
acquisition o f HCV may lead to a greater anti-HCV im m une response and higher ALT 
levels soon after infection (Rerksuppaphol et al 2004, M urakami 2000). These mechanisms 
require specific investigation and although evidence from Chapter four doesn’t support 
substantial differences between vertically and parenterally infected group, until they can be 
further defined it is im portant that the potential differences between vertically and 
parenterally HCV infected children are recognised in a clinical setting.
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8.6 Parenterally acquired paediatric HIV infection
The work presented in Chapter five was a unique study o f  the natural and treated history o f 
parenterally acquired HIV infection. To date, no such detailed or large investigation o f this 
understudied group exists and given the increasing num ber o f  parenterally infected children 
being diagnosed, specifically in resource limited settings, this research provides and 
invaluable resource and inform s evidence-based m anagem ent o f these children. 
Specifically, this work describes the disease progression o f  paediatric HIV acquired in this 
way, the natural history o f  parenterally acquired infection, the treated history o f 
parenterally acquired infection and additionally allows com parisons to be made between 
parenterally and vertically infected groups reported in the literature to ultimately assess 
whether m anagement and treatm ent o f  children infected via contact with contaminated 
blood, blood products or m edical instrum ents should differ from  that o f vertically HIV 
infected children.
Information on parenterally HIV infected children in the literature is sparse and access to 
data on these children is rare. This is due to the geographical distribution o f children with 
parenterally acquired infection and the fact that the m ajority o f  parenteral infections occur 
in resource limited countries were the diagnosis o f parenterally infected children and the 
collection and recording o f  clinical and epidem iological data on these groups is incomplete. 
The result is a lack o f  epidem iological cohorts from which inform ation can be obtained and 
a subsequent lack o f  evidence-based m anagem ent and treatm ent o f these children in all 
parts o f the world. The work presented in Chapter five is therefore a very exclusive insight 
into the natural history and disease progression o f  parenterally HIV infected children not 
available elsewhere. Furtherm ore, the Libyan Cohort Follow-up Study database is
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comprehensive and com plete and the analyses in Chapter five are therefore based on a 
group o f children for whom follow-up began within 12 m onths o f infection for 69% and for 
whom the majority (87%) have m easurem ents recorded from three or more follow-up 
visits.
The work presented in Chapter five shows that the m ean HIV RNA viral load within 12 
months o f infection was high, 4.76 logio cp/ml, regardless o f  receiving treatment, baseline 
CDC immunological stage, gender or age at infection. As so few children received 
treatment (11%) and in those who did, treatm ent was initiated at a median time from 
infection o f 15 months, the majority o f  m easurem ents contributing to this mean HIV RNA 
viral load calculation are pre-treatm ent. A fter 12 m onths o f infection the mean HIV RNA 
viral load decreased with each increasing age after infection until it began to level out 
around three years after infection. This pattern is sim ilar to that seen in vertically HIV 
infected children although more vertically infected children receive treatm ent early in 
infection, suggesting a possible better virological response to HIV infection in this 
parenterally infected group (ECS 2002). As expected, the m ean HIV RNA viral load 
increased with decreasing im m une com petency and those few children receiving treatment 
had a mean HIV RNA viral load 0.74 logio cp/ml lower than those untreated. Interestingly, 
girls had a mean HIV RNA viral load 0.23 logio cp/ml lower than boys, in contrast to an 
earlier ECS analysis w hich reported higher HIV RNA viral loads in vertically infected girls 
than boys, although only in the initial period after infection (ECS 2002). In vertically HIV 
infected children this may be a reflection o f  the increased susceptibility o f  girls to vertical 
transmission (Galli etal 2005) and their subsequent disease progression. This may also be
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relevant for parenterally infected children in a different way as it indicates an innate 
difference in girls’ and boys' immune response to HIV infection.
Only 11% o f this parenterally infected group received any treatm ent for HIV disease which 
is a low proportion in light o f recent studies on the benefits o f  early treatm ent initiation in 
vertically infected children (ECS 2006, Violari 2007). This suggests that this group o f 
parenterally infected children were being m anaged in a way more sim ilar to HIV infected 
adults than vertically infected children whereby treatm ent is initiated when clinical signs 
and symptoms indicate it is necessary. As this group has a low prevalence o f clinical 
symptoms and im m unosuppression, this seems appropriate. However, further analysis 
showed that those with CDC clinical or im munological statuses w hich w ould be indicative 
o f the need for treatm ent were not always those receiving treatm ent and similarly, 46% o f 
children with no or mild clinical sym ptom s and im m unosuppression were being treated. 
Moreover, 31% o f  those being treated were receiving dual therapy despite treatment 
initiation after 1999 when H AA RT use was widespread. These inconsistencies with 
paediatric or adults guidelines suggest that the m anagem ent o f  these children was extremely 
individualised, perhaps as a result o f  concerns about adherence and resistance, the cost o f or 
access to ART drugs in Libya -  w hich would explain why a relatively high proportion o f 
children were receiving dual therapy, or perhaps due to the lack o f clinical guidelines or 
consensus on optimal m anagem ent and treatm ent o f  parenterally infected children and 
uncertainties about w hen best to initiate treatment.
Despite the small proportion o f  children receiving treatment, it was possible to assess the 
response to treatm ent in those 14 children with enough inform ation available. Given the
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lack o f information in the literature on parenterally infected children this still represents a 
significant group. 71% o f parenterally infected children with information available 
achieved an UVL four to 18 m onths after treatm ent initiation. Nine out o f these ten 
received HAART while o f those who did not achieve an undetectable viral load, two were 
treated with HAART and two were treated with dual therapy. The 71% UVL response rate 
is high and indicates a promising treatm ent response in parenterally infected children 
treated with HAART. A dditionally it is higher than that found in a recent analysis o f 
vertically infected children (ECS 2006) and may be even higher if  a larger num ber o f 
treated children were available or if  fewer children had received dual therapy.
Only 12% o f parenterally infected children progressed to m oderate or severe AIDS- 
defining symptoms but only 28%  o f the whole group had CDC clinical category 
information recorded. It is likely that this is due to the low prevalence o f  clinical symptoms 
but could also be an underreporting o f  clinical sym ptom s and therefore the low prevalence 
found in this analysis could be an underestim ation o f  the true clinical wellbeing o f this 
group. In contrast, CDC im m unological category was available for 99% o f this group and 
similarly to their clinical status, only 10% progressed to severe im m unosuppression during 
follow-up. This low prevalence o f  im m une deficiency likely confirm s the genuine low 
prevalence o f AIDS defining sym ptom s in the group.
Twelve months after infection, progression to severe im munosuppression had only 
occurred in 2% o f parenterally infected children which is lower than would be expected 
from a vertically infected group with a similarly low prevalence o f  treatm ent (Gray et al 
2001). Additionally, 75% o f all children who progressed to severe im munosuppression
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during follow-up had done so by three years after infection, supporting the idea that 
delaying treatm ent in this group may be appropriate given the low prevalence o f disease 
progression. There were no effects o f gender or age at infection on progression to 
immunosuppression or AIDS-defining symptoms. The lack o f effect o f age at infection may 
be a result o f the way this was categorised (those progressing before and after the median 
age at infection o f  22 m onths) due to the distribution o f  m easurem ents and an effect may 
have been seen if  those parenterally infected at earlier ages, perhaps before 12 or 6 months 
o f  age, could have been com pared with those infected after this point, as has been seen with 
vertically infected children (Newell et al 2006).
The findings o f this investigation o f parenterally HIV infected children suggest a 
favourable disease progression and response to treatm ent and provide for the first time a 
detailed description o f  natural history and disease progression in this population. 
Additionally, the fact that disease progression in parenterally infected children with such a 
low prevalence o f treatm ent seem s to be better than in vertically infected children is a 
positive finding for the well being o f  children infected under difficult circumstances and 
often in parts o f the world where access to clinical expertise and treatm ent is lacking.
8.7 Paediatric H IV/H CV coinfection
Little is known about HIV/HCV coinfection in childhood, especially the impact o f  mode o f 
acquisition o f  infection on disease progression and its markers. U tilising data from three 
distinct paediatric cohorts, analyses in Chapter six described immunological, virological 
and clinical aspects o f HIV and HCV infection in the context o f  coinfection and mode o f
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acquisition. ALT levels in HIV treated versus untreated coinfected children were 
significantly higher. In children receiving HIV treatment, HIV RNA viral load decreased in 
two-thirds o f parenterally and vertically coinfected children 6-12 months after initiation. 
Although no differences were apparent in the overall proportion o f  parenterally and 
vertically coinfected children progressing to m oderate or severe im munosuppression, 
parenterally coinfected children progressed to this stage more rapidly than vertically 
coinfected children. No differences were seen in the proportions progressing or the time to 
progression to m oderate or severe AIDS-defining symptom s during follow-up, by mode o f 
acquisition.
At the most recent follow-up visit, vertically and parenterally HIV/HCV  coinfected 
children had been infected for significantly different periods o f  tim e, m edian duration 9.6 
years and 2.6 years respectively and this had the potential to introduce bias in terms o f the 
time since infection at which m easurem ents were recorded. This bias was minimised 
primarily by limiting the m axim um  duration o f  infection in vertically infected children to
6.4 years which was equivalent to the m axim um  duration o f  infection in parenterally 
coinfected children. Com parison o f  ALT z-score m easurem ents initially im plied more 
severely impaired liver function in vertically than parenterally coinfected children. 
However, limiting duration o f infection to account for the longer follow-up in vertically 
coinfected children showed this difference to be non-significant, highlighting the 
importance o f accounting for duration o f infection when assessing differences by mode o f 
acquisition.
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No children received HCV treatment, likely due to the asymptomatic nature o f HCV 
infection in the first decade o f infection and reflecting recent guidelines whereby IFN 
treatment is contraindicated in children younger than three years o f  age (EPHN 2005a, 
EPHN 2005b). N early a quarter o f  children were receiving ART for HIV disease and the 
decrease in HIV RNA viral load in approxim ately 66% o f  these children after treatment 
initiation was similar to the 58% with a decreased viral load six months after treatment 
initiation in a recent European study o f vertically HIV-only infected children (ECS 2006). 
Children receiving ART had a higher ALT z-score than those untreated, significantly so in 
vertically coinfected children possibly because o f the higher proportion o f treated children 
in the vertically coinfected group. This may be indicative o f a detrimental effect o f HIV 
treatment on liver function due to the hepatotoxic nature o f  some drugs com m only used in 
paediatric HIV therapy (England et al 2006, Nelson et al 2005). Specific problems 
associated with nevirapine use in HIV/HCV coinfected children have recently been 
highlighted (England et al 2006, N elson et al 2005) and the treatm ent profiles o f  the 
coinfected children here reveal that 25% o f  45 children were receiving nevirapine with a 
further 10% Efavirenz, another non-nucleoside reverse transcriptase inhibitor known to 
have hepatotoxic properties (Alberti 2005). However, no serious hepatic effects directly 
related to NNRTIs can be confirm ed in this group that would oppose recent WHO 
guidelines (WHO 2006). O f note is that the median age at treatm ent initiation in 
parenterally coinfected children was approxim ately three years, sim ilar to the median age at 
start o f follow-up and so more o f  the z-score measurem ents from parenterally infected 
children will have been while on treatm ent and this was there the group where the effect o f 
treatment on ALT z-scores was less pronounced.
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Progression to moderate or severe im m unosuppression occurred in similar proportions o f 
parenterally and vertically coinfected children but more children receiving ART therapy 
progressed to m oderate or severe im m unosuppression than those untreated, although this 
difference only reached borderline statistical significance. This result likely reflects 
confounding by indication as the num ber o f children receiving treatment limited any 
analysis o f timing o f  sym ptom s and timing o f ART initiation. Among those children who 
did progress to moderate or severe im m unosuppression during follow-up, progression in 
parenterally infected children was significantly faster. Differential m anagem ent might be 
considered a key reason for this finding but no differences in the rate o f clinical 
progression in treated versus untreated children were found although those on HAART 
progressed significantly slow er than those on dual therapy, confirm ing the superiority o f 
HAART in a coinfected population (Tedaldi et al 2003). An alternative explanation is that 
the persistence o f passively acquired m aternal antibodies (Thorne and Newell 2000) in 
vertically coinfected children gives a protective effect such that their initial progression is 
slower. Additionally, neonatal A RT prophylaxis in vertically infected children is a 
previously reported predictor o f  slower HIV progression (ECS 2006). It is also possible that 
this difference relates to thym ic function as vertically coinfected children are younger at 
infection with a larger thym us which could m ean they have a higher CD4 count and lower 
HIV RNA viral load (Vigano et al 1999). The finding that clinical progression was not 
significantly slower in those treated versus untreated, is likely a reflection o f the small 
numbers o f children receiving treatm ent rather than an indication o f  no treatm ent effect.
More parenterally coinfected children infected during the first year o f life progressed to 
moderate or severe im m unosuppression than vertically coinfected children indicating a
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difference relating to mode o f acquisition rather than age at infection. The prevalence o f 
progression to moderate or severe im m unosuppression in parenterally coinfected children 
infected after the first year o f life was less than those infected in the first year o f life but not 
as low as in vertically infected children indicating an additional difference relating to age at 
infection and a possible relationship between early parenteral infection and more severe 
disease progression. This suggests that thymic function and infection during early immune 
maturation may be im portant influences o f disease progression in parenterally coinfected 
children while vertically coinfected children are in some way additionally protected 
possibly due to persistence o f  maternal antibodies or neonatal ART prophylaxis.
The group o f coinfected children studied in Chapter six progressed more slowly than 
vertically HIV-only infected children from a European multi-centre study, 50% o f whom 
had progressed to m oderate or severe im munosupression by one year o f  age [ECS 2001]. 
These differences may be due to the small numbers o f vertically coinfected children 
progressing to moderate or severe im m unodeficiency in this group or, more likely, may be 
due to differences in treatm ent profiles between the two studies. The possibility exists that 
the interaction o f the HIV and HCV viruses in coinfected children provide some kind o f 
protective effect in terms o f  HIV progression but the data here were inadequate to explore 
this further.
The analysis o f progression to m oderate or severe A ID S-defining symptoms was limited by 
small numbers and the lack o f differences by mode o f  acquisition or age at infection may 
have been due to a lack o f statistical power. The findings on progression to symptomatic 
HIV disease were similar to those reported by the ECS on vertically HIV-only infected
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children, in which approximately 75% o f  children progressed to moderate or severe AIDS-
defining symptoms by 24 months o f  age (ECS 2001).
Any differences in disease progression between parenterally and vertically coinfected 
children could be due to varying durations o f infection. However, this investigation has 
shown that accounting for this, aspects o f HIV and HCV disease progression differ between 
parenterally and vertically HIV/HCV coinfected children. The findings suggest that the 
HIV therapeutic m anagem ent o f  HIV/HCV parenterally coinfected children, infected 
during the first year o f life should be more aggressive than for their older counterparts or 
vertically coinfected children. This result ties in with the debate on when to initiate 
treatment in vertically H IV-only infected children and suggests that early initiation may be 
appropriate for vertically and parenterally coinfected children who acquire infection early 
in infancy but may not be necessary for those infected later in childhood (ECS 2006, 
Violari et al 2007). Furtherm ore, the findings also point tow ards a difference in disease 
progression according to age at infection and clinical m anagem ent decisions m ust consider 
possible differences in children infected via similar routes but at different ages. ALT levels 
were significantly higher in coinfected children receiving HIV treatm ent em phasising the 
importance o f monitoring and individualising HIV treatm ent in coinfected children to 
account for possible hepatotoxicity in HIV drugs and their impact on liver function in 
HIV/HCV coinfected children. This however, if  com plicated by the limited paediatric HIV 
drugs available and requires a balance between the possible detrimental effects o f  HIV 
treatment and the effect o f  not treating HIV disease with the m ost appropriate HIV drugs. 
Issues relating to possible structured HIV treatm ent interruption to allow for a concentrated 
period o f HCV treatment need to be explored with an em phasis on optimising the
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management o f both infections and the possible im plications for drug resistance. Further 
research involving larger numbers o f vertically coinfected children would help clarify the 
differences found in this study, investigate further the possibility o f coinfection with HCV 
reducing disease progression in com parison to HIV only infected children and inform 
individual clinical managem ent and treatment o f this group o f  HIV/HCV coinfected 
children.
8.8 M anagem ent survey o f H IV/HCV coinfection
In the absence o f guidelines for the clinical management o f  children coinfected with HIV 
and HCV, practices in the European centres surveyed varied widely. Only one centre 
surveyed had a working policy for the management o f HIV/HCV  coinfected children and 
therefore most centres were relying on guidelines based on HIV or HCV-only infected 
children. As none o f the published guidelines on paediatric HIV or HCV managem ent make 
reference to coinfection, clinicians are forced to rely on personal clinical experience rather 
than the consensus o f  global clinical speciality on the treatm ent and m anagem ent o f  HIV 
and HCV singly infected children that has been pooled together and is constantly updated.
This survey highlights that individual centres see relatively few  coinfected children and 
therefore a lack o f  experience in the m anagem ent o f this group and the lack o f evidence- 
based policy may be a barrier to achieving optimal care and treatment. The centre which 
did have a HIV/HCV coinfection m anagem ent policy and the centre who was in the process 
o f compiling a policy were in Italy and Spain respectively. Both Italy and Spain have 
higher rates o f HIV and HCV infection than other parts o f  W estern Europe and therefore it
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is likely that they also have a higher prevalence o f HIV/HCV coinfection which may 
explain why written policies for coinfection m anagem ent are available in these centres and 
not in others.
The low response rate for the survey is a limitation in term s o f  the generalisability o f results 
but the geographical distribution o f responses was wide and both Italy and Spain were 
overrepresented which is appropriate given the likely higher prevalence o f  HIV/HCV 
coinfection in these countries.
The circumstances under which clinicians test for HIV/HCV coinfection vary but it is 
apparent that they would ascertain most cases o f coinfection in the paediatric population by 
current methods. Some centres however did report more thorough testing in specific 
groups, such as those with less common risk factors for coinfection, and a consensus on the 
circumstances for coinfection testing would be helpful to ensure that all risk groups are 
targeted.
The schedule for laboratory testing for specific H CV -related m arkers varied between 
centres and there seemed little agreement in terms o f w hich tests were appropriate and at 
what intervals these should be carried out. In term s o f  m onitoring HCV progression in 
coinfected children based on the evidence from long-term  m ulti-centre studies, a lack o f 
available information on biological markers o f infection would m ake this problem atic and 
therefore it is possible that the monitoring o f HCV infection in this group o f  coinfected 
children is inadequate.
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The treatment o f HIV/HCV coinfected children is very complex and as yet no definition o f 
the most appropriate treatment regimes exists other than to provide inform ation on specific 
drugs used to treat HIV infection which are inappropriate or which carry risks for a 
coinfected population. This lack o f consensus is reflected in the survey in Chapter seven 
and is compounded by the lack o f experience in treating HCV infection alone, as well as 
treating coinfected children. Treatment o f HCV singly infected children rem ains relatively 
rare but the possibility exists that it may be more necessary in coinfected children and 
therefore the concurrent treatm ent o f HIV and HCV disease needs to be explored. Very few 
clinicians stated that they would happily administer HIV and HCV treatm ent concurrently 
and it seems more appropriate that a scheduled HIV treatment break may be more suitable. 
Issues regarding optimal treatment regimes are usually resolved by clinical treatm ent trials 
and this may be the most appropriate course o f action for coinfected children as this survey 
highlights that management and treatment practices vary widely and therefore 
retrospectively looking at treatment outcomes in coinfected children is unlikely to provide 
definitive answers. However, the small number o f HIV/HCV coinfected children may be a 
barrier to treatm ent trials.
In the absence o f guidelines for the clinical management o f children coinfected with HIV 
and HCV, practices in the European centres surveyed varied widely. Individual centres see 
relatively few coinfected children and therefore a lack o f experience in the m anagem ent o f  
this group and the lack o f  evidence-based policy may be a barrier to achieving optimal care 
and treatment. This survey highlights the importance o f research focussed on this group o f  
children to inform guidelines for their best possible care and the need for a consensus 
among clinicians on the optimal management o f these children. The survey is lim ited by
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small numbers and subsequently in its generalisability but it is a much needed first step in 
emphasising this little studied area and highlighting issues for further investigation 
specifically with a view to developing treatment guidelines for HIV/HCV coinfected 
children.
8.9 Recom m endations for future research
Mode o f  acquisition o f  infection -  parenterally infected children
The results o f this thesis highlight the scarcity o f information regarding parenterally HIV 
infected children, largely due to the countries where parenteral infection occurs and 
subsequent difficulties in access to clinical information. Those countries where the 
parenteral epidemic is still important are to some extent in Eastern Europe, although the 
situation is greatly improved there, and to a greater extent central Asian countries w here 
acquisition o f HIV infection is largely among injecting drug users and blood safety is not 
yet a priority for econom ic and logistical reasons (Hauri et al 2004). In these countries the 
infrastructure in terms o f diagnosis and monitoring o f HIV infected individuals must 
improve before any epidemiological study would be feasible. Resources also need to be 
expended on gathering sufficient epidemiological data to clarify the natural history o f  
parenterally acquired HIV infection which appears from this research to result in slow er 
disease progression than vertically infected children and therefore may inform  m ore 
individualised treatment recommendations and help resource-limited settings prioritise their 
treatment programs. As surveillance and HIV prevention programs are established or 
improve in these Eastern European and Central Asian countries it would be ideal for
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epidemiological research programs on parenteral acquisition o f infection to run along side 
prevention and treatment programs to achieve this.
H1V/HCV coinfected children
The ideal future research recommendation for HIV/HCV coinfected children would be the 
establishment o f  a cohort o f HIV/HCV coinfected children infected vertically or 
parenterally with data collected from as wide an area as possible. This w ould inform 
knowledge in a number o f ways. Firstly, it would increase the am ount o f data available on 
HIV/HCV coinfected children, minimise the limitations encountered in this thesis with 
regards the small numbers o f children, specifically vertically infected, available for analysis 
and improve reliability o f the estimates. Secondly, a cohort specifically dedicated to 
coinfected children could collect all necessary HIV and HCV related inform ation from  all 
coinfected children, thus overcoming the problem encountered in this thesis w hereby the 
coinfected children enrolled in HIV cohorts had limited HCV-related inform ation and vice- 
versa for those enrolled in HCV cohorts. Now that a picture has been built by this thesis 
and other studies on what may be the differences between HIV or HCV only infected 
children and coinfected children and speculation about the optim um  treatm ent for 
coinfected children has been made, it is timely to study a group o f  coinfected children who 
are followed prospectively within a specifically designed cohort study in order to clarify 
many o f these still speculative results and provide an evidence base for m anagem ent and 
treatment guidelines for coinfected children. The survey presented in this thesis showed 
that there are a num ber o f confected children being cared for by W estern and Central 
European clinicians whose expertise on management and countries’ infrastructure w ould be 
useful in the establishm ent o f such a cohort. In addition, many Eastern European countries
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continue to report a great number o f both HIV and HCV infected children to birth cohorts 
and while M TCT rates are falling the HIV infected populations in these countries are so 
large that even a 4% transm ission rate as recently reported from Ukraine, results in a great 
many potentially coinfected children being born each year, inform ation about whom would 
greatly benefit a cohort o f  HIV/HCV coinfected children. Additionally, the infrastructure 
for follow-up o f coinfected children in many o f  these countries is already in place thanks to 
groups such as the ECS who expanded into Eastern Europe in 2000.
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FORM A
EUROPEAN PAEDIATRIC HCV NETWORK
Prospective Study
MATERNAL ENROLLMENT INFORMATION
EPHN ID number _ / _  _ /  _
centre no. mother no. child no.
Mother’s date of birth / /
M ost likely m o d e  o f  m aternal acq u is it io n  o f  HCV in fection
blood transfusion/blood products □
injecting drug use □
other □  please specify
not known □
R e a so n  for HCV te s t in g
mother’s request □
routine antenatal policy □
identified as high risk group □
(selective screening policy)
clinical (e.g. signs of hepatitis) □
other □  please specify
Has the mother u sed  intravenous d ru gs?
yes, during this pregnancy □
yes, but not during this pregnancy □
never □
don’t know □
Is the m other  HIV in fec te d ? Yes □ If yes, CDC stage: A1 A2 A3
No □ (p lease circle) B1 B2 B3
Don’t know □ C1 C2 C3
Has th is  m other  b een  p rev io u s ly  reported  to  the  N etw ork?  Yes □
No □
If yes, please give EPHN ID num ber(s):_____ /_______ /_______
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FORM B
EUROPEAN PAEDIATRIC HCV NETWORK
Prospective Study
MATERNAL CLINICAL AND LABORATORY INFORMATION DURING PREGNANCY
EPHN ID number /  /
centre no. mother no. child no.
HCV test results
Please give details of ALL tests carried out during th is  p r e g n a n c y  and at delivery, 
starting with most recent.
If available, please also give details of earlier tests.
ELISA Date
Result
RIBA Date
Result
PCR-RNA Date
Result
RNA
c o p ie s  per ml
Date
Result
ALT
IU/L
Date
Result
H as the  m o th er ’s  HCV g e n o ty p e  b e e n  d eterm ined ? Yes □
No □
If yes, please specify genotype:
Has the  m other  rece iv ed  trea tm en t during p reg n a n cy  or during delivery  for HCV
or HIV in fect ion ?
Yes □  If yes, name of drug dosage
No □  ..........................................................
date treatment started / /
date treatment stopped / /
W as a 1 ml seru m  s a m p le  taken  and s to red  from the m oth er  at or near delivery?
Yes □  Date:_____ /____ /__________
No □  If not, why not:.....................................................................................
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FORM C
EUROPEAN PAEDIATRIC HCV NETWORK
Prospective Study
DELIVERY INFORMATION 
EPHN ID number _ / _  _ /
centre no. mother no. child no.
Date of delivery / /
day month year
M ode o f  delivery
vaginal, spontaneous □ emergency Caesarean section □
vaginal, instrumented □ elective Caesarean section* □
*i.e. before onset of labour and rupture of membranes
unknown □
Total duration o f  l a b o u r : _____ hrs_____ mins
Time from rupture o f  m e m b r a n e s  to  d e l i v e r y : _____ hrs_____ mins
W ere any ob ste tr ic  in terven tion s  (e.g . fetal s c a lp  m on itors ,  fo r c e p s )  u s e d  during
d elivery?  Yes □  If yes, please specify............................................................................
No □
Don’t know □
"NEONATE INFORMATION
Birth w e ig h t  (grams) ..................
G esta tiona l a g e  (weeks) ...........
G en d er  male □
female □
W as any anti-retroviral trea tm en t to  red u ce  the risk o f  t r a n s m is s io n  o f  HIV 
a d m in istered  to the n e o n a te ?
If yes, name of drug dosage
Yes □  ....................  ..............
No □
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FORM DI
EUROPEAN PAEDIATRIC HCV NETWORK 
P r o s p e c t iv e  S tudy
PAEDIATRIC FOLLOW-UP: CLINICAL EXAMINATION 
For examinations at birth, 6 weeks and 3 months of age
EPHN ID number  I  I __ Date of examination / /___
centre no. mother no. child no. day month year
Date of birth / /
day month year
W eight (kq)
H eight (cm)
Is th is  child  HIV in fec te d ?  Yes □
No □
Indeterminate □
If yes, CDC stage (please circle): N1 N2 N3 A1 A2 A3 B1 B2 B3 C1 C2 C3
Clinical manifestations
Has th is  child d e v e lo p e d  any  o f  the  fo llow ing  s y m p to m s  s i n c e  th e  la s t  v is it?
Growth failure yes / no ..........
Please give details
Hepatomegaly yes / no ..........
Splenomegaly yes / no ..........
Nephropathy yes / no ..........
Cardio-pulmonary yes / no ..........
Skin disorders yes / no .........
Haematological disorders yes / no .........
Auto-immune disease yes / no .........
Other yes / no .........
W as th is  child ev er  b rea st- fed ?  Yes □  If yes, age stopped (weeks)
No □
Don’t know □  240
FORM D2
EUROPEAN PAEDIATRIC HCV NETWORK  
P r o s p e c t iv e  S tu dy
PAEDIATRIC FOLLOW-UP: CLINICAL EXAMINATION 
For examinations at 6 months of age and older
EPHN ID number __/ ____ /   Date of examination / /___
centre no. mother no. child no. day month year
Date of birth /__  /_____
day month year
W eight (kg)
H eight (cm)
Is th is  child  HIV in fec te d ? Yes □
No □
Indeterminate □
If yes, CDC stage (please circle) : N1 N2 N3 A1 A2 A3 B1 B2 B3 C1 C2 C3
Clinical manifestations
Has th is  child  d e v e lo p e d  an y  o f  th e  fo llow ing  s y m p to m s  s i n c e  th e  la s t  v is it?
Please give details
Growth failure yes / no
Hepatomegaly yes / no
Splenomegaly yes / no
Nephropathy yes / no
Cardio-pulmonary yes / no
Skin disorders yes / no
Haematological disorders yes / no
Auto-immune disease yes / no
Other yes / no
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FORM D2
Has th is  child  b een  v a c c in a te d  aga inst:
hepatitis  B? Yes □  
No □
If yes, date of first dose / 1
hepatitis  A? Yes □  
No □
If yes, date of first dose / /
Has th is  child had an u ltrasou nd  s in c e  the la s t  v is it?  Yes □
No □
If yes, date of ultrasound / /
result ..........................................................................................................
Has th is  ch ild  had a liver b io p sy  s in c e  the last v is it?  Yes □
No □
If yes, date of biopsy / /
reason for biopsy .....................................................................................
result .........................................................................................................
Is th is  child  rece iv ing  trea tm en t for HCV in fection? Yes □
No □
Date treatment started / /
Reason for starting treatment ...............................................
D rug..................................... Dosage............................
If child is no longer being treated, date treatment stopped / /
Reason for stopping treatment ............................................
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FORM El
EUROPEAN PAEDIATRIC HCV NETWORK
Prospective Study
PAEDIATRIC FOLLOW-UP - LABORATORY TEST INFORMATION 
For tests done at birth, 6 weeks, and 3 months of age __
EPHN ID number
centre no. mother no. child no.
Details of laboratory tests carried out since the last visit: 
HCV PCR t e s t s
Date of test Result (positive/negative) Viral load* - copies per ml
*method used:
HCV A ntibod y t e s ts
Date of test Type of test
ELISA or RIBA, 
generation
Result
positive/negative/
indeterminate?
no. of bands
ALT le v e ls
Date of test ALT level (IU/1)
S a m p le s  to be s to red
Was a Guthrie card (filter paper) sample taken and stored (birth & 3 mths)?
Yes □  Date:______/____ /__________
No D  If not, why n o t:....................................................................
Was a 1 ml serum or plasma sample taken and stored (3 mths)?
Yes □  Date:______/____ /______ ___
No □  If not, why not:.....................................................................
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FORM El
Other tests
Date of test Result
haemoglobin g/di
m
g/dl
WBC 10B/ml
106/ml
106/ml
lymphocytes %
%
%
neutrophils %
%
%
platelets /ml
/ml
/ml
coagulation screen 
normal or abnormal: 
if abnormal please specify
igG mg/d I
mg/d I
mg/d I
igM mg/d I
mg/d I
mg/d I
igA mg/d I
mg/d I
mg/d I
igE I U/m I
lU/ml
lU/ml
total bilirubin mg/d I
mg/d I
mg/d I
albumin ..................................... .................
s M
g/dl
alpha fetoprotein ng/ml
ng/ml
ng/ml
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FORM El
Is the HCV g e n o ty p e  o f  th is  child  k n o w n ? Yes □  If yes, genotype 
No □
Have any  o ther  t e s t s  b e e n  carried o u t  for th is  ch ild ? Yes □
No □
If yes, please give details below (date, type of test, result):
Date Type of test Result
FORM E2
EUROPEAN PAEDIATRIC HCV NETWORK  
P r o s p e c t iv e  S tudy
PAEDIATRIC FOLLOW-UP - LABORATORY TEST INFORMATION 
For tests done at 6 months of age and older
EPHN ID number
centre no. mother no. child no.
Details of laboratory tests carried out since the last visit:
HCV PCR t e s t s
Date of test Result (positive/negative) Viral load* - copies per ml
*method used:
HCV A ntib ody t e s ts
Date of test Type of test
ELISA or RIBA, 
generation
Result
positive/negative/
indeterminate?
no. of bands
ALT le v e ls
Date of test ALT level (IU/1)
S a m p le s  to be  s to r e d
Was a 1 ml serum or plasma sample taken and stored (at 12 mths, 24 mths, then once 
a year)?
Yes □  Date:_____ /_____/__________
No □  If not, why not:........................................................................................
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FORM E2
Other tests
Date of test Result
haemoglobin g/dl
g/dl
g/dl
WBC 106/ml
106/ml
106/ml
lymphocytes %
%
%
neutrophils %
%
%
platelets /ml
/ml
/ml
coagulation screen 
normal or abnormal: 
if abnormal please specify
igG mg/d I
mg/d I
mg/d I
igM mg/d I
mg/dl
mg/dl
igA mg/dl
mg/dl
mg/dl
igE lU/ml
lU/ml
lU/ml
total bilirubin mg/dl
mg/dl
mg/dl
albumin g/dl
g/dl
g/dl
alpha fetoprotein ng/ml
ng/ml
ng/ml
247
FORM E2
Has this child been tested for the presence of auto-antibody since the last visit?
Yes □  If yes, result ________________________________
No □
Is the HCV genotype of this child known? Yes □  If yes, genotype
No □
Have any other tests been carried out for this child? Yes □
No □
If yes, please give details below (date, type of test, result):
Date Type of test Result
248
APPENIDIX 6 EUROPEAN COLLABORATIVE STUDY DATA COLLECTION  
FORMS
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ECS3
INTENSIVE PROSPECTIVE STUDY OF CHILDREN BORN TO HIV POSITIVE MOTHERS
MATERNAL INFORMATION AT DELIVERY
Centre
Mothers Study Number 
Child Study Number
Mother’s date of birth (day, month, year)
Country of b ir th ..........................................................................................................................................
Marital Status
Single (1), Married (2), Divorced, Separated, Widowed (3), Cohabiting (4)
Ethnic Group
Asian (1), White (2), Black (3), Oriental (4), Other (5)
Age when leaving full-time education, years.........................................................................................
Obstetric History
Number of previous livebirths .................................................................................................................
Number of previous stillbirths .................................................................................................................
Number of previous miscarriages............................................................................................................
Number of previous terminations............................................................................................................
Mothers Risk Group
History of intravenous Drug Abuse (Y/N)
Trimester of last use: pre-conception (0), 1st (1), 2nd (2), 3rd (3), unknown (9)
Needle sharing? never (1) past (2) present (3) unknown (9)
Sexual partner of Bisexual (Y/N)
Sexual partner of Haemophiliac (Y/N)
Sexual partner of Intravenous Drug Abuser (Y/N)
Sexual partner of Other high risk group (Y/N)
(Specify) ......................................................................................................................................................
O ther..............................................................................................................................................................
Mothers HIV History
Date of first HIV+ test (day, month, year)
Current clinical status
Current HIV staging (C D C )......................................................................................................................
Specify symptoms .......................................................................................................................................
Date of o n s e t ................................................................................................................................................
Details of treatment during pregnancy
Has the woman received any antiretroviral therapy at any time during this pregnancy? Y/N 
Please give details of both ART and other prophylaxis (eg. TMP-SMX)
Drug Date started Date stopped Currently taken? 
(yes/no)
2-bO
ECS 3
PROSPECTIVE STUDY OF CHILDREN BORN TO HIV POSITIVE MOTHERS
Page 2
MATERNAL INFORMATION
Laboratory investigations during pregnancy and at delivery;
Centre Number 
Mothers Study Number 
Child Study Number
1-2
6
3-5
Virology
Date: Date: Date:
HIV-DNA PCR Pos / Neg Pos / Neg Pos / Neg
HIV-RNA PCR copies/ml copies/ml copies/ml
Sample type Plasma / Serum Plasma / Serum Plasma / Serum
Assay used
Other laboratory investigations
Date: Date: Date:
Total lymphocytes
CD4 (109/litre)
CD8 (109/litre)
IgG (gm/litre)
IgA (gm/litre)
IgM (gm/litre)
p24 Ag
HIV Elisa
I S \
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ECS3
INTENSIVE PROSPECTIVE STUDY OF CHILDREN BORN TO HIV POSITIVE MOTHERS
MULTI CENTRE EEC STUDY
MEDICAL EXAMINATION
Please circle or complete as appropriate
A ssessm ent a t : 3w, 6w, 3m, 4.5m  and 6 m
Centre
Mothers Study Number 
Child Study Number 
Date of Examination 
Weight (kg) 
Height (cm) 
OFC (cm)
1-2
3-5
7-12
13-16
17-20
21-23
Recurrent fever of unknown origin requiring medical attention............................. Y/N
Chronic or Recurrent diarrhoea requiring medical attention..............................Y/N
Specify organism.............*....................................................................................
Bacterial infection ................................................................................................Y/N
If yes, specify:
Septicaemia, Meningitis, Urinary tract infection, Pneumonia, Other...................
Communicable D isease....................................................................................... Y/N
Measles (1) Mumps (2) Rubella (3) Varicella (4) Zoster (5) Other (6)............
Complications.......................................................................................................
Skin Infection requiring medical attention.............................................................Y/N
Staph (1) Strep (2) Herpes (3) Candida (4) Other (5).......................................
Non-infectious skin eruption .............................................................................. Y/N
Petechiae/Purpura (1) Eczema (2) Kaposi Sarcoma (3) Other (4)....................
Palpable Lymph N odes.........................................................................................Y/N
Axillary (1) Postoccipital (2) Cervical (3) Inguinal (4) Epitrochlear (5) Other (6)
Chronic parotid swelling ......................................................................................Y/N
Oral Candida persistent or recurrent despite therapy............................................ Y/N
Upper respiratory tract infection .........................................................................Y/N
Chronic otitis media (1) Sinusitis (2) Chronic purulent rhinitis (3) Other (4)......
Lower respiratory tract disease confirmed by X-ray............................................ Y/N
Lymphocytic intersitial pneumonitis or Pulmonary lymphoid hyperplasia (1)
Pneumonia (2) Bronchiolitis (3) Other (4)...........................................................
specify organism, if known....................................................................................
Opportunistic Infection.........................................................................................Y/N
PCP (1) CMV (2) Toxo (3) Candida (4) Mycobacterium (5) Other (6) ...........
Hepatomegaly......................................................................................................... Y/N
Splenomegaly......................................................................................................... Y/N
2 .6 3
24
25
26 
27
For office use only
28-30
31-33
34-35
n 36-38
41-43
44-46
49-50
51-53
□54
F 7  I -M  57-58
ECS3 page 2
Please circle or complete as appropriate 
Medical Examination
Date of Examination / / Centre
Mothers Study Number 
Child Study Number
1-2
3-5
□ 7
Neurological abnormality......................................................................................Y/N
encephalopathy (static/progressive) (1).............................................................
seizures (2) paresis (3) pathologic reflexes (4) increased tone (5) 
decreased tone (6) abnormal gait (7) other (8 )..................................................
Other Findings on exam Specify...........................................................................Y/N
Developmental Asessment
Gross motor Pass(1) Fail (2) Suspicious (3)
Fine motor/adaptive Pass(1) Fail (2) Suspicious (3)
Language Pass(1) Fail (2) Suspicious (3)
Personal/social Pass(1) Fail (2) Suspicious (3)
Loss of developmental milestones..................................................................... Y/N
specify.................................... ............................................................................
Neonate
Has the baby received any anti-retroviral therapy to reduce
the risk of vertical transmission?............................................................................ Y/N
If yes: which drug(s)?..................................................................................
for how long?..................................................................................
Treatment
Has this child been enrolled in an anti-retroviral treatment trial....................Y/N
If yes: which trial? .......................................................................................
Current treatment (excluding the above)
IVGG, AZT, DDi, Other........................................................................................
Hospital Admission(s)...........................................................................................Y/N
(Indicate dates of admission/discharge and diagnoses for each hospitalization)
Immunisations given since last visit......................................................................Y/N
DPT (1) DT(2) Oral Polio (3) Killed Polio (4) Measles (5) MM R (6)
Hepatitis B (7) Other (8)....................................................................................
Abnormal reactions.......................................................................................Y/N
Child care
mother / father / other relative / fostered / adopted / hospital / institution
Breast Feeding.......................................................................................................Y/N
If stopped, when .................................................................................................
Health of Mother .........................................................................................................
Is mother alive / dead?
if dead, was death HIV-related? ...................................................................Y/N
cause of death ....................................................................................................
Mother's current HIV staging (CDC) ..................................................................
defining symtoms...............................................................................................
date of diagnosis................................................................................................
current treatment? .............................................................................................
8-10
11-13
14-16
For office use onl
17
24
22-23
25-26
27
28
29-31
32-36
37-41
42
43-46
47-50
51-52
53-54
a
55
56
57-58
62-63
64-68
69-73
74-75
18 12 176'77
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ECS.1
PROSPECTIVE STUDY OF CHILDREN BORN TO HIV +VE MOTHERS
Assessment: 9 , 1 2 , 1 8  and 24 months; thereafter annually for antibody -ve, 
uninfected children and 6-m onthly for infected children
Please circle or tick as appropriate
Centre number 
Mother Study number 
Child Study number 
Weight (kg) 
Height (cm) 
Head circumference (cm)
1-3
4-6
S3, 2 - , s  
£  16-18
Is child alive?
Date of assessment (day, month, year) 
Name of paediatrician (initials) ..........
Y/N 19 For office use only
20-25TTTT
I 26-27
Is this child HIV infected?........................................................................Y/N
Has this child developed AIDS? (CDC de f).............................................Y/N
If AIDS has been diagnosed since previous report,
specify date of diagnosis ........................................................................
AIDS indicator disease.............................................................................
Care
mother / father / other relative / fostered / adopted / hospital / institution
Is mother alive / dead?
if dead, was death HIV-related? ........................................................ Y/N
cause of death.........................................................................................
Preschooling/Schooling
Does this child require special educational provisions........................... Y/N
if yes, specify...........................................................................................
Treatment
Has this child been enrolled in an anti-retroviral treatment trial .............Y/N
if yes, which trial? ...................................................................................
Current treatment (excluding the above)......................................................
Intravenous gammaglobulin/AZT/DDi/other, specify ...............................
Communicable diseases .....................................................................Y/N
if yes, specify: measles / whooping cough / varicella / tuberculosis / mumps / zoster
28
29
n 30-35
36-38
□39
40
41
35 43-44
45
46-48
49-53
54-58
□59
|G |2 | 1  I 60 62
EC3 .1 (page z; centre Motner
Oral Candida since last visit (persisting > 2m or recurring despite therapy) 
if yes, date on onset (day, month, year)........................................................
renal Y /N
hepatic Y /N
gastro-intestinal Y /N
cardio-vascular Y /N
central nervous system Y /N
respiratory Y /N
malignancy Y /N
other, specify
Y /N
Please complete this section, if the child has died
Date of death .............................................................
Cause of death............................................................
Post mortem results...................................................
Y /N
Hospital admission(s) Y /N
(indicate dates of admission/ discharge and diagnoses for each hospitalization)
Since the last visit, has this child had any of the following abnormalities:
yes/no date clinical method diagnosis
presentation of diagnosis
J_J L 1 1
a m  i i r
9-12
13-16
□H17-18
31-32
45-46
59-60
73-74
87-88
m  101-102
E
1115-116
n
135-137
138-140
129-134
19-24
25-30
33-38
39-44
47-52
53-58
61-66
67-72
75-80
81-86
89-94
95-100
103-108
109-114
117-122
123-128
1141-143
PROSPECTIVE STUDY OF CHILDREN BORN TO HIV POSITIVE MOTHERS
Centre
Mothers Study Number 
Child Study Number
Assessment at:
0-7 days, 3w, 6w, 4.5m, 6m, 9m, 12m, 18m, 24m, and then annually if 
child presumed not infected, or 6 monthly if infected
(Rin^)findings and specify as appropriate:
Date blood drawn:_____/ _____/ ____
day month year 
HIV / ELISA + / - Specify system used
antibodies .......................................................................................
Western blot + / -
Virus culture
+ / - Specify identification system(s) .................................................
+ / - Specify identification system(s) .................................................
Viral load
DNA-PCR .....................................................................................
RNA-PCR .....................................................................................
Antigen assay + / -
Specify identification system ............................................................
Other tests (eg IVAP, PCR, IgM) Specify method and result
+ / -      .........................................................
+ / -       .....................................
IgG (gm/litre)
IgA (gm/litre)
IgM (gm/litre)
T4 (109/litre)
T8 (10°/litre)
Absolute lymphocyte (109/litre)
Neutrophil (107litre)
Platelet (109/litre)
Haemoglobin (gm/dl)
Toxo IgG Latex (at 9 months to exclude congenital infection) (+/-)
Tetanus IgG (at least 1 month after third DT/DPT)
CMV IgG (+/-)
1-2
3-5
for office use only
I I L I..L
13-14
15-16
17-18
19-20
21-22
23-24
25-26
L_L 27-29
30-32
33-35
7-12
36-38
39-41
42-44
45-48
49-52
53-56
57-60
61-64
68
I
65-67
69-71
72
i n 173-74
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NATIONAL REGISTER
NATIONAL REGISTER OFHCV 
INFECTIONS WITH A KNOWN 
DATE OF ACQUISITION
REGISTRATION FORM
The national register contains information on HCV infections with known 
dates of acquisition, and provides a  facility for the future monitoring 
and long term assessment of HCV infection within the UK.
•  No patient nam es are held In the HCV National Register. It is 
therefore very important that you retain the register number in your 
records and that you are able to trace the patient from either the 
register number or the identifier/reference number that you supply 
on the registration form (Question 1).
•  Ethical approval for the register has b een  obtained from both the 
Public Health Laboratory Service and the Multi-Centre Research 
Ethics Committees.
Enquiries regarding either the HCV National Register or completion of 
the registration form should b e  directed to either:
Dr Helen Harris (Register Co-ordinator) 
Telephone: 020 8200 6868  
 
Ms Lisa Beck (HCV Research Assistant) 
Telephone: 020 8200 6868  
Register number:
A COLLABORATIVE PROJECT BETWEEN THE HEALTH PROTECTION AGENCY AND THE NATIONAL BLOOD AUTHORITY
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Section 1: PATIENT DETAILS (please insert details or tick boxes as appropriate)
1. Identifier by which you can recognise the patient In current and future correspondence (e.g. hospital number):
2. Date of birth (dd/mm/yy): A.
4. Ethnic group: W hite___ | Btack-Caribbean □  Black-African □
3. Sex:
Black, other (
Male Female [ {
Indian □  Pakistani □
Bangladeshi _ J  Chinese  Aslan, other _ j |  Other, please specify:
5. Country of birth: ...............................................................................................................................................
6. If you are not the patient s GP, please give the name and address of their GP below:
Nome: .. 
Address:
Has the patient ever injected drugs (even if only once)? Yes □
Does the patient have any other known risk factors for HCV infection? Yes j
If yes, please give details: ............   ,,......................... ............. ................................... ...............
To your knowledge, does the patient have any other significant chronic viral infection?
If yes. please specify: ......... ................................... .................. .........................................................................
10. Does the patient suffer from any ofher significant medical conditions?
If yes. please specify: .... ..............................................................................................
Are you still responsible for the HCV-related care of the patient?
Yes PLE A SE  CO M PLE TE  TH E  R E S T  O F  TH E F O R M
No _ J  Not k now n__ [
No  I Not known
Yes  | N o  [
No! j
NO PLEASE G IV E  TH E N A M E  A N D  A D D R E SS O F  TH E CLIN ICIAN  N O W  RESPO N SIB LE  F O R THE H CV -R E IAT ED  CARE OF THIS
PATIEN T (A N D  TH EN R E T U R N  THE F O RM  TO US). PLE A SE  A LSO  E N SU RE  THAT YOU IN SER T YOUR DETAILS A T  THE END O F  THIS 
FORM  SO  TH AT WE C A N  CONTACT YOU IF  W E N EED  M ORE INFORM ATIO N  A B O U T  TH IS PATIENT. TH AN K YOU VERY M UCH  FOR  
YOUR HELP.
Name: .. 
Address:
S e c tio n  2: CURRENT CLINICAL STATUS
The next questions ask abou t the patient's current clinical status. In this context, clinical status is intended to  reflect the patienf s signs and/or symptoms of liver 
disease, n o t  their test results.
1. Has th e  p a tien t d ie d  (p le a s e  tick  b ox )?  Vtos _ }  No □
If yes. please give d a te  of dea th  (dd/mm/yy):  ...... . ...... . / — r  and  cause of death: .................. ......... ....... ................................ .................. ......
If no, does the patienf have: No clinical signs or symptoms of liver disease t y - - PLE A SE  GO  TO SECTIO N  3
Clinical signs or symptoms of liver disease (HCV-related) □
Clinical signs or symptoms of Hver disease (not HCV-related) Details/cause:............... ..................................................
2. P lease  reco rd  a n y  signs or sym p tom s of liver d isea se :
Spider naevl □  H epatomegaly [ t Splenomegaly _ j Ascites □  Varices |  Bleeding varices J Liver tumor f j
Other (please give details): „.......          ............................ .............. ................................... ........... ..... ............. ........ ............
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S e c tio n  3 : TEST RESULTS
1. Date of last consultation lot HCV (dd/mm/yy): .. ........ .../.
2. Has the patient been tested for hepatitis B infection, and if so, what were the results?
HBsAg: Positive! t Negative j Not tested j Not sure j
anti-HBc. Positive __S Negative | Not tested Q Not sure i
3. Has the patient ever had a positive HCV PCR test? No Not tested i ' 1 Not known __j
If yes, please give d a te  of first known positive test (dd/mm/yy):
4. Date of latest HCV PCR test results (dd/mm/yy): ............... / .............. .. /.. Not done Not known. t
Results (please tick box): Positive 1 1 Negative ) Indeterminant i~ I Not known 1 }
S. Please insert the HCV genotype or serotype if known: Not known \ ~~[
6. Date of latest liver function tests (dd/mm/yy): . Not done 1 1 Not known ,__j
Results (please tick box or enclose copy of report form): Normal! j Abnormal J Not known
If abnormal, please give results an d  test ranges: ALT .... Range . ........  AST Ranae
Bilirubin............. .... R an g e .......... ..................  Albumin..................  Range
INR
7. Date of latest liver biopsy (dd/mm/yy): Not done _  j Not known
Results (please tick box): Normal __ | Abnormal Not known 1
if abnormal, please give results (enclose copy of report form, if possible):
Minimal change J  Chronic hepatitis i
Fibrosis score (If known):  .........  ,........         Scoring system:
Cirrhosis J Hepatocellular carcinoma 1 _ J
S e c tio n  4 : ANTIVIRAL DRUG TREATMENT
1. Has the patient had any antiviral treatment for HCV? Yes , p ij z a s e  CONTINUE W ITH THIS SECTION
NO r y >  PLEASE GO TO QUESTION 3
If yes, please insert details of treatm ent in the tab le below:
Date
started
(dd/mm/yy)
Date
finished
(dd/mm/yy)
Interferon 
preparation 
(eg. Intron A®, 
WeDferon®)
Interferon
dosage
(mU)
Interferon 
schedule 
(eg. dally, 
twice weekly)
Other 
antiviral 
(eg. Ribavirin)
Dosage of 
other antiviral 
(please give 
units)
Schedule for 
other antiviral 
(eg.doiy. 
twice weekly)
2. What was the response to treatment? (please tick only one of the 8 boxes below)
Not relevant (still on treatment)
Treatment stopped early (eg. due to  side effects)
No response (never becam e PCR negative)
Response - Late relapse (PCR negative >12/12 after treatm ent but b ecam e positive a t a  later date) □
- Long term response (remains PCR negative 12/12 after treatm ent com pleted)
- Sustained response (remains PCR negative 6/12 after treatm ent com pleted)
- Immediate/Initial response (PCR negative <6/12 after treatm ent com pleted) □
- Transient response (PCR negative during treatm ent but becam e positive after treatm ent) □ Section 4 continued overleaf
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Section 4: ANTIVIRAL DRUG TREATMENT continued
3. H as th e  p a tien t ta k e n  p a rt in a n y  antiviral drug  trials? Yes j. No
If yes, please give details: Nome of trial:.........1 .... ,.........       ,...... ............. ..................
Patient registration/code number: ......  V     Date of entry:  / ................ / ..............
4. Has th e  p a tien t re c e iv e d  a n y  o ther trea tm en ts  for HCV? (eg . h e rb a l tre a tm en ts  e tc )  Yes No . J
If yes, please give details: ............................................................................................................................................................................................................
S e c tio n  5 : CURRENT M ANAGEM ENT
1. During the last 12 months what care has the patient received for HCV-related illness?
None Outpatient only _ J  Inpatient (assessment only eg. liver biopsy) { Inpatient (medical care)
If the patient received inpatient (medical care) In the  last 12 months for HCV-related Illness, please give d a te  and  reason for each  admission:
Date (dd/mm/yy) 
Date (dd/mm/yy) 
D ate (dd/mm/yy) 
Date (dd/mm/yy)
 ......  / .......   Reason: ............. ...................... ....................... ........................................ .......' . ..........
  ........... /...J....  Reason: ...............       .................   *.............. ............
 ......... / .............. /..   Reason: ..................................... ...................... ............................ ..... .............. ..... ......... ....... .
 .....  / .............. /.    Reason: ...... ................... ............... ...... ........................................ ........................................
2. What was the patient's alcohol intake at first diagnosis (in units of alcohol/week, If possible)? ................................ Not known
3. What is the patient s current alcohol Intake (In units of alcohol/week, If possible)? ...........  Not known J
COM M ENTS
If you have any comments that you would like to make, please do so In the space below:
Please print your details below so that we can contact you If we need more information about this patient:
Your name:
Dote (dd/mm/yy): ................ / ................./ ................ Telephone number:
THANK YOU VERY MUCH FOR YOUR HELP
ALL THE INFORMATION YOU PROVIDE WILL BE TREATED IN CONFIDENCE
r L E A S E  R E T U R N  T H I S  F O R M  T O :
D r  H  E  H a r r i s  ( R e g i s t e r  C o - o r d i n a t o r )
H e a l t h  P r o t e c t i o n  A g e n c y  
I m m u n i s a t i o n  D i v i s i o n ,  C o m m u n i c a b l e  D i s e a s e  S u r v e i l l a n c e  C e n t r e  
6 1  C o l i n d a l e  A v e n u e ,  U n i  d o n  \ ’ \ V 9  5 E Q  
T e l :  0 2 0  8 2 0 0  6 S 6 S     
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NATIONAL REGISTER
NATIONAL REGISTER OF HCV 
INFECTIONS WITH AKNOWN 
DATE OFACQUISITION
The national register con ta in s Information on  HCV infections with known d a te s  
o f acquisition, a n d  provides a  facility for th e  future m onitoring a n d  long term  
assessm en t o f  HCV infection  within th e  UK.
•  N o p a tien t n a m es  are h e ld  In th e  HCV N ational Register. It Is therefore very 
Im portant th at you  retain th e  register num ber In your records a n d  th at you  
are  a b le  to  tr a c e  th e  p a tien t from either th e  register num ber or th e  
id entifier/reference num ber th at you supply on  th e  form (Q uestion 1).
•  Ethical app rova l for th e  register has b e e n  o b ta in e d  from both  th e  Public 
H ealth Laboratory Service a n d  th e  M ulti-Centre R esearch  Ethics 
C om m ittees. There is n o  formal requirem ent to  g a in  p a tien t con sen t.
Enquiries regarding either th e  HCV N ational Register or co m p le tio n  o f th e  form  
should b e  d irec ted  to:
Dr H elen Harris (Register Co-ordlnator)
T elephone: 020 8200 6868 ex t  
Pager:  
E-mail: 
F I R S T  F O L L O W - U P  F O R M
DATE OF REGISTRATION:
Register number: 
Date o f birth: 
Soundex/initials:
Your reference:
S e c tio n  1: PATIENT DETAILS (please insert details or tick boxes as appropriate)
1. Identifier by which you can recognise the patient In current and future correspondence (e.g. hospital number):
2. Are you  still responsib le  for th e  H CV -related c a re  of th e  patien t?
Yes _ r T P l e a s e  c o n t i n u e
No  r  _ P l e a s e  g i v e  t h e  n a m e  a n d  a d d r e s s  o f  t h e  c l i n ic i a n  n o w  r e s p o n s i b l e  f o r  t h e  H C V - r e la te d  c a r e  o f  t h i s  p a t i e n t
( a n d  t h e n  r e t u r n  t h e  f o r m  t o  u s ) .  P l e a s e  a l s o  e n s u r e  t h a t  y o u  i n s e r t  y o u r  d e t a i l s  a t  t h e  e n d  o f  t h i s  f o r m  s o  
t h a t  w e  c a n  c o n t a c t  y o u  i f  w e  n e e d  m o r e  i n f o r m a t i o n  a b o u t  t h i s  p a t i e n t .
T H A N K  Y O U  V E R Y  M U C H  F O R  Y O U R  H EL P.
Name: .............       - .... -.........................................................................................               ..
Address: ....................................................................................................................................................................... - ................... ............... ...........................
3. Has this patient been seen, treated, or tested for HCV-related illness since they were registered (see front of form for date of registration)?
Yes __P l e a s e  c o m p l e t e  t h e  r e s t  o f  t h e  f o r m
No J r s *  p *c a s e  8 °  s t r a i g h t  t o  S e c t i o n  6
The next questions ask about the patient's current clinical status In this context, clinical status Is intended to  reflect the patients signs and/or symptoms of 
liver disease. 0 B f their test results. For example, a  patient who has abnormal liver function, or whose biopsy indicates liver disease, should be classified as 
having 'no clinical evidence of liver d isease' if they have no physical signs or symptoms of liver disease.
1. Has the patient died (please tick box)? Y es_j N o _ )
if yes. please give d a te  of dea th  (dd/mm/yy): .............. / ............... / ............... and  cause of death: .........
if no, does the patient have: No clinical evidence of liver disease __P l e a s e  g o  t o  s e c t i o n  3
Clinical evidence of liver disease (HCV-related) ; |
Clinical evidence of liver disease (not HCV-related)__'r  y ,  Details/cause:
2. Please record any signs and symptoms of liver disease:
Spider noevl } Hepatomegaly | Splenomegaly |  Ascites; | Varices__J Bleeding varices J Liver tumor
Other fnlease aix/e detaHsY
1. Date of last consultation for HCV since registration (dd/mm/yy): . ........../....
2. Date of latest HCV PCR test results since registration (dd/mm/yy):
Results (please tick box):
, . /  I . . . . . . Not done 1 Not known 
Not known ~JPositive f j
— i
Negative |
3. Date of latest liver function tests since registration (dd/mm/yy):
Results (please tick box or enclose copy of report form):
!  f Not done: I Not known 
Not known ffrNormal | j
_JI
Abnormal
If abnormal please gjv© results and  test ranges: ALT Range ....................................  AST ................. R ange.....
Bilirubin............. Range Albumin ............ Range ....
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4. Date of latest liver biopsy since registration (dd/mm/yy):  /....... /.............
Results (please tick box): Normal
If abnormal, please give results (enclose copy of report form, If possible):
Minimal change Chronic hepatitis | |
Not done 
Abnormal |
Not known 
Not known
Cirrhosis □ Hepatocellularcarcinoma LI
Fibrosis score (If known):.............................................................................................  Scoring system:
S ection  4 : ANTIVIRAL DRUG TREATMENT
J. Has the patient had any antiviral treatment for HCV since registration? Yes Please continue with this section
No ; Please go to question 3
If yes. please insert details of treatm ent in the table below:
CO
UR
SE Date
started
(dd/mm/yy)
Date
finished
(dd/mm/yy)
Interferon 
preparation 
(eg. Intron A s. 
Wellferon“0
Interferon
dosage
(mil)
Interferon 
schedule 
(eg. daily, 
twice weekly)
Other 
antiviral 
(eg. Ribavirin)
Dosage of 
other antiviral 
(please give 
units)
Schedule for 
other antiviral 
(eg. daily, 
twice weekly)
A
B
C
2. What was the response to treatment? (please tick only one of the 8 boxes below)
Not relevant (still on treatment)
Treatment stopped early (eg. due to side effects)
No response (never b ecam e PCR negative)
Response - Late relapse (PCR negative >12/12 after treatm ent but becam e positive a t  a  later date)
- Long term response (remains PCR negative 12/12 after treatm ent completed)
- Sustained response (remains PCR negative 6/12 after treatm ent completed)
- Immediate/Initial response (PCR negative <6/12 after treatm ent completed)
- Transient response (PCR negative during treatm ent but becam e positive after treatment)
3. Has the patient taken part in any antiviral drug trials since they were registered?
If yes. please give details. Name of trial: ......................................................... .................................... .........
Patient registration/code number: ......................................................................................................................
u□□
u□
LI□□
a
Date of entry: ................/ .....
Section  5: CURRENT MANAGEMENT
1. W hat c a re  h a s  th e  p a tien t re c e iv e d  for H CV -related illness s in ce  registration?
None |  Outpatient only ( j Inpotlent (assessment only eg. liver biopsy) | Inpatient (medical core)1 |
If the patient has received inpatient (medical care) for HCV-related illness since they were registered, please give da te  and reason for each  admission:
Date (dd/mm/yy):  ...... ....... / ............._.../ ...............  Reason: ................... ............................................. ........... ........................................... ...... ................ ..........
Date (dd/mm/yy): .............../ ................../ ........... Reason: ....................................................  ................................................ ..............................................
Date (dd/mm/yy): .............../ ................../ ...............  Reason: ................     — ............................................................................................................ ...
Date (dd/mm/yy):.................. / ................./ ....... Reason; ............ .......................................................................................................... ........... ......... ................ ..........
2. W hat is th e  p atien t's  cu rren t a lco h o l in tak e  (in units of a lco h o l/w « « k , if p ossib le)? Not known | |
S e c t io n  5  c o n t in u e d  o v e r le a f
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S ec tio n  5: CURRENT MANAGEMENT continued
3. How many cigarettes does the patient currently smoke each day?
None □  0-9 [ | 10-19 20 or more
Section 6 : SUPPLEMENTARY INFORMATION TO SUPPORT OTHER RESEARCH PROJECTS
1. It known, please advise the HCV genotype? □
2. Please advise the results of the following tests taken at or around the time of the latest liver biopsy (regardless of whether this biopsy 
was undertaken before or after the date of patient registration).
If the patient hasn't had a liver biopsy, please place a tick in this b o x  | and go straight to question 3.
TEST Date of test Result (please give units) Test range (where appropriate)
Platelets
Bilirubin
INR
Albumin
ALT
3. tf we needed a blood specimen, would you be willing to send us one when you next routinely take blood 
from this patient? □
COMMENTS
If you have any comments that you would like to make, please do so in the space below:
Please print your details below so that we can contact you If we need more information about this patient:
Date (dd/mm/yy):  .............. /................ / ...............  Telephone number: .......... ....... ............................
THANK YOU VERY MUCH FOR YOUR HELP
ALL THE INFORMATION YOU PROVIDE WILL BE TREATED IN CONFIDENCE
PLEASE RETURN THIS FORM TO:
Dr H E Harris (Register Co-ordinator)
Immunisation Division, PHLS Communicable Disease Surveillance Centre 
61 Colindale Avenue, London NIV9 5EQ 
Tel: 020 8200 6868  
nhs.uk
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APPEN D IX  8 SURVEY ON THE CLINICAL M A N A G EM EN T OF CHILDREN  
CO INFECTD  W ITH HIV AND HCV
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CLINICAL MANAGEMENT OF CHILDREN DIAGNOSED WITH HIV AND HEPATITIS C VIRUS COINFECTION
We are currently carrying out research on children coinfected with HIV and Hepatitis C virus and are 
keen to find out how centres manage and treat these children in light of their coinfection, given the lack 
of guidelines for management of this group. We would be very grateful if you could take the time to 
complete our questionnaire and provide us with as much information as you can.
Respondent’s Name............................................................Centre.............................................
Position........................................................................................................................................
Address...................................................................................................................................................
Email
Background information
1. How many HIV/HCV coinfected children do you currently manage at your centre/clinic?
2.How many were Vertically coinfected...............................................................................
Parenterally coinfected..........................................................................
Unknown mode of acquisition................................................................
3.What is the age range of the HIV/HCV coinfected children currently in your care ?...........
4.Under what circumstances do you test children for possible HIV/HCV coinfection? (please 
circle/delete as appropriate)
Children followed from birth
Test all children born to HIV/HCV coinfected mothers for both HIV and HCV Y/N
Children presenting with HIV or HCV infection in childhood
Test all children with diagnosed HIV infection for HCV...........................................Y/N
Test all children with diagnosed HCV infection for HIV...........................................Y/N
Please specify any other conditions which would lead you to test for HIV or HCV infection:
5.What is your usual practice regarding HCV genotyping? (please circle/delete as appropriate)
Always perform........................................................................................................Y/N
Sometimes perform................................................................................................ Y/N
under what circumstances do you perform HCV genotyping?
Never perform........................................................................................................ Y/N
Policy for management of HIV/HCV coinfected children
6.Does your centre have a written policy for all or any aspects of the management of HIV/HCV
coinfected children?.................................................................................................................Y/N
If yes, please email/send a copy of this policy. If no, please go to question 9.
7.When was the policy drawn up?...................................................................................... .........
8. Have there been any recent changes to this policy?............................................................ Y/N
If yes, what changes?
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9.At what level are decisions about the clinical management of HIV/HCV coinfected children made? 
(please circle/delete as appropriate)
National / regional / hospital-based / departmental / individual clinician
Management of HIV/HCV coinfected children
10. Is the schedule for the management of HIV/HCV coinfected children at your centre affected by
whether the child is on HIV or HCV treatment?..................................................................Y/N
If yes, in what way? e.g. treated children seen more often, seen less often, more frequent follow-up in 
initial period of starting treatment
11. Is the schedule for the management of HIV/HCV coinfected children at your centre affected by the
age of the child, the duration of infection or the mode of acquisition of infection Y/N
If yes, in what way? e.g. younger children followed-up more regularly, vertically coinfected children 
followed-up more regularly than parenterally coinfected children
12. In comparison to HIV-only or HCV-only infected children, are HIV/HCV coinfected children followed 
up
more frequently / less frequently / at the same frequency?
13.Are any specific HCV-related laboratory tests requested for diagnosed HIV/HCV coinfected children 
that would not be requested for HIV-only infected children............................. Y/N
If yes, which ones and how frequently are they usually carried out?
HCV RNA PCR annually / every 6 months / every 3 months / other (please specify)
.....................................................................................................................................................  ALT
annually / every 6 months / every 3 months / other (please specify)
.....................................................................................................................................................  AST
annually / every 6 months / every 3 months / other (please specify)
Liver biopsy annually / every 6 months / every 3 months / other (please specify)
Liver ultrasound annually / every 6 months / every 3 months / other (please specify)
Other (please specify)..................................................................................................
annually / every 6 months / every 3 months / other (please specify)
Treatment of HIV-only infected children
14.Which paediatric guidelines do you follow when treating HIV-only infected children? 
CDC / PENTA / National guidelines / other (please specify)
15.Do you have a preferred 1st line therapy for HIV-only infected infants/children?............. Y/N
If yes, please specify
in children younger than 1 year of age.................................................................
in children older than 1 year of age.....................................................................
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Treatment of HCV-only infected children
16. Have you ever treated HCV-only infected children?....................................................... Y/N
If no, please go to Q 18.
If yes, have you ever initiated treatment before 3 years of age?................................. Y/N
If yes, under what circumstances?
17. Have you always treated HCV-only infected children in the context of a treatment trial?..Y/N 
If yes, please provide further details of the trial(s) and treatment(s)
Treatment of HIV/HCV coinfected children
18.Do you monitor HIV/HCV coinfected children receiving HIV treatment for evidence of 
hepatotoxicity? .Y/N
If no, please go to Q 21. If yes, please answer the following questions:
Please indicate below how you monitor possible hepatotoxicity?
ALT levels Y/N How often?...................................................................................
AST levels Y/N How often?....................................................................................
Other (please specify).................................. How often?.................................................
19.1s there a level of hepatotoxicity at which you would normally switch HIV therapy? Y/N
If yes, please provide further details e.g. how many elevated liver enzyme tests and at what threshold 
do you consider the liver enzymes to be elevated?
20.Do you monitor drug-related hepatotoxicity more intensively in coinfected children than in HIV-only
infected children? (e.g. more frequent testing)........................................................ Y/N
If yes, in what way?
21. Do you check for lipodystrophy more frequently in HIV/HCV coinfected children than HIV-only 
infected children?............................................................................................................Y/N
22.Do you have a preferred 1st line HIV therapy for HIV/HCV coinfected children?..............Y/N
If yes, please specify
in children younger than 1 year of age..................................................................
in children older than 1 year of age.......................................................................
23.Have you ever treated children for HIV and HCV infections at the same time?.................Y/N
If yes, are there specific HIV drug/drug combinations that you avoid? (please specify and give 
reasons)
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If no, would you ever consider treating children for HIV and HCV infection at the same time in specific
circumstances?............................................................................... Y/N
(please give details)
24. If you would not treat HIV and HCV concurrently, how would you respond to the following 
situations?
In a child with known HIV/HCV coinfection from birth where HIV treatment was necessary before HCV 
could be treated would you
stop HIV therapy if HCV treatment became necessary?.................................Y/N
OR
delay starting HIV therapy until HCV could be treated first?........................... Y/N
Other response to situation (please specify)
In a child diagnosed with HIV/HCV coinfection later in childhood would you
treat HCV infection before starting HIV treatment?.........................................Y/N
OR
start HIV treatment and stop if HCV treatment became necessary?.............. Y/N
Other response to situation (please specify)
Thank you for taking the time to fill out this questionnaire, your help is greatly appreciated and I will 
feedback the results when they are all collected. If there is any other information or comments on the 
management of HIV/HCV coinfected children you would like to add then please feel free to do so below.
Any other information or comments of the management of HIV/HCV coinfected children.
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A PPENDIX 9 PUBLICATIONS ARISING RFOM  THIS RESEARCH
England, K., Thorne, C., and Newell, M.L. (2006). Vertically acquired paediatric 
coinfection with HIV and hepatitis C virus. Lancet Infect.Dis.; 6: 83-90.
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Review
Vertically acquired paediatric coinfection w ith  HIV and  
hepatitis C virus
Ki f  :. t v  I ' n q l a n t i ,  C la ir e  T h o m e ,  M o n e - I .  o u i s e  N e w e l l
Both HIV and hepatitis C virus (HCV) can be transmitted from mother to child during pregnancy and delivery. 
Vertical transmission o f HIV and HCV separately is most likely from HIV/HCV-coinfected mothers; however, 
transmission of both infections is less frequent. The effect of HCV coinfection on HIV-related disease remains 
unclear; whereas most studies indicate no effect, recent results suggest HCV in adults accelerates HIV progression. 
Little is known about how HIV coinfection affects HCV progression in children and the information available is 
based on small numbers o f patients. Paediatric HIV treatment is extremely successful and it is vital to determine if  
HCV coinfection alters the effectiveness of this treatment. The hepatotoxicily o f many HIV therapies and the 
possible negative impact o f HCV on this treatment, alongside the interactions and contraindications o f many HIV 
and HCV therapies, further limits the choice of paediatric treatments for coinfected children. Future research must 
therefore focus on vertically acquired HIV/HCV coinfection to inform treatment trials addressing coinfection
management.
Introduction
H IV  a n d  h ep a t i t i s  C v irus  (HCV) a re  bo th  b lo o d -b o rn e  
v iruses  a n d  s h a re  t r a n s m is s io n  ro u te s  in  ad u l t s ,  
specifically in je c t in g  d r u g  u s e  a n d  b lood  t r a n s f u s io n ,  
m a k i n g  co in fec t io n  relat ively c o m m o n ,  a l t h o u g h  sexua l  
t r a n s m is s io n  o f  H C V  is m u c h  less  f r e q u e n t  t h a n  for  
H IV. "* W i th  an t i re t rov ira l  t r e a t m e n t  for H I V  in f e c t io n  
im p ro v in g  a n d  p ro lo n g in g  life in  in fec ted  in d iv id u a ls ,  4 ' 
the  p rev a len ce  a n d  effect o f  se c o n d a ry  in f e c t io n s  a n d  
c o m o rb id i t i e s  s u c h  as H C V  h a s  i n c r e a s e d  in  a d u l t  
p o p u l a t i o n s /  S y m p to m s  re la ted  to H C V  in f e c t io n  w e re  
n o t  p rev iously  o b se rv ed  in c o in fec ted  p a t i e n t s  b e c a u s e  
p r o g re s s io n  to liver  d ise a se  o r  a s so c ia ted  c a n c e r s  can  
take as lo n g  as 20 years a f te r  H C V  in fec t ion .  H o w e v e r ,  
with  su c cess fu l  H IV  t r e a t m e n t  H C V -re la te d  m o r ta l i ty  
h as  b e c o m e  a l e a d in g  ca u s e  o f  d e a th  in  H IV - in f e c te d  
ind iv idua ls . '1' T h e  ex ten t  to w h ic h  th is  s i tu a t io n  is t r u e  in  
c o in fec ted  c h i ld r e n  is unc lear .
Both  H IV  a n d  H C V  can  be  vert ically t r a n s m i t t e d  f ro m  
an in fec ted  m o t h e r  to h e r  child ,  b u t  in E u ro p e  th e  
n u m b e r  o f  co in fec ted  c h i ld r e n  is sm a ll  a n d  th e  p o o l in g  
o f  exper t ise  in th is  a rea  is vital i f  m a n a g e m e n t  
r e c o m m e n d a t i o n s  a re  to be  m a d e .  T h e  p re v a le n c e  o f  
a n te n a ta l  H IV  in fec t io n  in  w e s t e rn  E u ro p e  is 0 - 2 - 0 - 4 % ,  
re s u l t in g  in  ap p ro x im a te ly  3 8 0 0 -7 6 0 0  c h i ld r e n  b o r n  to 
H IV -in fec ted  m o t h e r s  in  w e s t e rn  E u ro p e  e a c h  year.  In  
this p o p u la t io n ,  m o s t  in fe c t io n s  a re  a c q u i re d  sexual ly  
a n d  occu r  in w o m e n  o f  s u b - S a h a r a n  A frican  o r ig in  w h o  
are rare ly  co in fec ted  with  H C V . In the  r e m a i n i n g  
w o m e n ,  w h o  have ac q u i re d  H IV  in fec t ion  t h r o u g h  d r u g  
use , co in fec t ion  with  H C V  is m u c h  m o r e  c o m m o n .  It 
can  be e s t im a te d  that  1 5 0 -3 0 0  c h i ld r e n  a re  b o r n  to 
m o th e r s  co in fec ted  w i th  H IV  a n d  H C V  in  w e s t e rn  
E u ro p e  each  year. B e cau se  o f  th e s e  s m a ll  n u m b e r s  th e  
g u id e l in e s  for m a n a g e m e n t  in  th is  g r o u p  o f  c h i ld r e n  
r e m a in  u n c le a r  a n d  as co in fec ted  n u m b e r s  i n c r e a s e  it 
b e c o m e s  m o r e  i m p o r t a n t  to u n d e r s t a n d  h o w  m a t e r n a l  
c o in fec t ion  affects r isk  o f  vertical in fe c t io n  w i th  H IV , 
H C V , o r  bo th ,  an d  the  s u b s e q u e n t  d i s e a s e  p r o g r e s s i o n . ’
In  a d d i t io n ,  a d v a n c e s  in p a e d ia t r i c  H I V  t r e a t m e n t  h ave  
m e a n t  th a t  t h e r a p y  in  c h i ld r e n  o f  all ages  is b o th  readily  
availab le  a n d  ex t re m e ly  effective a n d  th e  p o ss ib i l i ty  th a t  
c o in f e c t io n  w i th  H C V  m i g h t  h i n d e r  th is  e f fe c t iv e n e ss  is 
o f  vital im p o r t a n c e .  W e  rev iew  i n f o r m a t i o n  r e g a r d in g  
ver t ica l  t r a n s m i s s i o n  o f  H I V  a n d / o r  H C V  f ro m  
c o in f e c te d  m o t h e r s ,  d i s e a s e  p r o g re s s io n ,  a n d  t r e a t m e n t  
o f  b o th  H I V  a n d  H C V  in  c o in fe c te d  c h i ld r e n .
M other-to -ch ild  transmission o f HIV from  
coinfected mothers
T r a n s m i s s i o n  o f  H I V  in fe c t io n  f r o m  a m o t h e r  to c h i ld  
m a y  o c c u r  b e fo re  (ac ross  t h e  p la c e n ta ) ,  d u r i n g  (via 
e x p o s u re  to c o n t a m i n a t e d  m a t e r n a l  s e c re t io n s ) ,  a n d  
a f te r  de l ivery  ( t h ro u g h  b r e a s t f e e d i n g ) / ' ’ T h e  m o s t  
i m p o r t a n t  fac to rs  a s so c ia te d  w i th  a n  i n c r e a s e d  r i sk  o f  
m o th e r - to - c h i ld  t r a n s m i s s i o n  o f  H I V  a re  m a t e r n a l  
p l a s m a  H I V  R N A  viral  load ,  v a g in a l  de livery ,  a n d  m o d e  
a n d  d u r a t i o n  o f  b r e a s t f e e d i n g . ;(u:' E lective c a e s a r e a n  
s e c t io n  del ivery  b e fo re  o n s e t  o f  l a b o u r  a n d  r u p t u r e  o f  
m e m b r a n e s ,  p ro p h y la c t i c  a n t i r e t ro v i ra l  t h e r a p y  d u r i n g  
p r e g n a n c y  a n d / o r  neo n a ta l ly ,  a n d  b r e a s t f e e d in g  
av o id a n c e  i n d e p e n d e n t l y  s u b s ta n t ia l ly  r e d u c e  m o th e r - to -  
ch i ld  t r a n s m i s s i o n  r a t e s ,10 w h ic h  r a n g e  f r o m  15%  to 40%  
w i th o u t  i n t e r v e n t io n .  I n  s e t t in g s  w h e r e  all i n t e r v e n t io n s  
c a n  be  safely  i m p l e m e n t e d ,  th e  a d v e n t  o f  h ig h ly  active 
a n t i r e t ro v i ra l  t h e r a p y  (H A A R T ) h a s  r e d u c e d  H IV  
vert ical  t r a n s m i s s i o n  ra te s  to below' 2 % . !''
Vertical t r a n s m i s s i o n  o f  H I V  o c c u r s  m o r e  o f te n  f ro m  
w o m e n  c o in fec led  w i th  H IV  a n d  H C V  th a n  f ro m  th o se  
in fec ted  w i th  H I V  o n ly . '" " ’ F o r  e x a m p le ,  H IV  
t r a n s m i s s i o n  o c c u r r e d  f ro m  16%  (53 /326)  o f  m o t h e r s  
in fe c te d  w i th  H IV  only, c o m p a r e d  w i th  2 6 %  (42 /161)  o f  
H lV / H C V - c o m f e c t e d  w o m e n  (table),  s u g g e s t i n g  th a t  
H C V / H I V  c o in fe c t io n  nea r ly  d o u b le s  t h e  H I V  m o th e r -  
to -ch i ld  t r a n s m i s s i o n  ra te  (odds  r a t io  [OR] 1 -82 ,  
p = 0 • 00 1 ) .10 H o w e v e r ,  th e  t r a n s m i s s i o n  ra te s  r e p o r te d  
a n d  s a m p le  s iz e s  u s e d  in t h e s e  s tu d ie s  vary  c o n s id e ra b ly  
a n d  d o  n o t  a lways c o m p a r e  c o in fe c te d  m o t h e r s  w ith
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Review
Study M ethods/sam ple Total
HIVVTR
HIVVTR
from
HIV-only
infected
HIVVTR
from
coinfected
Total
HCVVTR
HCVVTR 
from  
HCV only  
infected
HCVVTR
from
coinfected
VTR o f  
coinfection
Significance 
o f results
Giovannini Prospective follow-up of 4 9  HIV-infected 14/49 2/24 12/25
et al'- mothers in Italy, 75 coinfected with HCV (2 8 -6 %) (83% ) (48%)
Pauagntni Prospective lollow-up of /n  HCV-infected 16/5 3 14/70 7/17 12/53 Higher HCV VTR from
et al1' mothers in Italy, 3 3 coinfected with HIV (30 2%) (2 0 %) (17%) (7 3%) comforted (p-; 0 os)
Hershow Prospective follow-up of 487  HIV-infected 9 5 /487 5 3 /326 42 /1 6 1 Higher HIV VTR from
et al”' mothers, l 6 l  confected with HCV (19-5%) (16%) (2 6 %) coinfected (OR 1 8 , p - 0  01)
1 ovo Prospective follow-up of 245 children 22/165 28/245 3 /80 25 /1 6 5 6 /165 Higher HCVVTR from
el al born to HCV-infected mothers in Italy, (133% ) (114% ) (37% ) (15 1%) (3 6 %) coinfected (p --0  0 0 1 )
165 mothers coinfected with HIV
Papaevan- Prospective study o f 100 HIV-infected 16/63 9 /6 2 6/63
gelou et al”' wom en in New York, 54  coinfected with (25%) (16-4%) (9-5%)
HCV and w ho had 63 children
Ihomas Prospective follow-up of 155 HIV/HCV-coinfected 4 1 /1 5 5 1 3 /155 7/155
et al" mothers (Women and Infants Transmission Study) (26  5%) (8-4%) (45% )
Nigro Prospective follow-up of 23 HIV-infected children 2/22 2/22
et al'1 born to 22 HIV/HCV-coinfected mothers (9%) (9%)
/anotti Piospective follow-up of 188 children born to 17/291 8/251 9 /4 0 1 lighei 1ICV VI R from
et al 291 HCV-infected mothers in Italy, 40 HIV coinfected (5 8 %) (32% ) (22 5%) coirifecled (p ■ 0  0 0 1 )
Gibb Pollow-up of 441 HCV-infected wom en in 30/441 21 /3 2 8 4 /2 2 Higher HCV VIR from
et ai'! UK and Ireland, 22 coinfected with HIV (6-7%) (6 4 %) ( 1 8 -6 %) coinfected (OR 3 8 . p=0 05)
IPHN" Piospective follow-up of 1474 HCV-infcctcd 5 5 /491 1 3 6 /1474 6 0 /9 1 6 7 0 /503 Higher HCV VTR from coinfccted
wom en in Furope, 503 coinfected with HIV ( 1 1 2 %) (92% ) (6 -6 %) (139% ) OR 2 3 (95% Cl 1 6 - 3  4)
Ferrero Prospective follow-up o f 170 HCV-infected 5/188 3/151 2 /37
et al's pregnant wom en and their 188 children in Italy (2-7%) (2%) (5-4%)
OfUodds ratio, VTR«vertical transmission rate, -mot reported
Table: M other-to-child  transm ission  o f  HIV, HCV, an d  HIV/HCV coinfection
H IV -on ly  in fec ted  m o t h e r s .  R e p o r t e d  H I V  t r a n s m i s s i o n  
ra tes  f ro m  H I V /H C V - c o in f e c t e d  m o t h e r s  r a n g e  f ro m
1 3 -3 %  to 3 0 %  in s e t t in g s  w h e r e  in i t ia t iv es  to p r e v e n t  
m o th e r - to -c h i ld  t r a n s m i s s i o n  o f  H I V  a re  availab le  a n d  
w h e r e  few H IV -in f e c te d  w o m e n  b r e a s t f e e d .17"20 T h e  
low es t  H I V  t r a n s m i s s i o n  ra tes ,  f r o m  th e  m o s t  r e c e n t  
s tud ie s ,  l ikely reflect t h e  u s e  o f  z id o v u d in e  in  p r e g n a n c y  
to r e d u c e  m o th e r - to - c h i ld  t r a n s m i s s i o n . 2'’ T h e r e  have  
b een  few  s tu d ie s  to a s se s s  t h e  effec t  o f  H I V / H C V  
c o in fec t ion  o n  H I V  t r a n s m i s s i o n  ra te s  in t h e  p a s t  5 
years.  D esp i te  o n e  r e c e n t  s tu d y  f in d in g  th e  H I V  m o th e r -  
to-child  t r a n s m is s io n  ra te  to be 6 - 2 %  (1 0 /1 6 1 ) ,27 lo w e r  
t h a n  the  1 1 -2 %  (55 /491)  o f  c o in fe c te d  w o m e n  f ro m  th e  
s a m e  s tu d y  in v e s t ig a te d  b e tw e e n  1992 a n d  20 0 0 ,21 the  
i m p a c t  o f  H A A R T  o n  th e  p r e v e n t io n  o f  H I V  m o th e r - to -  
ch ild  t r a n s m is s io n ,  w h ic h  b e c a m e  w id e ly  u s e d  a f te r  
2000, in  a m a te r n a l ly  H I V /H C V - c o in f e c t e d  p o p u l a t i o n  
r e m a i n s  u n c le a r .
M other-to-child  transmission o f HCV from  
coinfected mothers
T h e  effect o f  H I V / H C V  c o in fe c t io n  o n  vert ical  
t r a n s m i s s i o n  o f  H C V  h a s  rece ived  m o r e  r e c e n t  a t t e n t io n  
t h a n  tha t  o f  H i  V a n d  th e  e v id e n c e  to s u p p o r t  a n  in c r e a s e  
in  the  t r a n s m i s s i o n  ra te  f r o m  c o in f e c te d  m o t h e r s  in  
c o m p a r i s o n  w i th  m o t h e r s  o n ly  in fe c te d  w i th  H C V  is 
m o r e  c o m p le te .  T h e  H C V  m o th e r - to - c h i ld  t r a n s m i s s i o n  
ra te  in  H C V -o n ly  in fec ted  w o m e n  r a n g e s  f ro m  4 %  to 
J0% / I,M-/ 4 h i g h e r  in  w o m e n  w i th  a h i g h  H C V  viral
lo ad .22" T h e r e  is n o  e v id e n c e  to  s u p p o r t  a p ro tec t ive  
effect  o f  e lective c a e s a r e a n  se c t io n  o n  I I C V  vertical  
t r a n s m i s s i o n , 2124 a l t h o u g h  H C V  t r a n s m i s s i o n  can  o c c u r  
i n t r a p a r t u m . 12 S im ila r ly ,  n o  s u b s t a n t i a l  in c r e a s e  in 
t r a n s m i s s i o n  r a te s  h a s  b e e n  o b se rv e d  a m o n g  
b r e a s t f e e d in g  w o m e n . 24 T h e r e  is s u b s t a n t i a l  e v id e n c e  to 
s u p p o r t  a n  in c r e a s e  in H C V  vertical t r a n s m i s s i o n  f r o m  
m o t h e r s  c o in f e c te d  w i th  H I V  c o m p a r e d  w i th  m o t h e r s  
in fe c te d  w i th  H C V  only .  O n e  s tu d y  in c lu d in g  m o r e  th a t  
100 c h i ld r e n  f ro m  H C V /H IV - c o in f e c t e d  m o t h e r s  f o u n d  
H C V  t r a n s m i s s i o n  r a te s  to be  s ign i f ican t ly  h ig h e r  w ith  a 
2 - 3  t im e s  in c r e a s e  (95%  Cl 1 - 6—3 - 4) ( table).21 
F u r t h e r m o r e ,  a c q u i s i t i o n  o f  in fe c t io n  o f  H C V  is m o r e  
likely in  i n f a n t s  a lso  b e c o m i n g  in fe c te d  w i th  H I V , 1'"'’ 
w h i c h  h a s  b e e n  t a k e n  to im p ly  th a t  t r a n s m i s s i o n  o f  H IV  
in  u t e r o  m a y  fac i l i ta te  t r a n s m i s s i o n  o f  H C V . H o w e v e r ,  it 
is m o r e  p la u s ib l e  t h a t  w o m e n  t r a n s m i t t i n g  H I V  have  
b o th  h ig h  H I V  R N A  a n d  H C V  R N A  viral loads  a n d  are  
t h u s  p r o n e  to t r a n s m i t  b o th  v i ru ses .  T r e a t m e n t  d u r i n g  
p r e g n a n c y  to p r e v e n t  H I V  t r a n s m is s io n  by lo w er in g  
H I V  R N A  viral load m a y  also  low er  the  r isk  o f  H C V  
t r a n s m i s s i o n  a n d  m a y  t h u s  be vital to the  p r e v e n t io n  o f  
m o th e r - to - c h i ld  t r a n s m i s s i o n  o f  b o th  th e s e  v iruses .
Vertical transmission o f HIV/HCV coinfection
Few  s tu d ie s  h a v e  f o c u s e d  o n  vertical t r a n s m i s s i o n  o f  
H I V / H C V  c o in fe c t io n .  R e p o r te d  t r a n s m i s s i o n  ra te s  
r a n g e  f ro m  3 - 6 %  to 9- 5 % , 20 21 w i th  the  low er  
t r a n s m i s s i o n  r a te s  f ro m  the  two s tu d ie s  w ith  m o r e  t h a n
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150 coinfected mothers (table).” '10 These findings would 
suggest that, whereas single transmission o f HCV and 
HIV from coinfected mothers is more likely than from 
singly infected mothers, the mother-to-child 
transmission o f both viruses simultaneously occurs less 
frequently than single-virus transmission from a 
coinfected mother (figure 1, panel 1).
HIV disease progression in coinfected children
In the absence o f effective antiretroviral therapy or other 
supportive prophylactic management, a quarter of 
vertically HIV-only infected children will have 
progressed to serious disease or death by the age o f 
1 year, with a 40% cumulative incidence o f HIV-related 
disease or death by 6 years o f age.” HIV-related disease 
progression is measured by levels o f immunological and 
virological manifestations, specifically CD4 cell count 
and HIV RNA viral load, and the presence o f non­
specific clinical symptoms such as hepatomegaly,
splenomegaly, lymphadenopathy, and HIV-related
manifestations or opportunistic infections.” Since
recommendations for the use of more active
combination antiretroviral therapies were introduced in 
1997/98 and paediatric antiretroviral therapy became 
more widely available for children at an earlier stage in 
their disease progression before serious clinical or 
immunological deterioration, children have been shown 
to be substantially less likely to progress to serious HIV- 
related diseases or death. Most HIV-infected children 
now treated with combination antiretroviral therapy 
remain symptom free for at least 10 years.,s
The effect of paediatric HIV/HCV coinfection on 
progression o f HIV disease remains unclear, since only 
two studies have investigated this area in children. Two 
coinfected children in one study were without signs of 
HIV progression when last seen at 10 and 10-6 years of 
age. 1 The authors therefore suggest that coinfection may 
lead to slower progression o f HIV disease but the 
sample size and details do not warrant this conclusion. 
Papaevangelou and colleagues"1 found no significant 
differences in HIV disease progression between nine 
coinfected children and three infected with HIV only. 
Although the plasma HIV RNA viral load at 6 months o f  
age in coinfected children was higher than in infants 
with HIV infection only, the difference was not 
statistically significant.
Evidence o f the impact o f HIV/HCV coinfection on 
HIV disease progression in adult populations is a little 
more extensive, albeit still limited. Whereas in four 
studies including 116-1685 coinfected people there 
was no evidence o f an effect o f HCV coinfection on 
progression to HIV disease,k"'w in two studies with 
650-1157 coinfected patients, HIV progression was 
substantially accelerated.4041 Specifically, in a study by 
Carlos and co-workers40 on 902 HIV infected patients, 
72% (650/902) o f whom were also infected with HCV, 
CD4 cell count 2 years after the initiation o f therapy
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■  HIV VTR from coinfected mothers
■  HCV VTR from coinfected mothers
ESI VTR of HIV/HCV coinfection from coinfected mothers
■  Uninfected
Figure 1: E stim a ted  vertical tran sm iss io n  ra te  (VTR) o f  HIV a n d /o r  HCV from  
HIV/HCV-coinfected m o th e rs
Estim ated vertical transm ission rates are m ean rates from  th ree  studies 
providing inform ation on all types o f  vertical transm ission."I" ‘ Mean rates from  
these  th ree  studies are in line with m ean rates from  all studies.
was significantly lower in coinfected individuals 
compared with HIV-only infected individuals 
(p<0-001). In response to treatment, the mean 
increase in CD4 cell count over a 2-year period was 
significantly less than in HCV-coinfected individuals 
(11% vs 19%, p < 0  - 05) and the mean decrease in 
plasma HIV RNA over the same period was 
significantly lower in coinfected patients than in HIV- 
only infected individuals (5% vs 54%, p < 0 -05), 
although this association was not significant in 
multivariable analysis adjusting for sex, age, CD4 cell 
count, use o f HAART, and adherence to therapy.40 
Differences in the effect o f HIV/HCV coinfection on 
HIV disease progression between studies may be partly 
explained by suggestions that coinfected individuals 
with HCV genotype 1 are at an increased risk o f  
progression to AIDS-related mortality compared with 
those with HCV non-genotype 1, although this relation 
is not yet supported by strong evidence.47
Panel 1: M o th e r- to -c h ild  tra n s m is s io n  o f  HIV, HCV, a n d
HIV/HCV c o in fec tio n
•  HIV transm ission  rates from  HIV/HCV-coinfected m o thers 
range from  13 3% to  30% and  are substan tia lly  higher 
th an  th o se  from  HIV-only infected  m others.
•  HCV transm ission  rates from  HIV/HCV-coinfected 
m o th e rs  range from  5-4% to  23% and  are substantia lly  
h igher th a n  th o se  from  HCV-only infected  m others .
•  Vertical transm ission  o f HIV/HCV coinfection  occurs less 
frequen tly  th a n  transm ission  o f HIV or HCV alone.
Coinfection transm ission  rates range from  3-6% to  9-5%.
85
59 2% (95% Cl 
49 1-60-6)
HCV disease progression in coinfected children
T h e  p ro g re s s io n  o f  vert ical ly  a c q u i re d  H C V  infec t ion  is 
s low in th e  first 10 -1 5  years  o f  life, with  few clinical 
s y m p t o m s .  O n ly  2 2 %  o f  c h i ld r e n  e x p e r ien ced  at least 
o n e  m i n o r  clinical  m a n i f e s t a t i o n  b efo re  a m e d i a n  age o f  
4 -2  y ea rs  d u r i n g  p ro sp ec t iv e  fo llow -up in a large 
E u ro p e a n  c o h o r t .41 In th is  s tudy,  h e p a to m e g a ly ,  H C V  
RNA v i ra e m ia ,  a n d  in c r e a s e d  a l a n in e  a m in o t r a n s f e r a s e  
levels w e re  in d ica t ive  o f  active H C V  in fec t ion  in  30%  o f  
H C V -in fe c te d  c h i ld r e n .4’ O n ly  fo u r  s tu d ie s  have 
se p a ra te d  r e s u l t s  o n  p ro g re s s io n  o f  H C V  in co in fec ted  
in fan ts ,  w i th  b e tw e e n  two a n d  26 c o in fec ted  c h i ld r e n  
i n c lu d e d .  T h re e  s tu d ie s  rep o r t  ch ron ica l ly  evo lving  
h e p a t i t i s  in  at least 5 0 %  o f  co in fec led  c h i ld ren ,  
w h ic h  is s im i l a r  to tha t  f o u n d  in  H C V -o n ly  in fec ted  
c h i ld r e n .4’ O n e  s tu d y  r e p o r t s  th e  n u m b e r  o f  co in fec ted  
c h i ld r e n  w i th  p e r s i s t e n t ly  a b n o r m a l  a la n in e  
a m i n o t r a n s f e r a s e  levels ( > 4 0  IU /L)  to be  s im i la r  to tha t  
in  H C V -o n ly  in fec ted  c h i ld r e n ,  b u t  t h e  n u m b e r  o f  
co in fec ted  c h i ld r e n  w i th  a h ig h  p r o p o r t io n  o f  posi t ive  
H C V  RNA P C R  re s u l t s  is r e p o r t e d  to be  g r e a te r  t h a n  in  
H C V -on ly  in fec ted  c h i ld r e n ,  albeit  n o t  s ign if ican t ly  so .41 
No fo rm a l  c o m p a r i s o n  w as  m a d e  b e tw e e n  p r o g re s s io n  
in  co in fec ted  c h i ld r e n  c o m p a r e d  w i th  H C V -o n ly  i n fec ted  
c h i ld re n ,  a n d  in su f f ic ie n t  de ta i ls  w e re  g iven  to d r a w  f i rm  
c o n c lu s io n s  a b o u t  H C V  d i s e a s e  p r o g r e s s i o n  in  t h e  
con tex t  o f  p aed ia t r ic  H I V / H C V  c o in fec t ion .
T h e  effect o f  H C V / H I V  c o in f e c t io n  o n  l ive r-re la ted  
m o rb id i ty  a n d  m o r ta l i ty  in ad u l t  p o p u la t i o n s  h a s  b e e n  
m o r e  ex tensively  s tu d i e d  th a n  in c h i ld r e n  w i th  h i g h e r  
n u m b e r s  o f  co in fec ted  a d u l t s  th a n  c h i ld r e n .  In  H C V - 
in fec ted  ad u l t s  it is w idely  a c k n o w le d g e d  tha t  
c o in fec t io n  w i th  H IV  acce le ra te s  t h e  c o u r s e  o f  H C V - 
a s so c ia te d  liver  d i se a se  p ro g re s s io n ,  p a r t ic u la r ly  in  
p a t i e n t s  w h o  a re  m o r e  i m m u n o d e f i c i e n t .  H C V / H I V  
c o in fec t io n  is t h u s  a s so c ia te d  w i th  i n c r e a s e d  liver  
f ib ros is  p r o g re s s io n ,  i n c r e a s e d  ra te  o f  liver  
d e c o m p e n s a t io n ,  c i r rh o s is ,  h e p a to c e l lu la r  c a r c in o m a ,  
a n d  liver-related  m or ta l i ty ,  p a r t ic u la r ly  d u e  to the
Panel 2: D isease p ro g ress io n  o f  HiV a n d  HCV in vertica lly
c o in fec ted  ch ild ren
•  Paediatric HIV disease progression  in th e  co n tex t o f HCV 
coinfection rem ains unclear. Until recently  it w as accep ted  
th a t  disease progression  in HIV-only infected  individuals 
w as n o t d ifferent from  th a t  in coin fected  individuals, 
a lth o u g h  current evidence o f low er CD4 cell co u n ts  and  
higher HIV viral loads in co in fected  adu lt p a tien ts  
contradicts this. The effect o f HCV coinfection  on  HIV 
disease p rogression  in children rem ains unknow n.
•  Limited evidence does n o t su p p o rt an effect o f HIV/HCV 
coinfection on paediatric  HCV disease progression  b u t 
stud ies in adu lt popu la tions su g g es t th a t  th e  use o f  HIV 
tre a tm e n t m igh t accelerate HCV d isease progression  in 
coinfected  pa tien ts.
h ep a to x ic i ty  o f  m a n y  d r u g s  u s e d  to treat H IV  
in f e c t i o n . " 11' 414’' H o w e v e r ,  in H C V -o n ly  in fec ted  
c h i ld r e n ,  it is g e n e ra l ly  a s s u m e d  tha t  p ro g re s s io n  o f  
H C V -re la te d  d i s e a s e  is s lo w e r  t h a n  in H C V -only  
in fe c te d  a d u l t s  ( a l th o u g h  th e re  a re  l ew  s tu d ie s  w h e r e  
t i m i n g  o f  in f e c t io n  in a d u l t s  is k n o w n  w ith  an y  
p rec is io n ) ;  th e  s a m e  m a y  be  t r u e  o f  H C V /H 1 V -  
c o in f e c te d  c h i l d r e n  (pane l  2).4'v'°
Treatm ent o f H IV/HCV-coinfected adults
T h e  s u b s t a n t i a l  b e n e f i t s  o f  H A A R T  in d e c r e a s in g  
p r o g re s s io n  to A ID S -re la te d  d i s e a s e s  a n d  d e a th  p ro b ab ly  
o u tw e ig h  a n y  d e t r i m e n ta l  e ffec ts  o n  th e  liver  o r  H C V  
d i s e a s e  p r o g r e s s i o n . 444. H o w e v e r ,  th e r e  is c o n s e n s u s  that  
th e  h ep a to to x ic i ty  o f  s o m e  an t i r e t ro v i ra l  d r u g s  is a m a jo r  
l im i t i n g  fac to r  in  th e  t r e a t m e n t  o p t io n s  for c o in fec ted  
p a t ien ts ;  H C V  in fe c t io n ,  specif ica l ly  w i th  H C V  g e n o ty p e  
3, is a n  i n d e p e n d e n t  r i sk  f ac to r  for  H A A R T -a ss o c ia te d  
hep a to to x ic i ty  i n  a d u l t s . 14"  O n  th e  o t h e r  h a n d ,  H A A R T  
h a s  b e e n  a s so c ia te d  w i th  a r e d u c e d  l ik e l ih o o d  o f  liver  
f ib ros is  a n d  r e la te d  d i s e a s e  p r o g r e s s i o n  in  co in fec ted  
p a t ie n ts .  I n d e e d ,  Q u i r i s h i  a n d  c o l l e a g u e s ’ id en t i f ied  
H A A R T  as a n  i n d e p e n d e n t  p r e d i c to r  o f  s u rv iv in g  liver  
d i s e a se  (O R  0 - 1 1 ,  9 5 %  Cl 0 - 0 2 - 0 -  56 ) , ’ a n d  th e  d u r a t i o n  
o n  H I V  a n t i r e t ro v i r a l  t h e r a p y  h a s  a lso  b e e n  a s so c ia ted  
w i th  less  l iver  f ib ros is .  In  s u m m a r y ,  t r e a t m e n t  to 
p r e v e n t  H I V  d i s e a s e  p r o g r e s s i o n  in  c o in fe c te d  p a t i e n t s  
s h o u ld  be  a p r io r i ty ,  a l t h o u g h  th e  d r u g s  u s e d  m u s t  be  
c h o s e n  wise ly  to r e d u c e  th e  l ik e l ih o o d  o f  h e p a to to x ic i ty . ’’
T h e  d isp a r i ty  b e tw e e n  s tu d i e s  in  th e  effect  o f  I IA A R T  
o n  liver d i s e a s e  h ig h l ig h t s  th e  p r o b l e m  o f  c o m p a r i n g  
c o h o r ts ,  s im p ly  b e c a u s e  o f  the  v a ry ing  n a t u r e  o f  bo th  
H I V  a n d  H C V  d i s e a s e . ’4 H o w e v e r ,  it c.ould also  be  
e x p la in e d  by th e  type  o f  d r u g s  u se d ,  w i th  p ro te a se  
i n h ib i to r s  s u b s ta n t i a l l y  less  likely to r e su l t  in  liver 
f ib ros is  in  c o in fe c te d  p a t i e n t s  t h a n  n u c le o t id e  rev e rse  
t r a n s c r ip t a s e  i n h i b i t o r s  o r  n o n - n u c le o t id e  r ev e rse  
t r a n s c r ip t a s e  i n h i b i t o r s . "  O n  th e  o th e r  h a n d ,  th e r e  is 
e v id e n c e  th a t  H C V  in fe c t io n  r e d u c e s  th e  effect  H A A R T  
h a s  o n  in c r e a s i n g  C D 4  cell  c o u n t s  in  co in fec ted  
p a t i e n t s .4’ G r e u b  a n d  c o l l e a g u e s 41 f o u n d  th e  p robab i l i ty  
o f  f a i l in g  to  i n c r e a s e  C D 4  cell c o u n t s  by  at least .50 ce lls 
p e r  pL  1 y ear  a f t e r  th e  s t a r t  o f  H A A R T  w a s  2 5 %  (95%  Cl 
2 2 - 5 - 2 7 - 7 )  in  c o in f e c te d  p a t i e n t s  a n d  16%  (95% Cl
14-4—17-8)  in  H IV -o n ly  in fe c te d  p a t i e n t s  (h a z a rd  ra t io  
0 -7 9 ,  9 5 %  C l  0 - 7 2 - 0 - 8 7 ) . 41 G iv e n  th e  hepa to to x ic  n a tu r e  
o f  m a n y  H I V  t r e a t m e n t s  a n d  th e  p o ss ib le  d e t r im e n ta l  
e ffec ts  o f  H C V  o n  H IV  d i se a se  p ro g re s s io n ,  it is 
adv isab le  to s c r e e n  all H IV - in fe c te d  p a t ie n ts  for H C V  so 
th a t  H IV  in f e c t i o n  c a n  be  m a n a g e d  app ro p r ia te ly .
T h e  t r e a t m e n t  o f  H C V  in  co in fe c te d  p a t i e n t s  is also  
p ro b le m a t ic  s in c e  th is  g r o u p  m a y  n o t  r e s p o n d  as well to 
a n t i -H C V  th e r a p i e s  as H C V -o n ly  in fec ted  in d iv id u a l s / ’''"'1 
T h is  s i tu a t io n  is ex a c e rb a te d  by the  fact tha t  a n t i -H C V  
t h e ra p y  is o f te n  poor ly  to le ra ted  a n d  h ig h ly  toxic, w i th  u p  
to h a l f  o f  p a t i e n t s  d e v e lo p in g  s y m p t o m s  s u c h  as fa t igue ,  
fever, m ya lg ia ,  h a i r  loss ,  a n d  d e p re ss io n / '"  T h e s e  side-
h t tp : / / i n f e c t io n . t l i e l a n c e t .c o m  Vol 6  February 2 0 0 6
Review
effects lead to p o o r  c o m p l ia n c e ,  espec ia l ly  in co in fec ted  
p o p u la t io n s  w h e r e  the  in c id e n c e  o f  de p re ss iv e  
s y m p to m s  a n d  m i to c h o n d r ia l  toxicity d u e  to t r e a tm e n t  is 
h ig h e r  th an  in H C V -on ly  in fec ted  p a t i e n t s ,  a n d  a m o n g  
w h o m  it is e s t im a te d  on ly  2 0 %  will benef i t  f ro m  H C V  
therapy . '" ' ’ '' H o w ev er ,  s o m e  H C V  t r e a t m e n t s  a re  m o r e  
effective th an  o th e r s ;1'1 the  ra te  o f  s u s t a in e d  H C V  
virological r e s p o n s e  (SVR) in  co in fec ted  a d u l t s  t rea ted  
with  pegy la ted  i n te r fe ro n  alfa-2b (or alfa-2a) p lus 
r ibav ir in  (SVR 2 7 -4 4 % )  is s ign i f ican t ly  h i g h e r  th a n  in 
those  trea ted  w i th  in te r fe ro n  alfa-2b (or alfa-2a) p lus  
r ibavir in  (SVR 1 2 -2 1 % ;  p < 0 ■ 0 5 ) but  th is  is also  t rue  
in H C V -only  in fec ted  a du l ts .
A n t i -H C V  t r e a tm e n t  is g iven  on ly  for a l im i te d  t im e  
(usually  12.-48 w e e k s ) ,1"’ u n l ik e  H IV  th e ra p y  w h ic h  is for 
life. A recen t ly  p u b l i s h e d  c o n s e n s u s  s t a t e m e n t '7 f ro m  
th e  first  E u ro p e a n  c o n s e n s u s  c o n f e r e n c e  o n  the  
t r e a tm e n t  o f  c h ro n ic  h e p a t i t i s  B a n d  C in  H IV -c o in fec ted  
p a t ie n ts  s ta te s  that ,  m  a du l ts ,  the  in i t ia t io n  o f  H IV  
t r e a tm e n t  in co in fec ted  p a t i e n t s  s h o u ld  be as m  a n  HIV- 
only in fec ted  p o p u la t io n .  E u ro p e a n ,  UK, a n d  US 
g u id e l in e s  r e c o m m e n d  that  H IV  t r e a tm e n t  is o f fe red  to 
all p a t ien ts  w ith  C D 4  cell c o u n t s  less  t h a n  350 cells 
pe r  pL.' '-' " H o w ev er ,  in  ad u l t s  w i th  C D 4  cell c o u n t s  just 
above the  t h r e s h o ld  for in i t ia t io n  o f  H IV  t r e a tm e n t ,  
H IV -re la ted  i m m u n e  def ic iency  s h o u ld  be  im p ro v e d  
w ith  H A A R T  b e fo re  s ta r t in g  any  a n t i - H C V  t r e a tm e n t ,  
s ince  i n te r fe ro n -b a se d  H C V  th e ra p y  m a y  c a u s e  
d ec reases  in C D 4  cell co u n t .  7 I f  H C V  is d e te c te d  be fo re  
H A A R T  is cl inically i n d ic a te d  o r  at a p o in t  w h e r e  th e  
CD4 cell c o u n t  is n o t  yet in d ica t ive  o f  i m m u n e  
deficiency, t h e n  a p p ro p r ia te  I IC V  th e r a p y — u su a l ly  w ith  
pegy la ted  in te r fe ro n  alfa a n d  r ibav ir in— s h o u l d  b e g in  
im m e d ia te ly . ' '
Treatm ent of HIV/HCV-coinfected children
To date ,  th e re  a re  n o  s tu d ie s  f o c u s in g  specifically  o n  th e  
t r e a tm e n t  o f  e i th e r  H C V  or  EIIV in c h i ld r e n  co in fe c te d  
with both  v iruses .  T h e  r e c o m m e n d a t i o n s  r e g a r d in g  the  
t r e a tm e n t  o f  c o in fec t ion  a re  based  on  a du l t  da ta  o r  a re  
ex trapo la ted  f ro m  r e c o m m e n d a t i o n s  for the  t r e a tm e n t  o f  
paed ia tr ic  H IV  or H C V  a lone .  T h e  c o n c o m i t a n t  u s e  o f  
an t i re t rov ira l  th e r a p y  a n d  an t i -H C V  th e ra p y  is 
co m p l ica ted  by th e  in te ra c t io n s  o f  m a n y  d r u g s ,  s in c e  
m o s t  H A A R T  a g e n ts  have  th e  p o ten t ia l  to c a u s e  
hepato toxic i ty .6" T r e a t m e n t  w i th  in te r fe r o n  alfa-2b p lu s  
r ibavirin  is m o s t  c o m m o n l y  r e c o m m e n d e d  for effective 
H C V  t r e a tm e n t  in ch i ld ren .  A l th o u g h  re c e n t  tr ia ls  s h o w  
p r o m is in g  re su l t s  for the  u se  o f  p eg y la ted  in t e r f e r o n ,67 
r ibav ir in  can  e n h a n c e  the  p h o s p h o r y l a t io n  o f  
d id a n o s in e ,  t h u s  in c r e a s in g  th e  r isk  o f  a s so c ia te d  toxici ty 
and  th e re fo re  th e  u s e  o f  b o th  th e s e  a g e n t s  c o n c u r r e n t ly  
s h o u ld  be  avoided. S imilarly ,  r ibav ir in  a n d  z id o v u d in e  
are  bo th  assoc ia ted  w i th  a n a e m ia  a n d ,  w h e r e  poss ib le ,  
sh o u ld  n o t  be a d m in i s t e r e d  to g e th e r .6'’ D id a n o s in e  a n d  
z id o v u d in e  a re  bo th  m a jo r  c o m p o n e n t s  o f  m a n y  
an t i re t rov ira l  the rapy  r e g im e n s ,  especial ly  t h o se
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•  All evidence relating to  th e  tre a tm e n t  o f coin fected  
individuals com es from  adu lt p o p u la tio n s  o r is 
ex trapo la ted  from guidelines for th e  tre a tm e n t of 
paediatric  HIV and HCV separately .
•  The hepato tox ic  n a tu re  o f  m any HIV drugs, such  as 
nevirapine and  o th e r  non -nucleoside  reverse transcrip tase  
inhibitors, is th e  m ajor lim iting fac to r in th e  HIV tre a tm e n t 
o p tio n s  of coinfected individuals; how ever, th e  benefits  o f 
HAART on th e  HIV disease p rogression  o f th e se  p a tie n ts  
probably  ou tw eighs th e se  d e trim e n ta l effects.
•  Drug interactions m ake th e  tre a tm e n t o f co in fec ted  
children particularly p rob lem atic  an d  th e  use o f HIV and  
HCV tre a tm e n ts  s im ultaneously  sh o u ld  be carefully 
m anaged , in add ition  to  th e  careful choice o f HIV th e rap y  
to  ensure  p rogression  to  HCV d isease is n o t accelerated .
available  to c h i ld r e n ,  w h e r e  t h e  h e p a to to x ic  n a t u r e  o f  
m a n y  H I V  d r u g s  is m o r e  p r o b le m a t ic  g iv e n  th e  l im i te d  
n u m b e r  o f  p a e d ia t r ic  t r e a t m e n t s  availab le .  It is th e r e fo r e  
h a r d e r  to f ind  pa e d ia t r ic  a n t i - H IV  th e r a p y  th a t  d o e s  n o t  
ex h ib i t  h ep a to to x ic  p r o p e r t i e s .  All n o n - n u c l e o s i d e  
r e v e rse  t r a n s c r ip t a s e  i n h ib i to r s  a re  h e p a to to x ic ,  
e spec ia l ly  n e v i r a p in e ,  w h ic h  c a n  c a u s e  o r  in t e n s i f y  liver  
d i s e a s e  i n  H C V - in fe c te d  c h i ld r e n .  P ro t e a s e  in h ib i to r -  
b a s e d  c o m b i n a t i o n  a n t i r e t ro v i r a l  t h e r a p y  r e g i m e n s  
i n c l u d i n g  lop inav ir ,  r i tona v ir ,  n e l f in a v i r ,  a n d  in d in a v i r
HIV-only infected children
Initiate HCV t h e r a p y ^ \s 
only if CD4 count is 
above threshold at which 
HIV therapy would be 
started, since interferon 
can lower CD4 count
Initiate HIV therapy 
as in HIV-only 
infected children
HCV-only infected childrenHIV/HCV-coinfected children
Interferon-based anti-HCV 
therapy initiated after 3 years 
o f age and upon presentation  
o f clinical sym ptom s57
Com bination antiretroviral 
therapy initiated immediately 
or upon presentation of 
clinical sym ptom s or severe 
im m unological/virological 
impairment63
Treatment o f  HIV/HCV-coinfected children is w ithout clear 
m anagem ent guidelines and so close m onitoring is essential 
given the high risk o f adverse events in this group
HIV treatm ent should avoid nevirapine and on initiation of 
HCV therapy, HIV treatm ent should be m odified to avoid 
drug interactions, specifically betw een ribavirin and 
zidovudine and didanosine
Figure 2: R eco m m en d a tio n s  fo r th e  t r e a tm e n t  o f  HIV /H CV-coinfected children
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Panel 4: R ec o m m e n d a tio n s  for t r e a tm e n t  o f  co in fec ted
ch ild ren
•  HIV therapy  in HIV/HCV-coinfected children should  be 
in itia ted  as in HIV-only populations, a lthough  nevirapine 
shou ld  be avoided w here possible.
•  HCV tre a tm e n t shou ld  only be in itia ted  in children w ith a 
CD4 cell co u n t g rea te r th an  th e  level recom m ended  for 
the  initiation  o f HIV therapy, since in terferon  has been  
show n to  reduce CD4 cell count.
•  The m odification of HIV therapy during HCV therapy  m ay 
be necessary to  avoid concurrent use o f ribavirin and 
didanosine or zidovudine.
•  The close m onito ring  o f tre a tm e n t and  clinical s ta tu s  in 
coinfected children is vital given th e  high risk o f adverse 
even ts  in th is group.
a re  also a s so c ia ted  with  ex a c e rb a t io n  o f  c h r o n ic  liver  
d isease ,  a lbe it  in  r a re  c a s e s . N u c l e o s i d e  rev e rse  
t r a n sc r ip ta se  i n h ib i to r s  a re  m o r e  a p p ro p r ia te ,  a l t h o u g h  
s o m e  h ave  b e e n  s h o w n  to c a u s e  se v e re  h epa to tox ic i ty  in  
ra re  cas es .1''' At p r e s e n t  th e re  a re  n o  g u id e l in e s  o n  h o w  to 
resolve th e s e  i s s u e s  in c h i ld r e n  a n d  so  th e  m a n a g e m e n t  
o f  paediatr ic,  c o in fec t io n  r e m a i n s  d if f icu lt  a n d  c o n t in u e s  
to be b a s e d  o n  g u id e l in e s  for th e  t r e a t m e n t  o f  H IV  a n d  
H C V  separa te ly .
In te r f e ro n -b a s e d  H C V  t r e a t m e n t  is n o t  r e c o m m e n d e d  
in c h i ld re n  b e fo re  3 years  o f  age b u t  H I V  t r e a t m e n t  is 
o f ten  s ta r te d  im m e d ia te ly  in  in f a n t s  w i th  clinical  
s y m p t o m s  a n d  severe  im m u n o lo g ic a l  a n d  viro logical  
im p a i r m e n t . ' ’8 It h a s  b e e n  s u g g e s t e d  th a t  ear ly  in i t i a t io n  
o f  H IV  th e r a p y  in  all H IV - in fe c te d  c h i ld r e n  is m o r e  
su c c e ss fu l  t h a n  a de layed  a p p ro a c h ,  a n d  in  m a n y  cases  
H I V  t r e a t m e n t  will c o m m e n c e  lo n g  b e fo re  H C V  th e ra p y  
c a n  be  c o n s i d e r e d . ’7 As H C V -in fe c te d  c h i ld r e n  exh ib i t  
few clinical  s y m p t o m s  in  the  f irs t  10 -1 5  y ea rs  o f  life a n d  
a re  t h e re fo re  un l ike ly  to r e q u i re  H C V  t r e a tm e n t ,  HTV 
t r e a tm e n t  m a y  c o n t in u e  for m a n y  y ea rs  w i th o u t  the  
n e e d  for c o n c o m i ta n t  H C V  th erapy .  H o w e v e r ,  b e c a u s e  it 
r e m a i n s  u n c le a r  w h e th e r  H IV  c o in fe c t io n  in c re a s e s  
H C V  d ise a se  p r o g re s s io n  in c h i ld r e n ,  th e  p o ss ib i l i ty  tha t  
H C V  t r e a tm e n t  in th is  g r o u p  m a y  be  n e c e s s a ry  ea r l ie r  
t h a n  in H C V -on ly  in fec ted  c h i ld r e n  m u s t  be c o n s id e re d .  
As w ith  a d u l t  p o p u la t io n s ,  H IV  t r e a t m e n t  in H I V / H C V -  
co in fec ted  c h i ld r e n  sh o u ld  be in i t ia ted  as p e r  g u id e l in e s  
for H IV -on ly  in fec ted  c h i ld r e n .  H o w e v e r ,  c lose  
m o n i t o r i n g  is es sen t ia l  to e n s u r e  tha t  H I V  t r e a t m e n t  is 
n o t  ex a c e rb a t in g  H C V  p ro g re s s io n  a n d  th e  u s e  o f  
n e v i r a p in e  s h o u ld  be  avo id ed  w h e r e  p o ss ib le .  I f  an d  
w h e n  H C V  th e ra p y  b e c o m e s  n ec e s sa ry ,  ca re  s h o u ld  be  
tak en  to e n s u r e  th a t  C D 4  cell c o u n t s  a re  above  th e  
r e c o m m e n d e d  level for th e  in i t i a t io n  o f  H I V  th e r a p y  
before  in i t ia t io n  o f  in te r fe ro n ,  w h ic h  is k n o w n  to lo w er  
th e  C D 4  cell co u n t .  ’7 Addit ional ly ,  it m a y  be n e c e s s a ry  to 
m o d ify  the  H IV  t r e a t m e n t  to e n s u r e  d r u g  in te ra c t io n s ,  
specifically b e tw e e n  r ibav ir in  a n d  z id o v u d in e  o r
d i d a n o s in e ,  d o  not  r e su l t  in i n c r e a s e d  liver toxicity a n d  
f ib ros is  (pane l  3, p a n e l  4, a n d  f igu re  2).
Discussion
T h e  avai lab le  e v id e n c e  o n  p a e d ia t r i c  H C V / H I V  
c o in f e c t io n  s u g g e s t s  th a t  vert ical  t r a n s m i s s i o n  o f  bo th  
H IV  a n d  H C V  s e p a ra te ly  o c c u r s  m o r e  o f te n  f ro m  
m o t h e r s  c o in f e c te d  w i th  H I V  a n d  H C V  t h a n  f ro m  sing ly  
in fe c te d  m o t h e r s .  T r a n s m i s s i o n  o f  H I V / H C V  
c o in fe c t io n  h a s  b e e n  ra re ly  s tu d ie d  b u t  th e  ra tes  r e p o r te d  
im p ly  tha t  c o in f e c t io n  is t r a n s m i t t e d  less  f r e q u e n t ly  than  
e i th e r  H IV  o r  H C V  in fe c t io n  a lo n e  f ro m  co in fec ted  
m o th e r s .
T h e  b u lk  o f  the  e v id e n c e  d o e s  no t  s u p p o r t  any  c h a n g e  
in H IV  d i s e a s e  p r o g r e s s i o n  d u e  to c o in f e c t io n  w ith  
H C V . H o w e v e r ,  a s m a l l  n u m b e r  o f  r e c e n t ,  la rge  s tu d ie s  
h ave  s h o w n  c h a n g e s  in  H I V  d i s e a s e  p r o g re s s io n  in 
ad u l t s ,  i m p l y i n g  a d e t r i m e n ta l  effect  o f  H C V  o n  H IV  
d i s e a s e  r e s u l t i n g  in  m o r e  se v e re  l iver le s io n s  a n d  
in c r e a s e d  H C V  RNA . T h e r e  a re  few  s tu d ie s  
d o c u m e n t i n g  H C V  d i s e a s e  p r o g re s s io n  in  l igh t  o f  
vert ical ly  a c q u i r e d  H I V / H C V  c o in fe c t io n ,  a n d  th e s e  
s tu d i e s  h a v e  n o t  c o m p a r e d  H C V  in  c o in fe c te d  i n f a n t s  
w i th  t h a t  o f  H C V -o n ly  in fe c te d  in fan ts ;  t h e  effect  o f  H IV  
o n  H C V  p r o g r e s s i o n  in  c o in f e c te d  c h i ld r e n  r e m a i n s  
u n c le a r .
E v id e n ce  r e la t i n g  to  t h e  t r e a t m e n t  o f  co in fec ted  
in d iv id u a l s  p r e d o m i n a n t l y  c o m e s  f r o m  s tu d i e s  o f  a du l t  
p o p u la t i o n s  a n d  t h e r e  a re  m a n y  c o n f l ic t in g  f in d in g s .  
S o m e  e v id e n c e  s u g g e s t s  th a t  th e  h e p a to to x ic  n a t u r e  o f  
m a n y  H I V  t r e a t m e n t s  r e s u l t s  in  an  acc e le ra te d  or  
i n c r e a s e d  level o f  l ive r -re la ted  m o r b id i ty  in  c o in fec ted  
in d iv id u a l s  a n d  t h a t  H C V  th e r a p y  is m o r e  p oor ly  
t o le r a te d  in  c o in f e c t e d  p a t i e n t s  a n d  m a y  c a u s e  C D 4  cell 
c o u n t  d e c l in e .
H C V  t r e a t m e n t  w i th  i n t e r f e r o n  is n o t  c u r re n t ly  
ava i lab le  for  c h i l d r e n  u n d e r  3 years  o f  age. It is u n c l e a r  
w h e t h e r  c o in f e c t io n  a c ce le ra te s  H C V  d i se a se  
p r o g re s s io n  a n d  w h e t h e r  c o in fe c te d  c h i ld r e n  m a y  
t h e r e fo re  n e e d  to rece ive  H C V  t r e a tm e n t  at an  ear l ie r  
age t h a n  H C V -o n ly  in fec ted  c h i ld r e n ,  m o s t  o f  w h o m  
r e m a i n  s y m p t o m  f ree for  at least 15 years. A l th o u g h  
H C V  th e r a p y  is g iv en  for a relatively sh o r t  p e r io d  o f  
t im e ,  th e  p o ss ib le  n e e d  to in i t ia te  ea r l ie r  H C V  th e ra p y  
in  H I V /H C V - c o in f e c t e d  c h i ld r e n  m a k e s  c h o o s in g  
a p p r o p r i a t e  H I V  t h e r a p ie s  im p o r t a n t .  H IV  th e r a p y  in 
co in fe c te d  c h i ld r e n  s h o u l d  be in i t ia ted  as w o u ld  be the  
c as e  in H IV -o n ly  in fe c te d  c h i ld r e n ,  a l t h o u g h  n e v i r a p in e  
s h o u ld  be avo id ed  w h e r e  p o ss ib le  a n d  c lose  m o n i t o r i n g  
o f  H C V  p r o g re s s io n  is vital. W h e r e  th e  a d d i t io n a l  
in i t ia t io n  o f  H C V  t r e a t m e n t  b e c o m e s  necessa ry ,  H IV  
th e r a p y  m a y  n e e d  to be  m o d i f i e d  to avoid c o n c u r r e n t  u s e  
o f  r ib av i r in  w i th  d i d a n o s in e  o r  z id o v u d in e .
T h is  rev iew  o f  availab le  r e se a rc h  o n  p a e d ia t r ic  H IV  
a n d  H C V  c o in fe c t io n  h a s  h ig h l ig h te d  a n u m b e r  o f  vital 
a reas  w h e r e  e v id e n c e  is in s u f f ic ie n t  to i n f o r m  clinical 
p rac t ice  a n d  m a n a g e m e n t .  M os t  o f  th e  available
h t t p : / / i n fe c . t io n . t h e la n c e t . t o n i  Vol 6 February 2 0 0 6
Search s tra te g y  a n d  se lec tio n  crite ria
An English language literature search w as carried o u t using 
the  Pubm ed da tab ase  fo r s tud ies exam ining HIV/HCV 
coinfection. The keywords used  in th e  search w ere "HIV", 
"hum an im m unodeficiency virus", "AIDS", "acquired im m une 
deficiency syndrom e", "HCV", "hepatitis  C", "children",
"infants", "transm ission", "vertical transm ission", and 
"m other-to -ch ild -transm ission". Reference lists o f related 
articles were searched for relevant s tud ies, as w ere the  
abstracts  o f recent conferences.
i n fo rm a t io n  comes; f ro m  s lu d ie s  of m o lh c r - to -c h i ld  
t r a n s m is s io n  w ith  a focus o n  H IV  or  H C V  t r a n s m is s io n  
in the  l ight o f  m a te r n a l  c o in fec t ion .  W h a t  is n o w  
especia l ly  i m p o r t a n t  g iven  th e  m a n a g e m e n t  com p lex i ty  
is a n  e m p h a s i s  o n  the  t r a n s m is s io n  o f  c o in fe c t io n  a n d  
the  r e su l t a n t  H IV  an d  H C V  d ise ase .  T h e s e  s tu d ie s  
w o u ld  in  tu r n  i n f o rm  t r e a tm e n t  tr ials,  vitally a d d r e s s in g  
a p p ro p r ia te  m a n a g e m e n t  o f  th is  g ro u p ,  w h o s e  d ise a se  
p r o g re s s io n  in a d u l th o o d  h a s  b e e n  s h o w n  to vary f ro m  
th o se  only  in fec ted  w i th  H IV  or  H C V  a n d  w h o s e  
t r e a tm e n t  is c o m p l ic a te d  by th e  l im i te d  n u m b e r  o f  
available paed ia t r ic  d r u g s  a n d  th e  d if f icu lt ies  o f  t r e a t in g  
H IV  a n d  H C V  s im u l t a n e o u s ly  w h i le  av o id in g  d r u g  
in te ra c t io n s  a n d  th e  w o r s e n in g  o f  H I V  or  H C V  d isease .
Conflicts of in te res t
We dec la re  that  we  ha ve  n o  conflict? o f  inte res t .
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